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        Signaling lipids such as diacylglycerol (DAG) and the phosphatidylinositol 
polyphosphates (PIPns) play crucial roles in numerous cellular pathways. However, 
characterization of their activities is hindered by the complexity of associated signaling 
pathways and of the membrane environment.  To address this issue, we have 
developed lipid probes that are effective for characterizing biological events using 
different applications, including activity-based probing (PIPns and DAG) and microarray 
analysis (PIPns). The activity-based probes have been applied to label receptor targets 
in multiple cancer cell proteomes through photocrosslinking followed by click reactions. 
The probes were found to label several proteins, as judged by on-gel fluorescence, and 
labeling was abrogated through various controls, such as heat denaturation and 
competition. Proteomic studies have been successfully performed to identify protein 
targets through biotin enrichment followed by mass spectrometric analysis.  For 
microarray analysis, functionalized PIPn probes were synthesized and applied to 
develop a high throughput microarray analysis to measure protein-lipid binding affinity. 
These approaches will be invaluable for characterizing PIPn/DAG-regulated events and 
their involvement in disease. The design, synthesis and application of these lipid probes 
are included in this dissertation.  In addition, the design and synthesis of other lipid 
probes are discussed, such as bis(monoacylglycero)phosphate (BMP), and 
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1. CHAPTER 1 Introduction  
 
      Cell membranes consist of a complex array of molecules including lipid bilayers and 
membrane proteins. Different membranes of cellular compartments possess different 
lipid compositions, which is regulated by lipid metabolism and trafficking. The lipid 
molecules can be classified into two categories by their roles in membranes: bulk lipids 
and signaling lipids. Bulk lipids as the major composition primarily serve a structural 
role, while signaling lipids as the minor composition serve as site-specific ligands. 
Therefore, despite the minimal amounts of signaling lipids that are present in the 
membrane, they have been actively studied by many scientists in order to understand 
their activities in important processes include membrane-protein interactions. Examples 
of important signaling lipids include phosphatidic acid (PA), diacylglycerol (DAG) and 
the phosphatidylinositol polyphosphates (PIPns) (figure 1.1).  
       Protein-membrane binding interactions represent crucial molecular recognition 
events that control key cellular processes including signal transduction events, viral cell 
entry as well as other processes, and defects in binding have been linked to several 
diseases.1,2 For instance, DAG is involved in the onset of cancer3-5 and diabetes,5 etc. 
Another prominent example involves the conversion of PI-(4,5)-P2 to PIP3 by 
phosphotidyl 3-kinase (PI-3K), which then binds and activates Akt, activating numerous 
events that regulate the cell cycle (figure 1.2). The reverse conversion is promoted by 
PTEN. As a result, enzymes that interconvert PI-(4,5)-P2 and PIP3 are among the most 
heavily mutated proteins in cancer.6 Due to the key roles that lipids play in cancer and 
other diseases, it is necessary to characterize binding activities to fully understand their 
biological ramifications.  
2 
 
Figure 1.1 Membrane lipids include signaling lipids and bulk lipids: even though 
signaling lipids are the minor components comparing to other lipids, they act as the site-
specific ligands for the binding of peripheral proteins onto membrane. 
      It is well-documented that many proteins have binding sites that are specific to a 
particular signaling lipid. For example, C1 domains are an important family of DAG 
binding domains. C1 domains were named after “conserved region-1” in protein kinase 
C (PKC). The C1 domains are cysteine-rich modules whose distinct motif is 
HX12CX2CXnCX2CX4HX2CX7C (H is histidine, C is cysteine, X is any other amino acid).  
C1 domains were originally identified in protein kinase C (PKC) isozymes and thus were 
named after “conserved region-1” in PKC. Up to date, C1 domains have been also 
identified in protein kinase D (PKD) isozymes, chimaerins, RasGRPs, diacylglycerol 
kinases (DGKs) and etc. Because the lipid-protein binding is site-targeting, these 
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proteins were all found to be DAG receptors7. Similarly, it is evident that the PIPns also 
interact with a number of specific binding protein domains. Very diverse domains have 
been reported to bind PIPns: for instance, the PH, PX, FYVE, ENTH, ANTH, FERM, 
Tubby and PROPPIN domains8-11.  
       Through the elucidation of these lipid-targeting domains, efforts were made to 
unravel the mechanism by which the cytosolic proteins with these domains were 
recruited into the cell membranes.1 Cytosolic proteins can be categorized into three 
classes by the their relative position when interacting with membranes (see figure 1.3): 
1) S-type proteins: positioned at the membrane surface and outside the lipid backbone, 
thus interact primarily through the binding of polar lipid headgroups; 2) I-type proteins: 
penetrate into the interfacial region and interact with both lipid headgroups and 
backbones; 3) H-type proteins: insert deep into lipid bilayers and interact with both lipid 
headgroups and hydrophobic backbones. Therefore, some proteins only require the 
presence of polar lipid headgroups for the binding events whereas others require both 
the headgroup and the membrane environment. The PH domains, in particular, bind to 
the membrane primarily through its association to the polar lipid headgroups. The 
crystal structures of PH domains have a binding pocket outlining the minimal regions for 
membrane penetration.10 Even though we have begun to understand some of these 
binding events, the research of lipid-protein interaction is still in its childhood. The 
challenges we are facing include the elucidation of lipid binding receptors, the analysis 





Figure 1.2 Example of the key roles that lipids (PIPns) play in cellular signaling 
evengs events: PI-3K converts PI-(4,5)-P2 to PIP3, which binds and activates Akt. This 
activated Akt protein regulates the cell survival cycle. 
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Figure 1.3 Three types of peripheral proteins categorized by their relative position 
to the membrane: S-type proteins sit on the membrane surface and interaction mainly 
with the lipid headgroups; I-type and H-type proteins penetrate the interfacial region and 
hydrocarbon core to certain extent, thus they interact with both lipid headgroups and 
lipid backbones. 
        Besides the signaling lipids, other lipids serve important roles in biological 
processes in different fashions. For example, bis(monoacylglycero)phosphate (BMP) as 
a minimal component of cellular phospholipid content, has emerged as an important 
lipid in the regulation of biological pathways. In one of the studies, BMP was found to be 
one of the best stimulators of glucosylceramide hydrolysis.12 BMP was also reported to 
regulate endosomal cholesterol levels under the control of Alix/AlP1, a LBPA-interacting 
protein involved in sorting into multivesicular endosomes.13 Another recent proteomic 
study revealed that the association of Alix with late endosomal BMP plays a vital role in 
dengue virus infection in human endothelial cells.14 
       Another example is lysophosphatidic acid (LPA), which is found responsible for 
various cellular responses.15-17 It has been reported to facilitate cell proliferation and 
migration, neurite retraction, platelet aggregation, smooth muscle contraction, actin 
stress formation, cytokine and chemokine secretion, etc.17 LPA is produced from LPC 
by the enzyme autotaxin. 
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       All in all, lipids are critical to human health in numerous aspects. They have been 
hot research topics among biologists in order to fully understand many cellular 
processes. In recent years, chemistry techniques were employed in this field and 
proven to be highly effective in solving many issues, which are rather difficult to solve if 
solely relying on biological tools. A major application of chemical tools in this field is to 
develop lipid probes. Lipid probes are implemented lipid compounds that are developed 
to characterize lipid recognition events. For example, our group has developed a set of 
diacylglycerol (DAG) probes bearing various reporter groups to characterize DAG 
binding interactions.18  The precursor of these probes contains an azide tag at the sn-1 
position of the headgroup, which was then derivatized into various fluorophores 
(naphthyl, dansyl, coumarin, CBF) and photoactive group (benzophenone group) by 
click reaction. The binding efficacy of these lipid probes was analyzed with a known 
DAG receptor, PKC . In the SPR equilibrium binding analysis, these probes showed 
similar binding affinity to natural DAG lipids. Therefore, these DAG probes can be used 
to serve desired analytical functions while mimicing the binding of natural DAG lipids. In 

































Naphthyl Dansyl Coumarin 5(6) CBF Benzophenone  
 Scheme 1.1 DAG probes bearing various reporter groups  
 
 
    Some valuable PIPn probes have been developed to characterize PIPn binding. For 
example, Holmes and coworkers developed PIPn probes bearing amino tag, which can 
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be immobilized onto Affi-Gel 10 to purify out and identify the binding protein receptors 
(figure 1.4 A).20 Photoactive radio-labeled PIPn probes were also developed (figure 1.4 
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2. CHAPTER 2.  Design, Synthesis and Application of 
Phosphatidylinositol Polyphosphate (PIPn) Activity Probes as 
Chemical Tools to Characterize Protein-Membrane Binding 
Interactions. 
1. Introduction 
The family of phosphatidylinositol polyphosphates (PIPns), also known as 
phosphoinositides, is an important signaling lipid family with seven naturally existing 
isomers. These isomers only vary by the number and position of the phosphate groups, 
and include every combination of phosphate at the 3,4 and 5 position of the D-myo-
inositol ring. The myo-inositol ring is a cyclitol that consists of one axial group and five 
equatorial groups (figure 2.1). As the axial group is assigned as the 2-position, the 
numbering system is assigned D- for counterclockwise rotation and L- for clockwise 
rotation. As the PIP lipid backbone is connected to the inositol ring at the 1-position 
through a phosphadiester, a PIP molecule can be generally denoted as PI(a,b,c)Pn, in 
which the position and total number of phosphates on the inositol ring are  indicated by 
“a,b,c” and “n” respectively (“n” is usually omitted if equals to 1). Thus the PIPn isomers 
are written as follows: PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, PI(3,4,5)P3 
(figure 2.2).  
Surprisingly, with the minimal differences in structures, the PIP isomers bind protein 
receptors with very different specificity and affinity1,10. The consistent efforts made by 
scientists to elucidate these protein–PIPn interactions have yielded many important 
details: a great number of PIPn-binding protein modules have been identified, including 
but not limited to the PH, PX, FYVE, ENTH, ANTH, FERM, Tubby, and PROPPIN 
domains. However, further efforts are required to fully characterize these complex 
events. For instance, if we consider PH domain only, there are more than 250 PH-
domain-containing proteins, which can each exhibit different protein binding properties. 
Thus, the structural variations of PIPns lead to variations of both affinity and specificity 
of the binding to different family members. On the other hand, different proteins require 
9 
different motif of the PIPns to bind, with some requiring the presence of the membrane 
bilayers whereas others have been shown to bind strongly to soluble headgroups. In 
particular, outside of the membrane context, the PH domains exhibit binding interactions 
that are primarily driven by headgroup association. As a result of the structural 
complexity of the PIPns, the soluble headgroups themselves were shown to possess 
comparable binding affinities to the cognate natural lipids22-24. Based on this fact, we 
have targeted simplified headgroup analogs lacking the lipid backbone to study 
binding.25-27 
The PIPns play vital roles in many cellular events, such as lipid signaling, cell 
signaling, membrane trafficking and the regulation of protein functions.8,9,28 For 
example, one of the most actively studied PIPns binding proteins is Akt since this is 
among the most heavily mutated proteins in cancer.6,29-31 However, the studies of lipid-
protein binding are often hindered by the complex cellular environment and the kinetic 
binding of protein receptors. The goal of the research discussed herein is to develop 
activity-based probes corresponding to different PIP isomers that are effective for 
identifying and characterizing cognate protein binding targets from cell extracts (figure 
2.3).  
 
Figure 2.1 Structure and numbering of D-myo-inositol ring: the axial position is 
assigned as 2-position and D- indicates a counter-clockwise numbering system. 
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Figure 2.2 Seven isomers of PIPns family: PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, 
PI(4,5)P2, PI(3,4,5)P3. 
 
Figure 2.3 Cartoon depiction of the use of activity-based probe to fish out 
cognate binding proteins from cell extract using synthetic PIPns probes. 
Activity-based protein profiling 
The development of the activity-based probe strategy, along with complementary
proteomic studies has revolutionized the understanding of protein activity events at the 
molecular level. In 1999, Cravatt and coworkers described a universally applicable 
strategy, namely activity-based protein profiling (ABPP), through the development of 
probes for the serine hydrolase superfamily.32 In this strategy (figure 2.4 a), an active 
site-directed chemical probe was used to assess the functional state of enzymes in 
biological systems.33 Activity-based probes usually contain two motifs: a probing group 
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(yellow ball) and a detection tag. The probing group targets a specific set of enzymes by 
forming covalent bonds with the targets. The covalent binding is necessary for the 
bounded complex to survive latent analytical procedures. The detection tag can be a 
fluorophore, for example rhodamine so that the active enzyme can be labeled then 
visualized through SDS-PAGE. If a biotin tag is used, the labeled proteins can be 
purified by biotin-avidin affinity chromatography. The purified proteins are then digested 
on beads by trypsin and identified by LC/MS/MS.  On the other hand, ABPP is 
invaluable in evaluating the potency and selectivity of enzyme inhibitors in native 
biological samples through a competition strategy (figure 2.4 b). Inhibitors were 
incubated with the proteome first to compete with activity-based probes for enzyme 
targets, and this competition is read out by loss of fluorescence (for fluorophore-
















































































































Figure 2.4 Demonstration of activity-based protein profiling: (a) an activity probe 
contains a probing motif (yellow ball) and a detection tag which can be rhodamine for in-
gel analysis or biotin for protein enrichment and LC/MS/MS analysis in order to indentify 
the proteins; (b) ABPP used as a strategy to study enzyme inhibitor potency: cell 
extracts are subjected to inhibitors first, followed by labeling with rhodamine-tagged 
probe. The suppression of the fluorescent signal on SDS-PAGE is a scale to measure 





      Bio-orthogonal reactions are a set of reactions that are performed between 
functional groups that show limited or no reactivities with any other bio-molecules. At 
the same time, these reactions occur under ambient conditions. Their application to the 
labeling of biological molecules has revolutionized the field of chemical biology.34-40 
Examples of well-studied bio-orthogonal reactions are the azide-alkyne 1,3-dipolar 
cycloaddition (click reaction), copper-free azide-cyclooctyne ring strain-promoted 
cycloaddition (copper-free click reaction) and the Staudinger ligation (figure 2.5).34,41 
The conventional click reaction requires the presence of copper, which is toxic to live 
cells in most cases whereas the copper-free click reaction is driven solely by the ring 
strain of cyclooctyne and can be carried out without any other additives. However, the 
conventional click reaction occurs with a faster reaction rate (usually complete within an 
hour) and the synthesis of the probes is considerably simpler.  
      Scientists are under active study to improve both types of click reactions. For 
example, modification of the cyclooctyne has been made to speed up the copper-free 
click reaction.42  
      In a conventional click reaction, Cu(II) is usually added rather than the direct 
addition of the active form, Cu(I). Thus, the presence of a reducing reagent is required, 
such as sodium ascorbate and tris(2-carboxyethyl)phosphine (TCEP). Furthermore, 
ligands are often required for a transition metal-catalyzed reaction (figure 2.6). The 
most commonly used ligand for click reation is tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (TBTA).43,44 A water-soluble ligand tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) has also been developed.45 Most recently, 
Soriano del Amo and Wu developed a tris(triazolylmethyl)amine-based ligand (BTTES) 




Figure 2.5 Examples of bio-orthogonal reactions: 1,3-dipolar cycloaddition, namely 










































Figure 2.6 Click reaction ligands: TBTA, THPTA, BTTES
These bio-orthoganol reactions can be applied to activity-based protein profiling to 
minimize the non-specific interactions between activity probes and the biological 
samples induced by the detection tag (fluorophore, biotin, etc.).37,39 For example, biotin 
is known to covalently bind to the epsilon-amino group of specific lysine residues in 
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some carboxylases. 47 Therefore, instead of directly attaching the detection tag to the 
activity probe, a small bioorthogonal tag, generally as azide or alkyne, can be appended 
to avoid any non-specific interactions. Upon the completion of the probing, the 
azide/alkyne group can be derivatized to introduce reporter groups used for detection by 
click reaction with an alkyne/azide-tagged detection group (figure 2.7). The 
conventional copper-promoted click reaction is a good choice for applications using cell 
extracts in which toxicity is not problematic. 
 
Figure 2.7 Latent labeling of the alkyne/azido-tagged proteins using click 
reaction: To minimize non-specific interactions, the probe can be labeled with a 
minimal and bioorthogonal azide/alkyne group. After the probing event, this group can 
be derivatized into a detection tag by performing a click reaction with an alkyne or 
azide-tagged fluorophore or biotin. 
Photoactive groups and photo-cross-linking 
As was mentioned above, protein-membrane interactions are primarily non-covalent, 
which is often too weak to survive processing. Thus, it is necessary to enforce covalent 
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labeling for successful labeling. To address this issue, the phenomenon of  “cross-
linking” can be implemented. This method was originally used to “fix” live cells at a 
desired phase by cross-linking nearby proteins via chemical reactions or photolysis.  
Formaldehydes and NHS esters (DSG, DSS) are the most commonly used chemicals in 
chemical-induced cross-linking by creating “zero-distance” covalent bonds among 
nearby proteins.48 Photons can also trigger such reactions when photoreactive groups 
prior to photolysis, referred to as photo-cross-linking. Photo-cross-linking has several 
advantages over chemical-cross-linking such as lower background, higher reaction rate 
and yield, etc.49 Especially since two photoreactive amino acids (L-photo-leucine and L-
photo-methionine) recently became commercially available (Thermo Sci. Inc.), it is 
expected that this strategy can be more robustly and widely applied.  Examples of well-
studied photoreactive groups include diazirine, phenylazide and benzophenone (figure 
2.8). When these groups absorb photons, diazirine and phenylazide release nitrogen 
gas and generates a carbene or nitrene to react with protein backbones. Benzophenone 
results in cross-linking by generating stabilized radicals to react with proteins in 
proximity (figure 2.9).50 The photo-cross-linking strategy can be applied to ABPP, 
amending this protein profiling strategy to be suitable to probe non-covalent binding 
interactions such as sugar-protein binding and lipid-protein binding.  
Figure 2.8 Common photoreactive groups: photoreactive groups include diazirine, 
phenylazide, benzophenone and others. 
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Figure 2.9 Photo-cross-linking mechanism by benzophenone: first, benzophenone 
(BP) absorbs photons during photolysis and generates two radicals; second, the radical
on the oxygen rapidly undergoes hydrogen abstraction from the nearby protein 
backbone while the other radical at the benzylic position is stabilized by resonance; the 
remaining radical on the BP then recombines with the radical on the protein in proximity
yielded from hydrogen abstraction, thus forming a covalent bond between BP and the 
protein. 
Modified ABPP strategy
More specific ligands typically do not react with active site residues, so it is difficult to 
enforce covalent labeling. Therefore, ABPP strategy was extended to study 
receptor ligand binding interactions by the introduction of a photoreactive group to 
capture the non-covalent binding and a detection handle (fluorophore for visualization or 
biotin for purification), which can also be installed at a latent stage by click chemistry to 
minimize the non-specific interactions. This bifunctional activity probing method was 
successfully used for probing carbohydrate-galectin binding interactions by Pieters and 
coworkers (figure 2.10).51,52 In this approach, the probe was designed to include a 
lactose binding moiety, a photoreactive group (benzophenone) to capture non-
covalently bound proteins by generating a covalent bond to the nearby protein following 
photolysis, and an azide tag that can undergo a click reaction with rhodamine-alkyne for 
in-gel analysis of carbohydrate-galectin binding events. 
18
 
Figure 2.10 Illustration of activity-based probing mechanism for characterization of 
carbohydrate-receptor binding interactions. 
2. Results and discussion 
2.1. Design of PIPn activity-based probes 
Our lipid activity-based probes consist of the ligand moiety, a photoactive group and 
a functional tag (a tag used to perform a specific function). As was discussed earlier, 
some proteins primarily bind to the PIPn headgroups. Therefore, we designed this 
probing strategy using solely the PIPn headgroup as binding motifs. We then chose 
lysine as a “Y” shaped linker attaching to the headgroup, with one of the ends modified 
into a benzophenone photoactive group and the other into a functional tag. This can be  
a fluorophore for in-gel visualization, a biotin for protein enrichment or an alkyne/azide 
for latent derivatization by click chemistry (figure 2.11).  
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Figure 2.11 Design of PIPn activity-based probes: the probes consist of a binding 
moiety, PIPn headgroup; a Y-shaped lysine linker; photoaffinity group, benzophone 
group, and a functional tag that can be a fluorophore, biotin, alkyne or azide. 
The mechanism by which these probes fish out cognate protein binding targets is as 
follows (figure 2.12). First of all, the proteins or proteomes are incubated with the 
probe. During the incubation, the PIPn probe binds to the cognate protein receptors, 
however, these interactions are non-covalent. The presence of a photoaffinity group 
(the benzophenone group) allows the capturing of these interactions through photolysis, 
which promotes covalent cross-linking between the probe and nearby proteins. With the 
secondary functional tag, labeled proteins can be visualized on a protein gel by 
introducing a fluorophore tag, identified in mass spectrometry by labeling with isotopes, 
or purified and then characterized by attaching to a biotin tag. Alternatively, to minimize 
the size of the label and avoid non-specific protein labeling, a latent secondary tag can 
be derivatized by performing a click reaction between azido (alkyne)-tagged proteins 
and alkyne (azido)-tagged functional groups after the protein-lipid binding phase. 
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Figure 2.12 Illustration of the mechanisms of various PIPns probes: The lipid-
protein binding event is captured by photoreactive benzophenone group through 
radiation, followed by derivatization of the secondary functional tag with click chemistry 
into fluorophore for in-gel analysis or biotin for protein enrichment to identify proteins 
using multi-dimensional mass spectrometry. 
2.2. Synthesis of PIPn activity-based probes 
In order to develop chemical approaches to investigate the biological roles of PIPns, 
the initial requrement is the design and synthesis of natural or modified lipids. To 
accomplish this, issues to be addressed include the selective installation of phosphate 
groups onto the inositol ring and choices of protecting groups. Many groups have made 
significant contributions to the synthesis of phosphoinositides, leading to a number of 
reported syntheses.21,53,54 In 2009, our lab reported the synthesis of modifiable PIPn
isomers corresponding to all seven PIPns. In this study, PIPn-amine conjugates were 
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efficiently modified to produce multiple analogues through coupling reactions55. With 
these amine-tagged PIPns in hand, several PIPn functional probes described in the 










































3PIP : R1= -PO32-,  R2,R3= H
4PIP : R2= -PO3
2-,  R1,R3= H
5PIP : R3= -PO3
2-,  R1,R2= H
3,4PIP : R1,R2= -PO3
2-,  R3= H
4,5PIP : R2,R3= -PO3
2-,  R1= H
3,5PIP : R1,R3= -PO32-,  R2= H



















































































































Scheme 2.1 Modular syntheses of various PIPn lipid probes 
 
By following a reported procedure from our group.55 I have synthesized the amino-
tagged PI(4,5,)P2 and PI(3,4,5)P3 headgroups. The synthetic routes to the two 
compounds only differ by whether a third benzyl group is installed at the 3-position of 
compound 2.1.5. With this step performed, amino-tagged PI(3,4,5)P3 headgroup 2.2.6 is 
synthesized, while without this benzyl group, an amino-tagged PI(4,5,)P2 headgroup is 
instead generated. The synthesis of amino-tagged PI(3,4,5)P3 is illustrated in scheme 
2.2. This began with the protection of diol D-myo-inositol using a camphor acetal to 
2.1.2, followed by selective TBDPS protection of the hydroxyl at 6-position to form 
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compound 2.1.3. This selectivity is generated from the higher reactivity of the alcohol at 
3-position than others caused by its proximity to the axial position. The alcohols at the 3 
and 4 position were then protected by benzyol group (Bz) to yield 2.1.4, leaving only the 
5-position as a free alcohol due to the steric hindrance from the bulky TBDPS group 
nearby. The camphor group was then removed with TFA to obtain 2.1.5. The less 
sterically hindered alcohol at 3-position was then selectively protected by Bz to form 
2.1.6. Next, the remaining alcohols were protected by BOM ether, followed by the 
deprotection of all the Bz groups to obtain three free alcohols, which then were 
phosphorylated to yield 2.1.9. Deprotection of TBDPS by TBAF then released the 
alcohol at the 1-position. Phosphoramidite chemistry was performed at this position to 
generate the fully-protected PI(3,4,5)P3 headgroup, followed by global deprotection 
using hydrogenolysis to produce the amino-tagged PI(3,4,5)P3 headgroup 2.2.6.  
 
Scheme 2.2 Synthesis of amino-tagged PI(3,4,5)P3. 
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The second stage of the probe synthesis includes the functionalization of the lysine 
and the combination of the modified lysine and the headgroup (scheme 2.3). This 
synthesis of the bifunctional tag portions of these probes began with fully protected 
lysine 2.2.1 (Chem-Impex International, Inc.), which after Cbz group removal, was 
coupled to 4-benzoylbenzoic acid to produce Boc protected 2.2.2 (scheme 2.3). This 
product was then treated with trifluoroacetic acid to deprotect the Boc-protected amino 
group, which was coupled to carboxylic acids containing benzyl, benzyl (D5), 
carboxyfluorescein, azide, alkyne and biotin to form intermediates of 2.2.3a-e, g.  In an 
alternative route, a diazo transfer reaction was used to yield 2.2.3f. Intermediates 
2.2.3a-f were subjected to ester hydrolysis under basic conditions to 2.2.4a-f which 
were then coupled to the desired amino-tagged PIPn headgroup to generate probes 
2.2.5a-f. Specifically, a set of PI(3,4)P2 probes 2.2.5a-d were obtained by coupling 
amino-tagged PI(3,4)P2 2.2.5 to 2.2.4a-d. PI(3,4,5)P3 probes 2.2.6e and 2.2.6g were 
generated by the coupling of amino-tagged PI(3,4,5)P3 2.2.6 to 2.2.4e and 2.2.4g 
respectively. PI(3,5)P2 probe 2.2.7e was formed by the coupling of amino-tagged 




Scheme 2.3 Synthesis of various PIPns bifunctional probes
Since it has been reported in many other studies that successful cross-linking can 
depend on the location of photoaffinity tag52, a PI(3,4,5)P3 probe with a longer linker 
(2.2.10) was also synthesized with a slightly modified scheme (scheme 2.4). 
Functionalized lysine acid 2.2.4e was first coupled with 6-aminocaproic acid methyl 
ester hydrochloride to yield 2.2.8, followed by ester hydrolysis to generate acid 2.2.9. 
Acid 2.2.9 was then converted into the corresponding NHS ester and coupled to amino-
tagged PI(3,4,5)P3 2.2.6 to form probe 2.2.10.  
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Scheme 2.4 Synthesis of PI(3,4,5)P3 probe with longer linker 
2.3 Synthesis of click reagents 
     In order to perform the click reaction with the described probes, many clickable tags 
are needed, such as biotin-N3, biotin-alkyne, rhodamine-N3, rhodamine-alkyne, the 
ligand for click reaction, etc. The syntheses of these clickable tags are discussed below 
(scheme 2.5). 
     Azido-biotin 2.3.3 was obtained by the coupling of activated biotin 2.3.1 with 6-
azidohexyl amine 2.3.2 (figure 2.3). Azido-rhodamine 2.3.4 was also obtained in a 
similar manner. Another azido rhodamine (2.3.8) was kindly donated by Dr. Anna 
Speers from The Scripps Research Institute. A nucleophilic replacement of the chlorine 
of NBD chloride by the amino group of 2.3.2 to the formation of azido NBD 2.3.5. Lastly, 
in order to optimize the click reaction conditions of the probes, a previously reported 
water-soluble ligand, 2.3.7, was synthesized to compare with the commercially available 
ligand TBTA (tris-[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl]amine). The synthesis of 2.3.7




Scheme 2.5 Synthesis of various click reagents 
2.4 Initial labeling of purified Akt protein bearing PH domain  
     The initial labeling studies were performed by incubating the synthetic probes with 
the GST-tagged PH domain of Akt, expressed and purified as described previously by 
Nathan Lucas in the lab of our collaborator, Dr. Wonhwa Cho.56 One of the probes used 
was a PI(3,4)P2 probe directly conjugated with fluorescein (2.2.5c) (lane 1-3 in figure 
2.13). The general labeling procedures are as follows: the Akt protein was generally 
incubated with probe 2.2.5c for 1 hour at room temperature, followed by photolysis on 
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ice under 360 nm UV exposure for 1 hour. The samples were then subjected to 1D 
SDS-PAGE for in-gel fluorescent analysis. The results showed that the Akt protein (final 
concentration 60 ug/mL) (lane 2) was labeled compared to the heat denatured control 
(lane 3) and the no light control (lane 1). The other probe used was the PI(3,4,5)P3 
alkyne probe 2.2.6e, which requires derivatization of the probe after cross-linking 
through the attachment of rhodamine onto the alkyne by a click reaction (the red 
labeling in figure 2.13). The same click reaction conditions were applied to both lanes 4 
& 5 whereas only lane 4 with active Akt protein was labeled by rhodamine. This reveals 
that the labeling of the Akt protein is specific to the active site binding and that the 
photolysis procedure and the photo-affinity group are critical for the effective labeling. 
     To further verify that the lipid headgroup is the responsible motif for protein labeling, 
competition studies were also performed using a soluble lipid headgroup lacking the 
bifunctional linker (2.2.6) as a binding competitor. Interestingly, when following the 
typical competition study protocol to incubate the inhibitor (2.2.6) with Akt for 1 hour 
prior to probe incubation, we found no suppression of the labeling with up to 400x 
inhibitor concentration (data not shown).  We then attempted the competition study with 
















Lane 1 2 3 4 5 
Akt Protein (Heat Denatured) + + + + + 
Fluorescein Probe 2.2.5c (25 uM) + + + - - 
Alkyne Probe 2.2.6e (25 uM) - - - + + 
Latent Click Labeling 
with Rh-azide 2.3.8 
- - - + + 
hv - + + + + 













































Figure 2.13 Labeling of Akt protein bearing PH domain 
(fluorescent gel image) 
 
incubation time. After incubating the inhibitor with Akt protein overnight prior to the 
probe incubation, apparent suppression of labeling was observed with only 40x excess 
of the inhibitor, and increased with larger competitor concentration (figure 2.14, lane1-
4).  On the other hand, to rule out the possibility that the bifunctional lysine linker is the 
cause of the labeling, compound 2.2.3e was incubated with Akt protein in a separate 
sample and treated otherwise the same as lane1. The result showed no labeling of the 
Akt protein. However, it slightly labeled an impurity that exists in this Akt protein sample. 
More results of the labeling in cell lysate (result in section 2.5) showed that 2.2.3e 
labeled a different set of proteins from what the probe labeled. This might be due to the 
extra methoxy group that 2.2.3e bears, or its hydrophobicity, since the properties of this 
molecule differ significantly from the hydrophilic PIPn probes.  
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Lane 1 2 3 4 5 
Alkyne Probe 2.2.6e 
(50 uM) + + + + - 
PIP3 2.2.6(inhibitor) - 40x 100x 200x - 
Linker 2.2.3e (50 uM) - - - - + 















































Figure 2.14 Competition studies of Akt protein labeling (fluorescent gel image): In 
lanes 1-4, incubation of Akt protein with excess inhibitor (2.2.6, PIP headgroup lacking 
bifunctional lysine motif) prior to the incubation of probe 2.2.6e generated suppressed 
fluorescent signals of the Akt protein, indicating the suppressed labeling of the Akt 
protein due to the preoccupation of the binding sites. In lane 5, the bifunctional lysine 
lacking the PIP headgroup did not label the Akt protein. 
 
 30
2.5 PIPns probe labeling in cell extracts 
       After achieving the successful labeling of the known binding protein Akt, the probes 
were applied in a more complex environment, cancer cell extracts, to label and identify 
protein targets. The labeling experiments of the soluble fraction of human MDA-MB-435 
cancer cell extracts (all the cell extracts were prepared as previously described by Dr. 
Anna Speers in Dr. Benjamin Cravatt’s lab)36 were performed with various 
concentrations of probe and azido-rhodamine (for latent labeling) (figure 2.15). Heat 
denatured proteome samples were used as positive controls and were treated 
otherwise the same. The results showed that certain bands disappeared in the heat-
denatured samples, particularly in the low mass range. It is worthwhile to mention that 
some of the bands do get enriched in heat-denatured samples, particularly in the higher 
mass range. However, it is difficult to judge whether these enriched proteins were the 
same ones that were labeled in a regular sample. Images of coomassie blue stained 
gels showed identical bands for all lanes (data now shown), indicating the presence of 
the same amount of proteins in each sample. Probe concentrations of 25 uM or 50 uM 
were chosen for each of the following labeling studies considering the balance between 
high-intensity labeling and low-intensity background.  
       Next, both alkyne-labeled probe 2.2.6e and fluorecein-labeled probe 2.2.5c were 
used in the labeling studies with the human MDA-MB-435 cell extract (soluble fraction) 
(figure 2.16). The labeling with fluorescein-labeled probe 2.2.5c (lane1,2) appeared to 
have higher backgrounds than the labeling with alkyne probe 2.2.6e (lane 4-9). This is 
believed to be caused by the non-specific labeling yielded from the direct attachment of 
fluorescein. The result of a heat-denatured control with probe 2.2.6e (lane 5) remained 
the same at probe concentration of 25 uM, compared to labeling with a 50 uM 
concentration in figure 2.11. Also consistant with what was found in Akt protein labeling 
studies in section 2.4 (figure 2.13), the probe itself was responsible for the labeling 





 1 2 3 4 5 6 7 8 9 10 
MDA-MB-435 proteome 
(1mg/mL) + - + - + - + - + - 
MDA-MB-435 proteome 
(1mg/mL) 
(Heat denatured)  - + - + - + - + - + 
Alkyne Probe 2.2.6e (uM) 200 200 100 100 50 50 10 10 1 1 
Click rxn with Rh-azide 2.3.8 
(uM) 200 200 200 200 100 100 50 50 50 50 
                        
Figure 2.15 Probe concentration screening using MDA-MB-435 cancer cell extract 
(soluble fraction) (Fluorescent gel image). Concentrations ranging from 200 nM to 
1nM were used to label the same amount of the cell extracts with heat-denatured 
controls performed for each protein concentration. From the labeling result, probe 
concentrations of 50 and 25 uM were selected for other labeling studies. 
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 1 2 3 4 5 6 7 8 9 
MDA-MB-435 proteome 
(1mg/mL) 
+ - + + - + + + +
MDA-MB-435 proteome 
(1mg/mL) (Heat denatured) 
- + - - + - - - - 
Alkyne Probe 2.2.6e (25 uM) - - - + + - + + + 
Fluorescein Probe2.2.5c (25 uM) + + + - - - - - - 
Click rxn with Rh-azide (50uM) - - - + + + + + + 
hv + + - + + + + - + 
ligand TBTA + + + + + + + + - 
ligand 2.3.7 - - - - - - - - + 
       
Figure 2.16 Labeling of MDA-MB-435 cancer cell extract (soluble fraction) with 
various controls (fluorescent gel image) 
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       Again, the photolysis step was crucial to the successful labeling (lane 3 & 8), since 
no labeling was observed without photolysis. To optimize the click reaction conditions, 
the synthetic click reaction ligand 2.3.7 (described in section 2.3) was used to replace 
TBTA43, the traditional click ligand. The two samples (lane 5 and lane 9) showed very 
similar labeling to one another. Therefore, the commercially available TBTA (Sigma-
Aldrich) was used in all of the following labeling studies. 
       We then applied this labeling strategy to multiple cancer cell proteomes (MDA-MB-
435, MDA-MB-231, MCF7, T47D, prepared using a previously reported procedure36 by 
Dr. Anna Speers from Dr. Benjamin Cravatt’s lab) to test its global feasibility. Both the 
soluble portion and membrane portion of the cell extracts were tested and compared 
(figure 2.17). Heat denatured proteomes were used as positive controls. The results 
showed that most of the labeling occurred with the soluble portion of the proteomes, 
which is consistent with the fact that the majority of the PIP headgroup-binding proteins 
are soluble peripheral proteins. The results also indicate that this lipid-binding protein 
labeling strategy is universally applicable. 
 
Figure 2.17 Labeling of various cancer cell proteomes  





2.6 Exploring the effects of PIPns probe linker length on labeling 
      It is well documented that the nature of a linker can affect the efficiency of the 
labeling and in some cases is even critical.51,52,57 For example, different linker lengths 
can cause noticeable differences in protein labeling. To explore how the linker length of 
these PIPns probes affects the labeling, we synthesized and then compared probe 
2.2.6e and probe 2.2.9 in terms of labeling Akt protein and cell extracts. We found that 
probe 2.2.9 with the longer linker labeled neither Akt protein (figure 2.18) nor cell 
extracts (figure 2.19, lane 1,2). This could be rationalized as follows: even though the 
longer linker provides more flexibility for the bifunctional lysine motif, the benzophenone 
photoaffinity group can only interact with proteins in proximity, and this flexibility may 
provide too much freedom such that the benzophenone can move away from the bound 
protein. Again, as was mentioned in section 2.4, compound 2.2.3e labeled a very 
different set of proteins (figure 2.19, lane 3), which might be caused by its increased 





























































 1 2 
Akt protein (60 ug/mL) + + 
Probe 2.2.6e (50 uM)  + - 
Probe 2.2.9 (50 uM) - + 
                                                                                     
Figure 2.18 Akt protein labeling with probe 2.2.6e and probe 2.2.9  





 1 2 3 
MDA-MB-435 proteome 
(1mg/mL) + + + 
Probe 2.2.6e (50 uM) + - - 
Probe 2.2.9 (50 uM) - + - 
Linker 2.2.3e (50 uM) - - + 
                                
Figure 2.19 MDA-MB-435 Cancer cell extracts labeling with probe 2.2.6e and 
probe 2.2.9 (fluorescent gel image) 
 
2.7 Proteomics studies of the PIP probe labeled proteins in MDA-MB-435 cancer 
cell extracts 
      Finally, proteomic studies were performed with alkyne PI(3,4,5)P3 probe 2.2.6e. 
From cytosolic MDA-MB-435 cancer cell extracts, we identified 107 proteins that 
specifically bind to PI(3,4,5)P3 comparing to the results generated from lysine linker 
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2.2.3e as a negative control (Table 2.1). These proteins include a number of actin-
binding proteins. This is consistent with the results generated from PI(3,4,5)P3 beads 
without membrane context.58 Many kinases were also identified as expected, such as 
phosphoglycerate kinase 1&2, ribose-phosphate pyrophosphokinase 1. Other proteins 
identified were classified as oxidoreductases, transferases, hydrolases, chaperone, 
transport proteins and binding proteins.  A complete list of proteins identified is affiliated 





Protein Name Protein Function 
P61160 ARP2 Actin-related protein 2  Actin binding 
P12814 ACTN1 Alpha-actinin-1  Actin binding 
O43707 ACTN4 Alpha-actinin-4  Actin binding 
P21333 FLNA Filamin-A  Actin binding 
P04075 ALDOA Fructose-bisphosphate aldolase A  Actin binding 
P35579 MYH9 Myosin-9  Actin binding 
P35241 RADI Radixin Actin binding 
Q13813 SPTA2 Spectrin alpha chain, brain  Actin binding 
P30153 2AAA Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform 
Antigen binding 
P26038 MOES Moesin Cell adhesion 
Q93052 LPP Lipoma-preferred partner  Cell adhesion, 
protein binding 
P61221 ABCE1 ATP-binding cassette sub-family E member 1 Chaperone 
P56537 IF6 Eukaryotic translation initiation factor 6 Chaperone 
P06748 NPM Nucleophosmin  Chaperone 
Q99832 TCPH T-complex protein 1 subunit eta  Chaperone 
P06744 G6PI Glucose-6-phosphate isomerase  Cytokin 
P16104 H2AX Histone H2A.x  Enzyme binding 
P06576 ATPB ATP synthase subunit beta,mitochondrial Hydrolase 
Q92820 GGH Gamma-glutamyl hydrolase  Hydrolase 
P28070 PSB4 Proteasome subunit beta type-4 Hydrolase 
P13010 XRCC5 X-ray repair cross-complementing protein 5  Hydrolase 
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Q99497 PARK7 Protein DJ-1 Hydrolase, 
Chaperone 
Q14240 IF4A2 Eukaryotic initiation factor 4A-II  Hydrolase, 
Helicase 
P11586 C1TC C-1-tetrahydrofolate synthase, cytoplasmic  Hydrolase, 
Ligase, 
Oxidoreductase 
P49327 FAS Fatty acid synthase Hydrolase, Lyase, 
Oxidoreductase, 
Transferase 
P48147 PPCE Prolyl endopeptidase Hydrolase, 
Protease 
P31939 PUR9 Bifunctional purine biosynthesis protein PURH  Hydrolase, 
Transferase 
P38606 VATA V-type proton ATPase catalytic subunit A Hydrolase, 
Transport 
P21281 VATB2 V-type proton ATPase subunit B, brain isoform  Hydrolase, 
Transport 
P54819 KAD2 Adenylate kinase 2, mitochondrial Kinase 
P00568 KAD1 Adenylate kinase isoenzyme 1 Kinase 
P15531 NDKA Nucleoside diphosphate kinase A Kinase 
P00558 PGK1 Phosphoglycerate kinase 1 OS=Homo sapiens 
GN=PGK1 PE=1 SV=3  
Kinase 
P07205 PGK2 Phosphoglycerate kinase 2  Kinase 
P30085 KCY UMP-CMP kinase Kinase 
P68400 CSK21 Casein kinase II subunit alpha  Kinase, 
Transferase 
P19784 CSK22 Casein kinase II subunit alpha'  Kinase, 
Transferase 
Q9HA64 KT3K Ketosamine-3-kinase Kinase, 
Transferase 




P17931 LEG3 Galectin-3 lgE binding 
P49915 GUAA GMP synthase [glutamine-hydrolyzing] Ligase 
Q99798 ACON Aconitate hydratase, mitochondrial Lyase 
Q04760 LGUL Lactoylglutathione lyase  Lyase 
P33176 KINH Kinesin-1 heavy chain  Motor protein 
P15121 ALDR Aldose reductase  Oxidoreductase 
P16152 CBR1 Carbonyl reductase [NADPH] 1 Oxidoreductase 
O75828 CBR3 Carbonyl reductase [NADPH] 3  Oxidoreductase 
P09417 DHPR Dihydropteridine reductase Oxidoreductase 
P11413 G6PD Glucose-6-phosphate 1-dehydrogenase Oxidoreductase 
P04406 G3P Glyceraldehyde-3-phosphate dehydrogenase  Oxidoreductase 
P40926 MDHM Malate dehydrogenase, mitochondrial Oxidoreductase 
P30041 PRDX6 Peroxiredoxin-6 Oxidoreductase 
P49748 ACADV Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
Oxidoreductase 
P12268 IMDH2 Inosine-5'-monophosphate dehydrogenase 2  Oxidoreductase, 
Protein binding 
P04083 ANXA1 Annexin A1 Phospholipase 
A2 Inhibitor 
P07355 ANXA2 Annexin A2  Phospholipase 
Inhibitor 
P30086 PEBP1 Phosphatidylethanolamine-binding protein 1 Protease inhibitor 
P62191 PRS4 26S protease regulatory subunit 4  Protein binding 
Q00610 CLH1 Clathrin heavy chain 1  Protein binding 
P21399 ACOC Cytoplasmic aconitate hydratase Protein binding 
P30084 ECHM Enoyl-CoA hydratase, mitochondrial Protein binding 
P02533 K1C14 Keratin, type I cytoskeletal 14 Protein binding 
P08779 K1C16 Keratin, type I cytoskeletal 16  Protein binding 
P35527 K1C9 Keratin, type I cytoskeletal 9  Protein binding 
P13647 K2C5 Keratin, type II cytoskeletal 5  Protein binding 
O95983 MBD3 Methyl-CpG-binding domain protein 3  Protein binding 
Q15365 PCBP1 Poly(rC)-binding protein 1  Protein binding 
P26599 PTBP1 Polypyrimidine tract-binding protein 1  Protein binding 
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O60568 PLOD3 Procollagen-lysine,2-oxoglutarate 5-dioxygenase Protein binding 
P61289 PSME3 Proteasome activator complex subunit 3  Protein binding 
Q92597 NDRG1 Protein NDRG1  Protein binding 
Q92616 GCN1L Translational activator GCN1  Protein binding 
P23381 SYWC Tryptophanyl-tRNA synthetase, cytoplasmic Protein binding 
P31150 GDIA Rab GDP dissociation inhibitor alpha Protein binding, 
Lyase 
P46940 IQGA1 Ras GTPase-activating-like protein IQGAP1 Protein 
Phosphatase 
binding, Ras 
GTPase activator  




THIC Acetyl-CoA acetyltransferase, cytosolic  Transferase 
P53396 ACLY ATP-citrate synthase Transferase 
P06737 PYGL Glycogen phosphorylase, liver form  Transferase 
Q9Y617 SERC Phosphoserine aminotransferase Transferase 
P34897 GLYM Serine hydroxymethyltransferase, mitochondrial Transferase 
Q06210 GFPT1 Glucosamine--fructose-6-phosphate 
aminotransferase [isomerizing] 1 
Transferase, 
Aminotransferase 
P43490 NAMPT Nicotinamide phosphoribosyltransferase Transferase,Glyc
osyltransferase 
Q16831 UPP1 Uridine phosphorylase 1  Transferase,Glyc
osyltransferase 
P25705 ATPA ATP synthase subunit alpha, mitochondrial  Transport 
P53621 COPA Coatomer subunit alpha Transport 
Q14204 DYHC1 Cytoplasmic dynein 1 heavy chain 1  Transport 
P55060 XPO2 Exportin-2  Transport 
P62826 RAN GTP-binding nuclear protein Ran  Transport 
P68133 ACTS Actin, alpha skeletal muscle   
P63261 ACTG Actin, cytoplasmic 2   
O00429 DNM1L Dynamin-1-like protein  
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Q9NRV9 HEBP1 Heme-binding protein 1  
P42704 LPPRC Leucine-rich PPR motif-containing protein, 
mitochondrial 
 
Q9UL46 PSME2 Proteasome activator complex subunit 2   
Q15019 2-Sep Septin-2   
P02768 ALBU Serum albumin   
P17987 TCPA T-complex protein 1 subunit alpha   
P50991 TCPD T-complex protein 1 subunit delta  
P50990 TCPQ T-complex protein 1 subunit theta   
P40227 TCPZ T-complex protein 1 subunit zeta  
Q8NBS9 TXND5 Thioredoxin domain-containing protein 5  
P23193 TCEA1 Transcription elongation factor A protein 1  
Q71U36 TBA1A Tubulin alpha-1A chain  
P68371 TBB2C Tubulin beta-2C chain  
Q13509 TBB3 Tubulin beta-3 chain OS=Homo sapiens 
GN=TUBB3 PE=1 SV=2  
 
Q9BUF5 TBB6 Tubulin beta-6 chain   
 
Table 2.1 Summery of proteins by functions 
 
      Furthermore, a number of known PIP-binding domains were identified, such as 
Annexin, FERM, Filamin-A, HEAT, PH, PX, Septin. This result further validated this 
protein identification method.  
Domains Protein ID Protein Name 
Actin ARP2 Actin-related protein 2  
 ACTS Actin, alpha skeletal muscle  
 ACTG Actin, cytoplasmic 2  
   
Annexin ANXA1 Annexin A1 
 ANXA2 Annexin A2  
   
CH ACTN1 Alpha-actinin-1  
 
 41
 ACTN4 Alpha-actinin-4  
 FLNA Filamin-A  
 IQGA1 Ras GTPase-activating-like protein IQGAP1 
   
FERM MOES Moesin 
 RADI Radixin 
   
Filamin-A K1C14 Keratin, type I cytoskeletal 14 
 K1C16 Keratin, type I cytoskeletal 16  
 K1C9 Keratin, type I cytoskeletal 9  
 K2C5 Keratin, type II cytoskeletal 5  
 FLNA Filamin-A  
   
HEAT 2AAA 
Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform 
 GCN1L Translational activator GCN1 
   
Spectrin SPTA2 Spectrin alpha chain, brain  
 ACTN1 Alpha-actinin-1  
 ACTN4 Alpha-actinin-4  
   
Septin 2-Sep Septin-2  
   
PH SPTB2 Spectrin beta chain, brain 1  
   
PX SNX4 Sorting nexin-4  
 
Table 2.2 Summery of proteins by domains 
3. Materials and methods 
3.1 Synthesis of PIPn activity-based probes 
General Experimental. Generally, reagents were purchased from Acros, Aldrich or 
FisherSci and used as received. Dry solvents were obtained from a Pure Solv solvent 
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delivery system purchased from Innovative Technology, Inc. Column chromatography 
was performed by using 230-400 mesh silica gel purchased from Sorbent Technologies 
and C18 (17%) reverse phase column (6 mL, 2 g) purchased from Silicycle. NMR 
spectra were obtained by using a Varian Mercury 300 spectrometer. Mass spectra were 
obtained with ABI DE Pro MALDI spectrometers with high-resolution capabilities.  
Benzophenone-Lys-OMe (2.2.2). Cbz-Lys(Boc)-OMe (2.2.1) (262 mg, 0.664 mmol) 
was dissolved in 5 mL methanol. Palladium(II) hydroxide (26 mg, 10% wt) was added to 
the solution. The reaction was stirred under hydrogen atmosphere overnight. Then 
reaction solution was filtered through a pad of cellite and the filtrate was concentrated to 
yield Lys(Boc)-OMe, which was used in the next step without further purification. 
Lys(Boc)-OMe was dissolved in 10 mL DMF. To this solution was added 4-benzoyl 
benzoic acid (150 mg, 0.664 mmol), EDCI (153 mg, 0.797 mmol), DMAP (97 mg, 0.791 
mmol), NMM (0.26 mL, 2.32 mmol). The solution was stirred at room temperature 
overnight and then concentrated under reduced pressure. The crude was purified by 
silica gel column chromatography with a solvent system of 50% ethyl acetate to 
hexanes to yield benzophenone-Lys(Boc)-OMe as a white foam (279 mg, 90% over 2 
steps).  The characterization of benzophenone-Lys(Boc)-OMe matches with the 
literature18. Benzophenone-Lys(Boc)-OMe was then dissolved in 4 mL of TFA/CH2Cl2 
(v/v 1:1). The reaction was allowed to stir at room temperature for 2 hours and then was 
concentrated under reduced pressure to yield benzophenone-Lys-OMe (2.2.2) as a 
yellowish gum (quantitative yield). 
1H NMR (300MHz, CDCl3)  7.88 (d, J = 9Hz, 1H), 7.70-7.67 (m, 4H), 7.57-7.52 (m, 2H), 
7.44-7.40 (m, 2H), 4.67-4.65 (m, 1H), 3.66 (s, 3H), 2.89-2.87 (m, 2H), 1.86-1.64 (m, 4H), 
1.46-1.43 (m, 2H).   
Benzophenone-Lys(benzoyl)-OMe (2.2.3a). Benzophenone-Lys-OMe (2.2.2) (64 mg, 
0.178 mmol) was combined with benzoyl chloride (0.041 mL, 0.356 mmol) along with 
triethyl amine (1 mL) in 10 mL dichloromethane. The reaction was allowed to stir at 
room temperature overnight. The solvent was then removed under reduced pressure. 
The crude was purified by column chromatography with a gradient solvent system of 20-
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70% ethyl acetate to hexanes to yield benzophenone-Lys(benzoyl)-OMe (2.2.3a) as a 
white foam (33 mg, 39%). 
1H NMR (300MHz, CDCl3)  7.94-7.92 (m, 2H), 7.77-7.70 (m, 5H), 7.62-7.59 (m, 1H), 
7.51-7.34 (m, 5H), 7.26-7.24 (m, 2H), 6.53-6.51 (m, 1H), 4.80-4.73 (m, 1H), 3.76 (s, 3H), 
3.54-3.52 (m, 1H), 3.44-3.42 (m, 1H), 2.00-1.96 (m, 2H), 1.72-1.66 (m, 2H), 1.54-1.48 
(m, 2H).   
Benzophenone-Lys(benzoyl D5)-OMe (2.2.3b). Benzophenone-Lys-OMe (2.2.2) (120 
mg, 0.249 mmol) was combined with benzoic acid D5 (32 mg, 0.249 mmol), EDCI (62 
mg, 0.324 mmol), DMAP (40 mg, 0.324 mmol), NMM (0.27 mL, 2.49 mmol) in 10 mL 
dichloromethane. The reaction was allowed to stir at room temperature overnight. The 
solvent was then removed under reduced pressure. The crude was purified by column 
chromatography with a gradient solvent system of 40-60% ethyl acetate to hexanes to 
yield benzophenone-Lys(benzoyl D5)-OMe (2.2.3b) as a white foam (64 mg, 54%). 
1H NMR (300MHz, CDCl3)  7.93-7.90 (m, 2H), 7.75-7.71 (m, 3H), 7.62-7.57 (m, 1H), 
7.49-7.44 (m, 2H), 7.38-7.35 (m, 1H), 6.74-6.73 (m, 1H), 4.76-4.69 (m, 1H), 3.74 (s, 3H), 
3.53-3.48 (m, 1H), 3.42-3.36 (m, 1H), 1.70-1.62 (m, 2H), 1.52-1.46 (m, 2H). 13C NMR 
(300MHz, CDCl3)  196.2, 173.1, 168.5, 167.0, 140.3, 134.5, 133.1, 130.3, 130.2, 128.7, 
127.5, 53.0, 52.7, 39.1, 31.6, 29.3, 22.7. MALDI-HRMS [M + H]+ calcd for 500.2182; 
found 500.2247. 
Benzophenone-Lys(5(6)-carboxy fluorescein)-OMe (2.2.3c). Benzophenone-Lys-
OMe (2.2.2) (175 mg, 0.475 mmol) was combined with 5(6)-carboxy fluorescein (197 
mg, 0.522 mmol), EDCI (118 mg, 0.618 mmol), DMAP (70 mg, 0.570 mmol), NMM (0.21 
mL, 1.90 mmol) in 8 mL dry DMF. The reaction was allowed to stir at room temperature 
overnight. The solvent was then removed under reduced pressure. The crude was 
dissolved in 50 mL methanol/chloroform (v/v 1:4) and extracted by 50 mL 2N HCl 
aqueous solution. The aqueous layer was washed twice by methanol/chloroform (v/v 
1:4), 50 mL each time. The organic layers were collected, dried by magnesium sulfate, 
concentrated and then purified by column chromatography with a gradient solvent 
system of 5-10% methanol to chloroform to yield benzophenone-Lys(5(6)-carboxy 
fluorescein)-OMe (2.2.3c)  as an orange solid (159 mg, 46%). 
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1H NMR (300MHz, CD3OD/CDCl3 (v/v 1:2))  8.40-8.39 (m, 1H), 8.03-7.98 (m, 2H), 
7.95-7.83 (m, 2H), 7.85-7.75 (m, 3H), 7.66-7.69 (m, 1H), 7.54-7.49 (m, 2H), 7.25-7.22 
(m, 1H), 6.72-6.70 (m, 2H), 6.57-6.53 (m, 4H), 4.76-4.72 (m, 1H), 3.80 (s, 3H), 3.50-
3.48 (m, 1H), 3.36-3.35 (m, 1H), 2.67 (bs, 1H), 2.06-1.94 (m, 2H), 1.74-1.46 (m, 4H). 
Benzophenone-Lys(TEG-N3)-OMe (2.2.3d). Benzophenone-Lys-OMe (2.2.2) (162 mg, 
0.584 mmol) was combined with N3-TEG-COOH (272 mg, 0.738 mmol), EDCI (146 mg, 
0.759 mmol), DMAP (93 mg, 0.759 mmol), NMM (0.19 mL, 1.752 mmol) in 20 mL 
methanol/chloroform (v/v 1:4). The reaction was allowed to stir at room temperature 
overnight. The solvent was then removed under reduced pressure. The crude was 
purified by column chromatography with a gradient solvent system of 30-90% ethyl 
acetate to hexanes to yield benzophenone-Lys(TEG-N3)-OMe (2.2.3d) as a colorless 
gum (241 mg, 66%). 
1H NMR (300MHz, CDCl3)  8.04-8.01 (m, 2H), 7.85-7.78 (m, 3H), 7.66-7.60 (m, 1H), 
7.53-7.48 (m, 2H), 7.39-7.37 (m, 1H), 7.14 (t, J = 6Hz, 1H), 4.78-4.71 (m, 1H), 4.00-3.87 
(m, 2H), 3.78 (s, 3H), 3.67-3.63 (m, 12H), 3.39-3.36 (m, 2H), 3.33-3.28 (m, 2H), 2.59 
(bs, 1H), 1.99-1.94 (m, 2H), 1.62-1.45 (m, 4H). 13C NMR (300MHz, CDCl3)  196.2, 
173.0, 170.6, 166.7, 140.3, 133.1, 130.3, 130.1, 128.6, 127.6, 71.1, 70.8, 70.7, 70.6, 
70.5, 70.3, 70.2, 53.1, 52.7, 50.8, 38.0, 31.3, 29.4, 22.7. MALDI-HRMS [M + Na]+ calcd 
for 650.2796; found 650.3725. 
4-Oxo-4-(2-propyn-1-ylamino) butanoic acid (2.4.1). Propargyl amine (0.50 mL, 7.29 
mmol) was dissolved in 10 mL mixture of acetonitrile/DMF (v/v 1:1) at 0 °C under 
nitrogen. Succinic anhydride (in 10 mL acetonitrile) was added to this solution. The 
mixture was stirred at room temperature overnight. The solvent was then removed 
under reduced pressure. The residue was washed with hexanes then ethyl ether 
several times to generate 2.4.1 as a white solid (305 mg, 27%). 
1H NMR (300MHz, CD3OD)  3.94 (d, J = 3Hz, 1H), 2.61-2.56 (m, 2 H), 2.49-2.44 (m, 
2H).  
Benzophenone-Lys(alkyne)-OMe (2.2.3e). Benzophenone-Lys-OMe (2.2.2) (911 mg, 
1.890 mmol) was combined with 4-oxo-4-(2-propyn-1-ylamino) butanoic acid (293 mg, 
1.89 mmol), EDCI (543 mg, 2.83 mmol), DMAP (346 mg, 2.83 mmol), NMM (2.08 mL, 
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18.9 mmol) in 10 mL methanol/chloroform (v/v 1:4). The reaction was allowed to stir at 
room temperature overnight. The solvent was then removed under reduced pressure. 
The crude was purified by column chromatography with a gradient solvent system of 50-
100% acetone to hexanes to yield benzophenone-Lys(alkyne)-OMe (2.2.3e) as a 
colorless crystal (760 mg, 80%).  
1H NMR (300MHz, CDCl3)  7.99-7.96 (m, 2H), 7.81-7.75 (m, 3H), 7.61-7.57 (m, 1H), 
7.50-7.42 (m, 3H), 6.81-6.79 (m, 1H), 6.55-6.51(m, 1H), 4.74-4.67 (m, 1H), 3.95-3.93 (m, 
2H), 3.75 (s, 3H), 3.27-3.15 (m, 2H), 2.42-2.41 (m, 4H), 2.17-2.14 (m, 1H), 1.90-1.86 (m, 
2H), 1.53-1.42 (m, 4H). MALDI-HRMS [M + Na]+ calcd for 528.2105; found 528.2134. 
Benzophenone-Lys(N3)-OMe (2.2.3f). Benzophenone-Lys-OMe (2.2.2) (219 mg, 0.595 
mmol) was dissolved in 10 mL methanol. To this solution was added potassium 
carbonate aqueous solution (1.26 mL, 0.804 M), copper sulfate aqueous solution (6 mL, 
0.010 M) and imidazole-1-sulfonyl azide hydrochloride (150 mg, 0.714 mmol).  The 
reaction was allowed to stir at room temperature overnight. The solvent was then 
removed under reduced pressure. The crude was dissolved in ethyl acetate (50 mL) 
and extracted by 2N HCl aqueous solution (50 mL x 2). The organic layer was collected, 
dried by magnesium sulfate, concentrated and then purified by column chromatography 
with a solvent system of 50% ethyl acetate to hexanes to yield benzophenone-Lys(N3)-
OMe (2.2.3f) as a colorless glass (233 mg, 99%).  The characterization matches the 
literature59.  
Benzophenone-Lys(TEG-NHBoc)-OMe (2.9.2). Benzophenone-Lys-OMe (2.2.2) (237 
mg, 0.491 mmol) was combined with compound 2.9.1 (157 mg, 0.447 mmol), which was 
prepared from our previously reported procedure60, EDCI (129 mg, 0.671 mmol), DMAP 
(109 mg, 0.894 mmol), NMM (0.50 mL, 4.47 mmol) in 10 mL methanol/chloroform (v/v 
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1:4). The reaction was allowed to stir at room temperature overnight. The solvent was 
then removed under reduced pressure. The crude was purified by column 
chromatography with a gradient solvent system of 50-100% acetone to hexanes to yield 
benzophenone-Lys(TEG-NHBoc)-OMe (2.9.2) as a colorless oil (167 mg, 54%).   
1H NMR (300MHz, CDCl3)  8.05-8.02 (m, 2H), 7.85-7.78 (m, 4H), 7.65-7.60 (m, 1H), 
7.53-7.50 (m, 2H), 7.33-7.31 (m, 1H), 7.20-7.18 (m, 1H), 5.11-5.10 (m, 1H), 4.78-4.71 
(m, 1H), 3.95-3.78 (m, 2H), 3.78 (s, 3H), 3.65-3.61 (m, 12H), 3.54-3.50 (m, 2H), 3.36-
3.28 (m, 4H), 1.99-1.95 (m, 2H), 1.60-1.56 (m, 2H), 1.50-1.43 (m, 11H). 13C NMR 
(300MHz, CDCl3)  196.0, 172.8, 170.4, 166.4, 140.1, 137.0, 132.9, 130.1, 130.0, 128.4, 
127.4, 105.0, 71.0, 70.5, 70.4, 70.3, 70.1, 52.9, 52.5, 40.3, 37.7, 31.1, 29.3, 28.4, 22.4.  
Benzophenone-Lys(biotin)-OMe (2.2.3g). Benzophenone-Lys(TEG-NHBoc)-OMe 
(2.9.2) (167 mg, 0.243 mmol) was dissolved in 5 mL TFA/dichloromethane (v/v 1:1). 
The solution was stirred at room temperature for 3 hours before it was concentrated to 
yield the Boc deprotected product benzophenone-Lys(TEG-NH2)-OMe. The crude was 
dissolved in 20 mL dry DMF. To this solution was added 2 mL triethylamine and biotin-
pentafluorophenyl ester (100 mg, 0.243 mmol) (2.9.3). The resulting solution was stirred 
at room temperature overnight and then concentrated. The crude was purified by 
column chromatography with a gradient solvent system of 5-10% methanol to 
dichloromethane to yield benzophenone-Lys(biotin)-OMe (2.2.3g)  as a yellowish gum 
(198 mg, 100%).   
1H NMR (300MHz, CD3OD/CDCl3 (v/v 1:4))  8.22 (d, J = 6 Hz, 1H), 8.05-8.02 (m, 2H), 
7.87-7.79 (m, 4H), 7.68-7.63 (m, 1H), 7.55-7.50 (m, 1H), 4.71-4.70 (m, 1H), 4.54-4.50 
(m, 1H), 4.05-4.03 (m, 2H), 3.79 (s, 3H), 3.72-3.66 (m, 12H), 3.58-3.57 (m, 2H), 3.43-
3.42 (m, 2H), 3.29-3.27 (m, 2H), 3.18 (m, 1H), 2.94-2.89 (m, 1H), 2.75-2.71 (m, 1H), 
1.98-1.91 (m, 2H), 1.63-1.56 (m, 6H), 1.47-1.41 (m, 4H). 13C NMR (300MHz, 
CD3OD/CDCl3 (v/v 1:4))  196.9, 173.3, 171.2, 167.7, 140.4, 137.3, 133.3, 130.3, 130.1, 
128.7, 127.7, 70.5, 70.2, 70.0, 60.4, 55.8, 53.3, 52.6, 49.6, 49.3, 49.0, 48.7, 48.4, 40.4, 
38.8, 35.8, 31.2, 31.0, 29.0, 28.6, 25.7, 23.2. MALDI-HRMS [M + Na]+ calcd for 
850.3673; found 850.4567. 
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Benzophenone-Lys(benzoyl)-OH (2.2.4a). Compound 2.2.3a (33 mg, 0.070 mmol) 
was dissolved in a mixture of 5 mL ethanol and 2 mL methanol. To this solution was 
added 5 mL of 2M NaOH aqueous solution. The reaction was stirred at room 
temperature for 3 hours and then was quenched by adjusting the pH to neutral with 
addition of 2N HCl aqueous solution. The alcohols were removed from the solution by 
rotary evaporation. The resulting solution was extracted by 2N HCl aqueous 
solution/dichloromethane. The aqueous layer was washed with dichloromethane (100 
mL x 2). The combined organic layers were dried by magnesium sulfate and 
concentrated to yield benzophenone-Lys(benzoyl)-OH (2.2.4a) as a colorless oil (28 mg, 
87 %). 
1H NMR (300MHz, CDCl3)  7.83-7.26 (m, 14H), 6.74-6.76 (m, 1H), 4.85-4.83 (m, 1H), 
3.64-3.60 (m, 1H), 3.48-3.38 (m, 1H), 2.00-1.98 (m, 2H), 1.68-1.64 (m, 2H), 1.55-1.51 
(m, 2H). 
Benzophenone-Lys(benzoyl D5)-OH (2.2.4b). Compound 2.2.3b (64 mg, 0.134 mmol) 
was dissolved in 2 mL ethanol. To this solution was added 2 mL of 2M NaOH aqueous 
solution. The reaction was stirred at room temperature for 40 minutes and then was 
extracted by 2N HCl aqueous solution (50 mL)/dichloromethane (100 mL). The aqueous 
layer was washed with dichloromethane (50 mL x 2). The combined organic layers were 
dried by magnesium sulfate and concentrated to yield benzophenone-Lys(benzoyl D5)-
OH (2.2.4b) as a colorless oil (58 mg, 93 %). 
1H NMR (300MHz, CDCl3)  7.88-7.86 (m, 1H), 7.79-7.76 (m, 2H), 7.69-7.66 (m, 2H), 
7.57-7.55 (m, 2H), 7.47-7.42 (m, 2H), 7.01-6.99 (m, 1H), 4.82-4.80 (m, 1H), 3.58-3.54 
(m, 1H), 3.34-3.32 (m, 1H), 1.96-1.92 (m, 2H), 1.64-1.46 (m, 4H). 13C NMR (300MHz, 
CDCl3)  196.3, 174.8, 169.3, 167.5, 167.0, 140.2, 137.1, 136.8, 134.0, 133.2, 130.3, 
128.7, 127.4, 52.9, 39.4, 31.4, 30.0, 29.2, 22.5. 
Benzophenone-Lys(5(6)-carboxy fluorescein)-OH (2.2.4c). Compound 2.2.3c (36 mg, 
0.050 mmol) was suspended in 5 mL methanol. To this solution was added 5 mL of 2M 
NaOH aqueous solution. The reaction was stirred at room temperature for 10 minutes 
and then was added 2N HCl aqueous solution (30 mL). A orange solid was formed 
immediately upon addition of the acid. The solid was filtered and washed with 2N HCl 
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aqueous solution (10 mL x 2) to yield the crude compound 2.2.4c. The crude was 
dissolved in acetonitrile/water and purified on a C18 reverse phase column (2g) with a 
gradient solvent system of 0-80% acetonitrile/water. Compound 2.2.4c came out with 
the elution of 45-60% acetonitrile/water. The collected fractions were concentrated by 
rotary evaporation to remove acetonitrile. Water was removed by lyophilization to yield 
benzophenone-Lys(5(6)-carboxy fluorescein)-OH (2.2.4c) as a yellow powder (19 mg, 
53%).  
1H NMR (300MHz, CD3CN/D2O (v/v 1:1))  8.73-8.71 (m, 1H), 8.42-8.29 (m, 4H), 8.14-
8.07 (m, 4H), 7.92-7.87 (m, 2H), 7.53-7.50 (m, 1H), 7.10 (s, 2H), 6.97-6.93 (m, 4H), 
4.95-4.85 (m, 1H), 3.82-3.80 (m, 1H), 3.67-3.65 (m, 1H), 2.40-2.38 (m, 2H), 1.94-1.80 
(m, 4H). MALDI-HRMS [M + H]+ calcd for 713.2130; found 713.2072. 
Benzophenone-Lys(TEG-N3)-OH (2.2.4d). Compound 2.2.3d (117 mg, 0.186 mmol) 
was dissolved in 5 mL ethanol. To this solution was added 5 mL of 2M NaOH aqueous 
solution. The reaction was stirred at room temperature for 2 hours and then was 
extracted by 2N HCl aqueous solution (50 mL)/dichloromethane (100 mL). The aqueous 
layer was washed with dichloromethane (50 mL x 2). The combined organic layers were 
dried by magnesium sulfate and concentrated to yield benzophenone-Lys(TEG-N3)-OH 
(2.2.4d) as a colorless oil (114 mg, 100 %). 
1H NMR (300MHz, CDCl3)  7.96-7.88 (m, 3H), 7.72-7.67 (m, 3H), 7.63-7.58 (m, 1H), 
7.50-7.41 (m, 3H), 4.96-4.94 (m, 1H), 3.98 (dd, J1 = 3Hz, J2 = 18 Hz, 2H), 3.66-3.56 (m, 
13H), 3.37 (t, J = 6 Hz, 2H), 3.24-3.23 (m, 1H), 1.97-1.96 (m, 2H), 1.59-1.43 (m, 4H).  
MALDI-HRMS [M + Na]+ calcd for 636.2640; found 636.2403. 
Benzophenone-Lys(alkyne)-OH (2.2.4e). Compound 2.2.3e (135 mg, 0.267 mmol) 
was dissolved in a mixture of 5 mL methanol and 5 mL ethanol. To this solution was 
added 8 mL of 2M NaOH aqueous solution. The reaction was stirred at room 
temperature for 15 minutes and then was extracted by 2N HCl aqueous solution (100 
mL)/dichloromethane (200 mL). The aqueous layer was washed with 
methanol/chloroform (v/v 1:4) (50 mL x 3). The combined organic layers were dried by 
magnesium sulfate, filtered and concentrated to yield benzophenone-Lys(alkyne)-OH 
(2.2.4e) as a white solid (94 mg, 72 %).  
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1H NMR (300MHz, CD3OD)  8.01-7.99 (m, 2H), 7.84-7.76 (m, 4H), 7.65-7.63 (m, 1H), 
7.55-7.53 (m, 2H), 4.59-4.57 (m, 1H), 3.95-3.93 (m, 1H), 3.65-3.61 (m, 2H), 3.21-3.19 
(m, 2H), 2.57-2.45 (m, 5H), 1.99.92 (m, 2H), 1.56-1.54 (m, 4H).  
Benzophenone-Lys(N3)-OH (2.2.4f). Compound 2.2.3f (233 mg, 0.591 mmol) was 
dissolved in 2 mL methanol. To this solution was added 2 mL of 2M NaOH aqueous 
solution. The reaction was stirred at room temperature for 30 minutes and then was 
extracted by 2N HCl aqueous solution (50 mL)/dichloromethane (50 mL). The aqueous 
layer was washed with dichloromethane (60 mL x 2). The combined organic layers were 
dried by magnesium sulfate, filtered and concentrated to yield benzophenone-Lys(N3)-
OH (2.2.4f) as a colorless oil (216 mg, 96 %).  
Benzophenone-Lys(Biotin)-OH (2.2.4g). Compound 2.2.3g (270 mg, 0.308 mmol) 
was dissolved in 3 mL methanol. To this solution was added 1 mL of 2M NaOH 
aqueous solution. The reaction was stirred at room temperature for 30 minutes and then 
was added proton resin to adjust the pH to ~4. The resin was afterwards filtered off.  
The filtrate was concentrated to yield benzophenone-Lys(Biotin)-OH (2.2.4g) as a 
colorless gum (204 mg, 81%).  
1H NMR (300MHz, CD3OD/CDCl3 (v/v 1:1))  8.01 (d, J = 6 Hz, 1H), 7.86-7.78 (m, 4H), 
7.67-7.62 (m, 1H), 7.55-7.50 (m, 2H), 4.70-4.68 (m, 1H), 4.52-4.50 (m, 1H), 4.34-4.32 
(m, 1H), 3.99-3.97 (m, 2H), 3.67-3.64 (m, 12H), 3.55-3.53 (m, 2H), 3.41-3.40 (m, 2H), 
3.29-3.27 (m, 2H), 3.18-3.19 (m, 1H), 2.94-2.90 (m, 1H), 2.75-2.71 (m, 1H), 2.23-2.18 
(m, 2H), 1.98-1.90 (m, 2H), 1.64-1.42 (m, 10H). 13C NMR (300MHz, CD3OD/CDCl3 (v/v 
1:4))  196.6, 174.4, 170.8, 167.2, 140.0, 137.1, 136.8, 133.1, 130.0, 130.0, 128.4, 
128.2, 127.4, 70.6, 70.3, 70.2, 70.0, 69.9, 69.7, 60.2, 55.6, 49.0, 48.8, 48.5, 40.2, 39.1, 
38.4, 35.6, 31.1, 28.9, 28.3, 28.0, 25.4, 22.9.  
General procedure for the synthesis of 2.2.5 a,b,d,f and 2.2.6 g. The acid 2.2.4 a-g 
was dissolved in 5 mL THF. To this stirred solution was added DCC and then N-hydroxy 
succinimide. The reaction was stirred for 8 hours and then concentrated. The crude was 
washed by hexane, ethyl ether, and hexane/ethyl ether mixture. The yielded NHS ester 
was then stirred in 1 mL DMF. To this solution was added 2.2.5 or 2.2.6 in 1 mL TEAB 
(1 M, pH=7.5). 0.5-1 mL of THF was added to enhance the solubility. The reaction was 
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allowed to stir at room temperature overnight. The solvent was then removed under 
reduced pressure. The crude product solid was washed by acetone (20  mL x3) and 
then dissolved in deionized water to stir with 500 mg sodium form at room temperature 
for 2 hours.  The reaction solution was directly loaded onto a C18 reversed-phase 
column (2 g) and the column was eluted by deionized water (20 mL). The water elution 
was lyophilized to yield 2.2.5 a,b,d,f and 2.2.6 g. 
General procedure for the synthesis of 2.2.5 e, 2.2.6 e, 2.2.7 e, 2.2.10. The acid 
2.2.4 a-g or 2.2.9 was dissolved in 5 mL THF. To this stirred solution was added EDCI 
and then N-hydroxy succinimide. The reaction was stirred for 8 hours and then 
concentrated. The crude was dissolved in 30 mL chloroform and washed by water (20 
mL x 3). The organic layer was concentrated and added ethyl ether (30 mL). The white 
precipitate was filtered and redissolved in chloroform (15 mL). The solution was filtered 
and the filterate was concentrated to yield the NHS ester as a colorless oil. The NHS 
ester was then stirred in 1 mL DMF. To this solution was added 2.2.5 or 2.2.6 in 1 mL 
TEAB (1 M, pH=7.5). 0.5-1 mL of THF was added to enhance the solubility. The 
reaction was allowed to stir at room temperature overnight. The solvent was then 
removed under reduced pressure. The crude product solid was washed by acetone (20  
mL x3) and then dissolved in deionized water to stir with 500 mg sodium form at room 
temperature for 2 hours.  The reaction solution was directly loaded onto a C18 
reversed-phase column (2 g) and the column was eluted by deionized water (20 mL). 
The water elution was lyophilized to yield 2.2.5 e, 2.2.6 e or 2.2.7 e.
Benzophenone-Lys(benzyol)-PI(3,4)P2 (2.2.5a). Acid 2.2.4a (41 mg, 0.090 mmol), N-
hydroxy succinimide (12 mg, 0.108 mmol), DCC (22 mg, 0.108 mmol) and amino-
tagged PI(3,4)P2 2.2.5 (13 mg, 0.025 mmol) were used to yield 2.2.5a as a white solid 
(8.2 mg, 34%). 
1H NMR (300MHz, D2O)  7.68-7.22 (m, 14 H), 4.22-4.12 (m, 3H), 3.78-3.68 (m, 6H), 
3.38 (t, J = 9 Hz, 2H), 3.05-2.90 (m, 2H), 1.49-1.21 (m, 14H). 31P NMR (121.5 MHz, D2O) 
 3.47, 2.52, 1.04.  
Benzophenone-Lys(benzyol D5)-PI(3,4)P2 (2.2.5b). Acid 2.2.4b (50 mg, 0.108 mmol), 
N-hydroxy succinimide (15 mg, 0.129 mmol), DCC (27 mg, 0.129 mmol) and amino-
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tagged PI(3,4)P2 2.2.5 (10 mg, 0.0193 mmol) were used to yield 2.2.5b as a white solid 
(8.3 mg, 45%). 
1H NMR (300MHz, CD3OD/D2O (v/v 1:1)):   7.69-7.43 (m, 9 H), 4.22-4.12 (m, 3H), 
3.88-3.68 (m, 6H), 3.36-3.30 (m, 2H), 2.80 (t, J = 9 Hz, 2H), 1.53-1.09 (m, 14H). 31P 
NMR (121.5 MHz, CD3OD/D2O (v/v 1:1)):  4.60, 3.10, 1.32. MALDI-HRMS [M + H]
+ 
calcd for 987.2619; found 987.5374. 
Benzophenone-Lys(5(6)carboxy fluorescein)-PI(3,4)P2 (2.2.5c). The acid 2.2.4c (28 
mg, 0.039 mmol) was dissolved in 4 mL DMF/THF (v/v 1:2). To this stirred solution was 
added DCC (16 mg, 0.078 mmol) and then N-hydroxy succinimide (9 mg, 0.078 mmol). 
The reaction was stirred for 8 hours at room temperature and then filtered. The filtrate 
was concentrated to ~0.5 mL and was added 50 mL ethyl ether. An orange precipitate 
was formed and filtered. The solid was redissolved in 10 mL THF and filtered. The 
filtrate was concentrated to yield the NHS ester which was then stirred in 1 mL DMF. To 
this solution was added amino-tagged PI(3,4)P2 2.2.5 (10 mg, 0.019 mmol) in 1 mL 
TEAB (1 M, pH=7.5) and 0.5 mL of THF. The reaction was allowed to stir at room 
temperature overnight. The solvent was then removed under reduced pressure. The 
crude product solid was washed by acetone (20  mL x3) and then dissolved in deionized 
water to stir with 500 mg sodium form at room temperature for 2 hours.  The reaction 
solution was directly loaded onto a C18 reversed-phase column (2 g) and the column 
was eluted by deionized water (20 mL). The water elution was lyophilized to yield 2.2.5c 
as a yellow solid (8.0 mg, 35%).
1H NMR (300MHz, CD3OD/D2O (v/v 1:1))  7.75-7.00 (m, 12 H), 6.55 (s, 2 H), 6.30-6.28 
(m, 2H), 5.89-5.86 (s, 2 H), 4.30-4.28 (s, 2 H), 4.02-3.98 (m, 2H), 3.72-3.31 (m, 14H), 
1.53-1.04 (m, 14H). 31P NMR (121.5 MHz, CD3OD/D2O (v/v 1:1)):  5.05, 3.64, 1.09, 0.12. 
MALDI-HRMS [M + H]+ calcd for 1214.2696; found 1214.7771. 
Benzophenone-Lys(TEG-N3)-PI(3,4)P2 (2.2.5d). Acid 2.2.4d (12 mg, 0.0192 mmol), N-
hydroxy succinimide (2.2 mg, 0.0192 mmol), DCC (4 mg, 0.0192 mmol) and amino-
tagged PI(3,4)P2 2.2.5 (5 mg, 0.0096 mmol) were used to yield 2.2.5d as a yellowish 
solid (6.0 mg, 56%). 
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1H NMR (300MHz, D2O)  8.00-7.75 (m, 9 H), 3.94-3.60 (m, 33 H), 2.26-2.24 ( m, 4 H), , 
1.83-1.66 (m, 13 H), 1.40-1.28 (m, 13 H).. 
Benzophenone-Lys(alkyne)-PI(3,4)P2 (2.2.5e). Acid 2.2.4e (15 mg, 0.0305 mmol), N-
hydroxy succinimide (4.6 mg, 0.040 mmol), EDCI (7.7 mg, 0.040 mmol) and amino-
tagged PI(3,4)P2 2.2.5 (5.0 mg, 0.0096 mmol) were used to yield 2.2.5d as a yellowish 
solid (3.0 mg, 31%). 
Benzophenone-Lys(N3)-PI(3,4)P2 (2.2.5f). Acid 2.2.4f (14 mg, 0.038 mmol), N-hydroxy 
succinimide (5.3 mg, 0.046 mmol), DCC (10.4 mg, 0.046 mmol) and amino-tagged 
PI(3,4)P2 2.2.5 (10 mg, 0.019 mmol) were used to yield 2.2.5f as a white solid (10.6 mg, 
63%). 
Benzophenone-Lys(alkyne)-PI(3,4,5)P3 (2.2.6e). Acid 2.2.4e (47 mg, 0.096 mmol), N-
hydroxy succinimide (22 mg, 0.192 mmol), EDCI (37 mg, 0.192 mmol) and amino-
tagged PI(3,4,5)P3 2.2.6 (10 mg, 0.0167 mmol) were used to yield 2.2.6e as a white 
solid (11 mg, 61%). 
1H NMR (300MHz, D2O)  7.71-7.52 (m, 7H), 7.37 (t, J = 6 Hz, 2 H), 4.24-4.18 (m, 3H), 
3.88-3.63 (m, 10H), 3.03-2.97 (m, 4H), 2.79 (t, J = 6 Hz, 2H), 2.10-2.05 (t, J = 6Hz, 2H), 
1.67-1.68 (m, 1 H), 1.46-1.34 (m, 10H), 1.22-1.16 (m, 9H).  31P NMR (121.5 MHz, D2O):  
1.33, 1.02, 0.40, -0.89. MALDI-HRMS [M+Na]+ calcd for 1095.2178; found 1095.2285 
Benzophenone-Lys(bitoin)-PI(3,4,5)P3 (2.2.6g). Acid 2.2.4g (138 mg, 0.173 mmol), N-
hydroxy succinimide (40 mg, 0.345 mmol), DCC (71 mg, 0.345 mmol) and amino-
tagged PI(3,4,5)P3 2.2.6 (5 mg, 0.0083 mmol) were used to yield 2.2.6g as a white solid 
(2.0 mg, 17%). 
1H NMR (300MHz, CD3OD/D2O (v/v 1:1))  7.98-7.80 (m, 9H), 4.46-4.43 (m, 4H), 4.12-
3.93 (m, 10H), 3.73-3.71 (m, 2H), 2.98 (t, J = 6 Hz, 2H), 2.41-2.35 (m, 4H), 1.88-1.89 (m, 
2H), 1.66-1.64 (m, 6H), 1.47-1.43 (m, 5H). MALDI-HRMS [M + Na]+ calcd for 1417.37; 
found 1417.40. 
Benzophenone-Lys(alkyne)-PI(3,5)P2 (2.2.7e). Acid 2.2.4e (47 mg, 0.096 mmol), N-
hydroxy succinimide (22 mg, 0.192 mmol), EDCI (37 mg, 0.192 mmol) and amino-
tagged PI(3,5)P3 2.2.7 (11 mg, 0.0212 mmol) were used to yield 2.2.7e as a white solid 
(9.0 mg, 43%). 
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1H NMR (300MHz, CD3OD/D2O (v/v 1:1))  8.05-7.68 (m, 9H), 3.95-3.86 (m, 13 H), 
3.22-3.18 (m, 4H), 2.78-2.65 (m, 2H), 1.67-1.39 (m, 20H). 31P NMR (121.5 MHz, 
CD3OD/D2O (v/v 1:1)):  4.28,3.63, -0.60. MALDI-HRMS [M + Na]
+ calcd for 1015.2520; 
found 1015.2452.
Benzophenone-Lys(alkyne)-hexanoate (2.2.8). Acid 2.2.4e (144 mg, 0.293 mmol) 
was combined with 5-aminocaproic acid methyl ester hydrochloride (69 mg, 0.381 
mmol), EDCI (72 mg, 0.381 mmol), DMAP (47 mg, 0.381 mmol), NMM (0.32 mL, 2.92 
mmol) in 15 mL methanol/chloroform (v/v 1:4). The reaction was allowed to stir at room 
temperature overnight. The solvent was then removed under reduced pressure. The 
crude was purified by column chromatography with a gradient solvent system of 50-
100% acetone to hexanes to yield compound 2.2.8 as a colorless crystal (91 mg, 50%).
1H NMR (300MHz, CDCl3)  8.00-7.97 (m, 2H), 7.83-7.77 (m, 4H), 7.64-7.59 (m, 1H), 
7.52-7.47 (m, 2H), 7.21-7.19 (m, 1H), 6.83-6.81(m, 1H), 4.68-4.66 (m, 1H), 3.98-3.96 (m, 
2H), 3.64 (s, 3H), 3.25-3.23 (m, 4H), 2.54-2.48 (m, 4H), 2.29 (t, J = 6 Hz, 2H), 2.21-2.18 
(m, 1H), 1.92-1.83 (m, 2H), 1.62-1.34 (m, 10H). 13C NMR (300MHz, CDCl3)  196.1, 
174.1, 172.5, 172.4, 171.7, 166.8, 140.3, 136.9, 133.0, 130.1, 130.0, 128.5, 127.4, 79.7, 
71.31, 53.7, 51.6, 39.4, 33.8, 31.3, 29.1, 26.3, 24.4, 22.8. MALDI-HRMS [M + Na]+ calcd 
for 641.2951; found 641.2953. 
Benzophenone-Lys(alkyne)-hexyl-PI(3,4,5)P3 (2.2.10). Compound 2.2.8 (80 mg, 
0.129 mmol) was dissolved in 2 mL methanol. To this solution was added 2 mL of 2M 
NaOH aqueous solution. The reaction was stirred at room temperature overnight and 
then was added proton resin to adjust the pH to ~4. The resin was then filtered off.  The 
filtrate was concentrated to yield acid 2.2.9 as a colorless gum (68 mg, 87%). Acid 2.2.9 
(68 mg, 0.112 mmol), N-hydroxy succinimide (26 mg, 0.224 mmol), EDCI (43 mg, 0.224 
mmol) and amino-tagged PI(3,4,5)P3 2.2.6 (8 mg, 0.0106 mmol) were used to yield 
2.2.7e as a white solid (11.2 mg, 93%). 
1H NMR (500MHz, D2O)  7.86-7.80 (m, 4H), 7.76-7.74 (m, 2H), 7.67 (t, J = 3 Hz, 1H), 
7.53-7.50 (m, 2H), 4.36-4.33 (m, 3H), 4.03-4.02 (m, 1H), 3.96-3.95 (m, 2H), 3.83-3.79 
(m, 3H), 3.16-3.02 (m, 5H), 3.02-2.78 (m, 2H), 2.35-2.31 (m, 4H), 2.09-2.06 (m, 2H), 
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1.80-1.78 (m, 2H), 1.51-1.18 (m, 18H).  31P NMR (202.5 MHz, D2O):  0.70, 0.31, -0.28,  
-0.90.  
N-Biotinyl-6-azidohexanamide (2.3.3). 6-Azido-1-hexylamine (2.3.2) was prepared 
according to a previously reported procedure. Biotin-pentafluorophenyl ester (750 mg, 
1.83 mmol) and 6-azido-1-hexylamine 2.3.2 (390 mg, 2.74 mmol) were combined in 10 
mL methanol, along with triethylamine (1.27 mL, 9.15 mmol). The solution was stirred at 
room temperature overnight. The solvent was removed under reduced pressure. The 
crude was purified by column chromatography with a gradient solvent system of 1-10% 
methanol to dichloromethane to yield compound 2.3.3 as a colorless crystal (527 mg, 
78%). 
1H NMR (300MHz, CDCl3)  6.19-6.18 (m, 1H), 5.94-5.92 (m, 1H), 5.31-5.30 (m, 1H), 
4.54-4.50 (m, 1H), 4.34-4.30 (m, 1H), 3.29-3.15 (m, 3H), 2.92 (dd, J1 = 12Hz, J2 = 6 Hz, 
1H), 2.74 (d, J = 12 Hz, 1H), 2.21 (t, J = 6 Hz, 2H), 1.72-1.58 (m, 8H), 1.51-1.36 (m, 8H). 
MALDI-HRMS [M + Na]+ calcd for 391.1887; found 391.1825. 
N-rhodamine-6-azidohexanamide (2.3.4). Lissamine rhodamine B sulfonyl chloride 
was dissolved in 0.5 mL dry dichloromethane. To this solution was added 6-azido-1-
hexylamine 2.3.2 (62 mg, 0.433 mmol) and triethylamine (60 ul, 0.433 mmol). The 
solution was stirred at room temperature overnight. The solvent was then removed and 
the crude was purified by column chromatography with a gradient solvent system of 5-
30% ethanol to ethyl acetate to yield compound 2.3.4 as a red solid (13 mg, 23%). 
1H NMR (300MHz, CDCl3)  8.68-8.67 (m, 1H), 8.06-8.03 (m, 1H), 7.31 (t, J = 9 Hz, 1H), 
7.16 (t, J = 9 Hz, 2H), 6.87 (dd, J1 = 9 Hz, J2 = 3 Hz, 2H), 6.77-6.76 (m, 2H), 3.61  (q, J 
= 6 Hz, 8H), 3.36-3.35 (m, 1H), 3.30 (t, J = 6 Hz, 2H), 3.02 (t, J = 6 Hz, 2H), 1.63-1.60 
(m, 4H), 1.43-1.41 (m, 4H), 1.32 (t, J = 6 Hz, 12H).  13C NMR (300 MHz, CDCl3):  158.2, 
157.5, 155.8, 146.8, 142.5, 133.9, 133.0, 130.5, 128.0, 114.4, 113.9, 96.0, 51.6, 46.1, 




N-NBD-6-azidohexanamide (2.3.5). NBD-Cl was dissolved in 2 mL dry DMF. To this 
solution was added 6-azido-1-hexylamine 2.3.2 (55 mg, 0.385 mmol) and triethylamine 
(0.27 mL, 1.925 mmol). The solution was stirred at room temperature overnight. The 
solvent was then removed and the crude was purified by column chromatography with a 
gradient solvent system of 10-20% acetone to hexanes to yield compound 2.3.5 as an 
orange solid (75 mg, 64%). 
1H NMR (300MHz, CDCl3)  8.47 (d, J = 9 Hz, 1H), 6.50 (bs, 1H), 6.19 (d, J = 9 Hz, 1H), 
3.57-3.53 (m, 2H), 3.30 (t, J = 6 Hz, 2H), 1.88-1.84 (m, 2H), 1.67-1.51 (m, 6H). 
Ligand 2.3.7. The ligand 2.3.7 was prepared exactly according to the published 
procedure45  and the characterization matched. 
1H NMR (300MHz, CD3OD)  8.00 (s, 3H), 4.52 (t, J = 6 Hz, 6H), 3.75 (s, 6H), 3.57 (t, J 
= 6 Hz, 6H), 2.16-2.07 (m, 6H).  MALDI-HRMS [M + Na]+ calcd for 457.2395; found 
457.2876. 
3.2 Labeling of Akt protein and proteomes. 
General Materials. The GST-tagged PH domain of Akt was expressed and purified as 
described previously by Nathan Lucas in the lab of our collaborator, Dr. Wonhwa Cho.56 
All the cell extracts were prepared as previously described36 by Dr. Anna Speers in Dr. 
Benjamin Cravatt’s lab.  
General procedure for the labeling of proteins.  In a 96-well plate, Akt protein (10 ul 
of 300 ug/mL stock) or proteome samples (50 ul or 43 ul of 1.0 mg/mL protein in PBS, 
50 ul for samples without click chemistry labeling, 43 ul for samples with click chemistry 
labeling) were incubated with synthetic PIPns probes for 1 hr at room temperature. For 
heat-denatured controls, Akt protein or proteome samples were heated at 90°C for 5 
min and cooled to room temperature before the addition of probes. For amino-tagged 
PIPns competition samples, the corresponding amino-tagged PIPn was incubated with 
the samples overnight at 4 °C prior to the incubation of probes. After the probe 
incubation, the 96-well plate was placed on ice and photolyzed for 1 hour under 350 nm 
UV lamp.  Click reaction was then performed to the samples with alkyne-tagged 
PI(3,4,5)P3 probes (2.2.6e, 2.2.7e). Samples with fluorescein-tagged PI(3,4)P2 probe 
(2.2.5c) were directly quenched by SDS-PAGE sample buffer (2x). The proteins were 
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separated by 1D SDS-PAGE (30 ul of quenched sample/gel lane) and visualized in-gel 
by a Hibachi FMBio lle flatbed laser-induced fluorescence scanner (MiraiBio, Alameda, 
CA).  
General procedure of click reactions to derivatize alkyne tag into reporter group.  
The procedure follows a reported protocol36,37,39,61 developed by Dr. Anna Speers in Dr. 
Benjamin Cravatt’s lab. After the photolysis procedure, to each sample was added 50 
uM rhodamine-N3 (2.3.8) (50x stock solution in DMSO), 1mM TCEP (50x stock in H2O), 
100 uM ligand (TBTA or ligand 2.3.7) (17 x stock in DMSO:t-butanol 1:4) and 1mM 
CuSO4 (50x stock in water). The samples were shaken for 30 seconds after each 
addition. After all the addition, the samples were incubated at room temperature for 1 
hour before being quenched by adding 50 ul of SDS-PAGE sample buffer (2x) to each 
well. Same as described above, the proteins were separated by 1D SDS-PAGE (30 ul 
of quenched sample/gel lane) and visualized in-gel by a Hibachi FMBio lle flatbed laser-
induced fluorescence scanner (MiraiBio, Alameda, CA).  
LC/MS/MS sample preparation.  
The procedure follows a reported protocol36,37,39,61 developed by Dr. Anna Speers in Dr. 
Benjamin Cravatt’s lab. Cytosolic MDA-MB-435 cancer cell extracts 1 mg/mL in PBS 
(900 ul) were incubated with 20 ul alkyne PI(3,4,5)P3 probe 2.2.6e (5 mM in H2O, gives 
a final concentration of 100 uM) for 1 hour, followed by photolyzing on ice at 350 nm for 
1 hour. Next, 6ul of biotin-azide 2.2.3 (50 mM in DMSO, gives a final concentration of 
300 uM) was added, followed by 20 ul TCEP (50 mM in H2O, gives a final concentration 
of 1 mM), 66 ul of TBTA Ligand (1.67 mM in 1:4 DMSO/t-BuOH, giving a final 
concentration of 100 uM) and 20 ul CuSO4 (50 mM in H2O, gives a final concentration of 
1 mM). The mixture was incubated at room temperature for 1 hour. Each sample was 
transferred into three centrifuge tubes containing MeOH (4mL, 4 x volume). CHCl3 (1mL, 
1x volume) was added and vortexed. H2O (3mL, 3x volume) was next added and the 
mixture was vortexed, then centrifuged. The top and bottom layers were removed, 
leaving the protein pallet. The pallet was then transfered into microcentrifuge tube in 
600ul MeOH. 150ul CHCl3 and 600ul H2O were added, vortexed, then centrifuged at 
14,000 rpm for 3 min. Top and bottom layers were removed, leaving protein interface. 
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MeOH (600 ul) was added, sonicated with probe sonicator for 10sec. The mixture was 
centrifuged at 14,000 rpm for 5 min to pellet the protein and MeOH was removed. The 
pellet was re-suspended in 500 ul of 6 M urea/25 mM ammonium bicarbonate. The 
volume was brought up to 1 mL with mQ water. The mixture was heated (65 °C x 5min) 
to re-suspend pellet. TCEP (50ul 100x (0.1M), giving a final concentration of 10 mM) 
was added. The mixture was incubated at 65 °C for 15min, then cooled to room 
temperature. IAA (40ul, 0.55M, giving 40mM IAA) was added and the solution was 
Incubated at 37 °C for 30min in the dark. 140ul of 10% SDS (giving a final concentration 
of 2%) was added. The mixture was heated to 65 °C for 5min. The sample was diluted 
to ~0.2% SDS with 3mL PBS and 3.5mL 50mM Tris buffer. 100ul aliquot of 50% slurry 
was removed and washed 3x with PBS. Avidin beads was transfered to sample using 
minimal volume buffer or sample. The beads were incubated with sample room 
temperature, rotating 1 hrs. The mixture was spinned at 4000rpm for 3 min to pellet, 
~90% of supernant was removed. The beads were washed with 2 x 8mL 1% SDS buffer, 
then  2 x 6 M urea,  3 x 10mL DPBS. The beads were next transfered to a tube in 200ul 
2M Urea/25mM ammonium bicarbonate. 2ul of 100x (100mM) CaCl2 was added, giving 
a final concentration of 1mM CaCl2. Trypsin (4ug) was added. The sample was 
incubated at 37 °C overnight. The beads were then removed and washed with 100ul 
PBS. The solution were combined and acidified to 5% formic acid for LC/MS/MS 
analysis. A separate sample was prepared with Lysine linker 2.2.3e under the same 
condition and the results were used as a background control.
     Digested peptide mixtures were pressure-loaded on to a biphasic (strong cation 
exchange/reverse phase) capillary column and analyzed by two-dimensional liquid 
chromatography (2D-LC) separation in combination with tandem mass spectrometry as 
previously described62-64 using an Agilent 1100-series quaternary pump and Thermo 
Scientific LTQ ion trap mass spectrometer. The proteomic data search was performed 
by Dr. Sherry Niessen from The Scripps Research Institute. The total proteomic data 
was then filtered to display only proteins (Table 1) with more than 5-fold higher spectral 
counts in PIPn probe proteomes compared to lysine negative control proteomes. 
Proteins that were identified in at least two out of three cell extract samples were 
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considered as PIPn binding receptors. Another list of proteins (in attachment, file 2) with 
more than 2-fold but less than 5-fold higher spectral counts in PIPn probe proteomes 
than in lysine negative control proteomes.
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3. CHAPTER 3.  Design, Synthesis and Application of 
Diacylglycerol (DAG) Activity Probes as Chemical Tools to 
Characterize Protein-Membrane Binding Interactions 
1. Background and significance 
     Diacylglycerol (DAG), also known as diglyceride, consists of a glycerol molecule in 
which two hydroxyls have been esterified with fatty acid chains (figure 3.1 left). In 
biological systems, diacyglycerols are synthesized from glycerol-3-phosphate chains65
(figure 3.1 right). Glycerol-3-phosphate is first acylated by acyl-coenzyme A (acyl-CoA) 
to yield lysophosphatidic acid and then acylated by another molecule of acyl-CoA to 
generate phosphatidic acid. Lastly, phosphatidic acid is de-phosphorylated to form 
diacylglycerol by phosphatidic acid phosphohydrolases (PAP). The reverse reaction of 
the last step can be promoted by diacyglycerol kinase (DGK). 
 
Figure 3.1 An example of DAG: 1-palmitoyl-2-oleoylglycerol (left);  
biosynthesis of DAG (right). 
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      Although DAG has the simplest structure among all the signaling lipids, it plays 
critical roles in several biological pathways66-73. DAG acts as an intracellular second 
messenger, generally by binding to protein receptors containing hydrophobic domains, 
that subsequently regulates protein functions.74 A particularly important example is the 
DAG activation of protein kinase C enzyme family (PKCs), which are known to regulate 
proliferation, differentiation and malignant transformation. The understanding of DAG-
PKCs binding interactions is also essential to cancer research as it was found that 
tumour-promoting phorbol esters activate PKCs by mimicking the activity of DAGs. 
Further investigation into these binding events reveals that DAG mainly binds to the 
highly conserved cysteine-rich C1 domain.2,7,69,75,76 C1 domains are generally 
composed of ~50 amino acids with a distinctive motif. It was originally identified in PKC 
isozymes and then found in many other signaling families as well, such as protein 
kinase Ds (PKDs), chimaerins, RasGRPs and others. The binding of DAG and PKDs, a 
family of cytosolic serine-threonine kinases, regulates transport of proteins to the cell 
surface, and thus the absence of DAGs blocks the protein transportation. It is also 
worthwhile to mention that calcium ions are necessary in DAG-receptor binding process 
as they are necessary for the interactions of the C2 domains of the PKCs in the 
recruitment to the inner leaflet of the plasma membrane.  
      A significant amount of work has been invested in understanding DAG-binding 
proteins.  However, we are still lacking an effective tool in identifying these proteins. 
This field would benefit from an approach for efficient and collective labeling of DAG-
binding proteins. As was described in the previous chapter, the application of activity-
based probes may fulfill this purpose using a similar approach. As a result, we set out to 
design DAG activity probes. Considering that the alkyne-tagged PIP activity probes 
described in the previous chapter provided the best signal-to-noise ratio (see section 
2.5), we only synthesized alkyne-tagged DAG activity probes. Three DAG activity 
probes were designed with different connection formats (triazole v.s. amide) or linker 

















































Figure 3.2 Structures of DAG activity probes 
2.  Results and discussion. 
2.1 Syntheses of DAG activity probes. 
    We originally attempted to synthesize DAG activity probes bearing ester-linked acyl 
chains. However, we consistantly encountered significant problems with acyl chain 
migration, as has previously been a problem.18 We then designed probes with ether tails 
to avoid this migration problem, and additionally to prevent the enzymatic hydrolysis 
(scheme 3.1). The initial attempt to synthesize these probes began with the protection 
of the hydroxyl groups of (4R,5R)- 2,2-dimethyl-1,3-dioxolane-4,5-dimethanol (3.1, 
synthesized in two steps according to a reported procedure77) to yield 3.2. The 
acetonide was then deprotected to 3.3 in order to install the two ether tails of 3.4. The 
PMB groups were next deprotected to 3.5, and one of the resulting alcohols was 
converted into a tosylate leaving group to produce 3.6. However, the desired 
substitution of tosylate 3.6 into azide 3.7 was hindered by the cyclization to form the 
five-membered ring of 3.9. Our group has successfully performed this tosylate into azide 
reaction when the two secondary alcohols were tied by acetonide. Therefore, we 
propose that the promotion of the cyclization is due to the free rotation of the bond 




Scheme 3.1 Initial attempt to synthesize the DAG activity probes. 
     To circumvent this probe, we next designed an alternative route to synthesize DAG 
activity probes (scheme 3.2). Using the same starting material (4R,5R)- 2,2-dimethyl-
1,3-dioxolane-4,5-dimethanol 3.1.1, the synthesis began with the selective tosylation of 
one of the two alcohols to generate a mono-tosyl intermediate, which was then 
converted into azide 3.1.2 by nucleophilic substitution. Next, the remaining free alcohol 
was protected with a PMB group to form 3.1.3 and the acetonide was deprotected to 
yield diol 3.1.4.  The alcohols were alkylated using standard Williamson ether synthesis 
condition to yield compound 3.1.5.  The PMB group was then deprotected to form 
compound 3.1.6. For the route to synthesize probes 3.1.8 and 3.1.9, the azido moiety of 
compound 3.1.6 was reduced into an amino group by hydrolysis. The amine of 3.1.7
was then coupled with acid 2.2.4e to yield probe 3.1.8 or with acid 2.2.9 to yield probe 
3.1.9. In a different route to synthesize a triazole-linked DAG probe, azide 3.1.6 was 
clicked to alkyne 3.1.11 to form a triazole between the DAG moiety and the linker. The 
amine of the intermediate was then coupled to 4-oxo-4-(2-propyn-1-ylamino)butanoic 
acid to yield probe 3.1.10. 
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Scheme 3.2 Synthetic routes to DAG activity probes. 
       As is required by the competition studies, we also synthesized DAG lacking the 
bifunctional linker. To the PMB-protected glycerol 5.2.3 (synthesis described in chapter 
5) was installed two ether tails to form 3.1.11, and then the PMB was deprotected to 
generate DAG 3.1.12.  
 
Scheme 3.3 Synthetic route to DAG. 
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2.2 Labeling of SKOV3 cancer cell extract (cytosol) using DAG activity probes. 
     All three DAG probes (3.1.8, 3.1.9, 3.1.10) were used to label DAG binding proteins 
in Skov 3 cancer cell extracts (figure 3.3. lanes 1-3: DAG probe 3.1.10; lanes 4-6: DAG 
probe 3.1.9; lanes 7-9: DAG probe 3.1.8). As discussed previously, the labeling process 
consists of three stages: probe-protein binding, photo-cross linking and latent functional 
labeling by click reaction. Each labeling was compared with a DAG competition control 
(lanes 2, 5, 8) and heat-denatured control (lanes 3, 6, 9). For the competition studies, 
DAG 3.1.11 (10x) was incubated with proteome sample 1 hour prior to probe incubation.  
The same volume of heat-denatured proteome samples were used as the heat-
denatured control, which were otherwise treated the same. The gel results showed that 
DAG probe 3.1.9 labeled the least amount of proteins. DAG probe 3.1.8 and 3.1.10 
gave similar results, however, DAG probe 3.1.8 labeled slightly more proteins. In the 
competition studies, consistent with all three probes, a band at mass ~60kDa was 
heavily competed off. Though a heavier band at the same position showed up in the 
heat-denatured control, it is hard to say if this is the same protein that was enriched in 
heat-denatured samples.  
       In similar fashion to previous results, bifunctional lysine linker 2.2.3e as a probe 
labeled a different set of proteins (lane 10). Because all probes were dissolved in 
DMSO, a control study was performed where DMSO itself was used as a probe under 
the same labeling conditions (lane 11) and no labeling was observed, indicating that 
DMSO does not cause the labeling.  
      Next, DAG probe 3.1.8 was used to label the membrane fraction of cancer cell 
extracts ((MDA-MB-435, MDA-MB-231, MCF7, T47D) and barely any labeling was seen 
(data now shown). Lastly, DAG probe 3.1.8 was subjected to live cells for labeling 
studies. However, the cells immediately aggregated upon the addition of the probe. We 
believe this is due to the toxicity of the unnatural ether lipid tails. On the other hand, 
these DAG probes also suffer from their low solubility in the cell extracts. Further 
research will focus on incorporating this DAG probe into liposomes and using these 
liposomes as probes to fish out protein receptors from live cells. In these liposome 
probes, the ether linkages are not exposed to the live cells and thus we expect them to 
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have lower to none toxicity to the living system. Furthermore, since the majority of the 
liposome composition is water soluble, such as phosphatidylcholine (PC), 
phosphatidylethanoamine (PE), these probes will have greatly increased solubility in the 
cell extracts. 
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 1 2 3 4 5 6 7 8 9 10 11 
Skov 3 proteome 1mg/mL (42ul) + + - + + - + + - + + 
Skov 3 proteome (heat denatured) - - + - - + - - + - - 
DAG Probe 3.1.10 (100 uM) + + + - - - - - - - - 
DAG Probe 3.1.9 (100 uM) - - - + + + - - - - - 
DAG Probe 3.1.8 (100 uM) - - - - - - + + + - - 
10x DAG 3.1.11 (1 mM) - + - - + - - + - - - 
2.2.3e  (100 uM) - - - - - - - - - + - 
DMSO - - - - - - - - - - + 
                             




3. Materials and methds 
3.1 Synthesis of DAG activity-based probes. 
General Experimental. Generally, reagents were purchased from Acros, Aldrich or 
FisherSci and used as received. Dry solvents were obtained from a Pure Solv solvent 
delivery system purchased from Innovative Technology, Inc. Column chromatography 
was performed by using 230-400 mesh silica gel purchased from Sorbent Technologies. 
NMR spectra were obtained by using a Varian Mercury 300 spectrometer. Mass spectra 
were obtained with ABI DE Pro MALDI spectrometers with high-resolution capabilities.  
 ((4S,5S)-5-(Azidomethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-methanol (3.1.2).  
Compound 3.1.2 was prepared according to a reported procedure18. The 
characterization matched with the literature. 
(2S,3S)-1-Azido-4-(4-methoxybenzyloxy)butane-2,3-diol (3.1.4). To the stirred cold 
100 mL DMF solution of compound 3.1.2 (2.86 g, 15.3 mmol) was added sodium 
hydride (1.22 g, 30.6 mmol, 60 %). The solution was stirred at 0 °C for 30 minutes. 
PMBCl (4.17 mL, 30.6 mmol) was then added to this solution. The reaction was stirred 
at room temperature for 2.5 hours before it was quenched by 3 mL methanol. The 
solvent was removed under reduced pressure. Ethyl acetate (250 mL) was added to 
dissolve the crude and the solution was extracted by saturated ammonium chloride 
solution (200 mL), brine (200 mL), then water (200 mL). The organic layer was dried by 
magnesium sulfate, filtered and concentrated to yield the crude product 3.1.3. The 
crude 3.1.3 was used in the next reaction without further purification. Crude 3.1.3 was 
re-dissolved in 10 mL methanol. To this solution was added 0.40 g H+ resin. The 
reaction was stirred at room temperature overnight. The resin was then filtered off and 
the filtrate was concentrated to yield the crude 3.1.4. The crude was purified by column 
chromatography with a gradient solvent system of 40-80% ethyl acetate to hexanes to 
yield compound 3.1.4 as a colorless oil (1.925 g, 47% from 3.1.2). The characterization 
of the compound matched that was the previously reported18. 
1-(((2S,3S)-4-azido-2,3-bis(hexadecyloxy)butoxy)methyl)-4-methoxybenzene 
(3.1.5). To a cold solution of diol 3.1.4 (74 mg, 0.277 mmol) in 10 mL dry DMF was 
added sodium hydride (66 mg, 1.66 mmol, 60%). The solution was stirred at 0 °C for 30 
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minutes under nitrogen. Then 1-bromohexadecane (0.34 mL, 1.11 mmol) and TBAI 
(catalytic) were added to the solution which was stirred at room temperature overnight. 
The reaction was then quenched by 2 mL methanol.  Ethyl acetate (150 mL) was added 
to the solution and extracted by saturated sodium chloride (100 mL), brine (100 mL) and 
water (100 mL). The organic layer was dried by magnesium sulfate, filtered and 
concentrated to yield the crude product. The crude was purified by column 
chromatography with a gradient solvent system of 2-20% ethyl acetate to hexanes to 
yield compound 3.1.5 as a colorless oil (190 mg, 96%).  
1H NMR (300MHz, CDCl3)  7.23 (d, J = 9 Hz, 2H), 6.86 (d, J = 9 Hz, 2H), 4.44 (s, 2H), 
3.79 (s, 3H), 3.59-3.46 (m, 8H), 3.32-3.30 (m, 2H), 1.56-1.54 (m, 4H), 1.25-1.23 (m, 
52H), 0.87 (t, J = 6 Hz, 3H). 13C NMR (300MHz, CDCl3)  159.2, 130.1, 129.3, 113.7, 
79.0, 78.5, 73.0, 71.8, 71.4, 68.6, 55.2, 51.2, 31.9, 30.1, 29.7, 29.6, 29.5, 29.4, 26.1, 
22.7, 14.1.  MALDI-HRMS [M + Na]+ calcd 738.6125; found, 738.6169. 
 (2S,3S)-4-azido-2,3-bis(hexadecyloxy)-1-butanol (3.1.6). Compound 3.1.5 (189 mg, 
0.264 mmol) was dissolved in 3 mL dichloromethane. To this solution was added DDQ 
(90 mg, 0.396 mmol) and 0.3 mL water. The reaction was stirred at room temperature 
for 3 hours. Ethyl ether (150 mL) was added and then extracted by by saturated sodium 
chloride (100 mL), brine (100 mL) and water (100 mL). The organic layer was dried by 
magnesium sulfate, filtered and concentrated to yield the crude product. The crude was 
purified by column chromatography with a gradient solvent system of 10-20% ethyl 
acetate to hexanes to yield compound 3.1.6 as a white solid (115 mg, 73%).  
1H NMR (300MHz, CDCl3)  3.80-3.74 (m, 1H), 3.64-3.54 (m, 7H), 3.39-3.35 (m, 2H), 
2.20 (t, J = 6Hz, 1H), 1.62-1.55 (m, 4H), 1.28-1.24 (m, 52H), 0.88 (t, J = 6 Hz, 6H). 13C 
NMR (300MHz, CDCl3)  79.5, 78.7, 71.6, 71.1, 61.1, 50.8, 31.9, 30.0, 29.7, 29.6, 29.5, 
29.4, 29.3, 26.1, 26.0, 22.7, 14.1. MALDI-HRMS [M + Na]+ calcd 618.5550; found, 
618.5639. 
(2S,3S)-4-amino-2,3-bis(hexadecyloxy)-1-butanol (3.1.7). Compound 3.1.6 (132 mg, 
0.221 mmol) was dissolved in 10 mL ethyl acetate. To this solution was added 
palladium on carbon (26 mg, 20% by w.t.). The reaction was stirred under a hydrogen 
gas atmosphere overnight. The palladium over carbon was then filtered and washed by 
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ethyl acetate. The combined filtrate was concentrated under reduced pressure to yield 
amine 3.1.7 (110 mg, 87%). 
1H NMR (300MHz, CDCl3)  3.68-3.60 (m, 3H), 3.53-3.45 (m, 5H), 3.01-2.96 (m, 1H), 
2.85-2.81 (m, 1H), 1.57-1.53 (m, 4H), 1.26-1.24 (m, 52H), 0.87 (t, J = 6 Hz, 6H). 13C 
NMR (300MHz, CDCl3)  80.0, 79.2, 70.5, 70.1, 58.9, 39.4, 31.9, 30.1, 30.0, 29.7, 29.6, 
29.5, 29.3, 26.2, 26.1, 22.7, 14.1. MALDI-HRMS [M + H]+ calcd 570.5825; found, 
570.5822. 
Bifunctional Benzophenone/Alkyne DAG Probe (3.1.8). Amine 3.1.7 (56 mg, 0.098 
mmol) was combined with acid 2.2.3e (48 mg, 0.098 mmol), EDCI (24 mg, 0.127 mmol), 
DMAP (16 mg, 0.127 mmol), NMM (22 ul, 0.196 mmol) in 5 mL dry dichloromethane. 
The reaction was allowed to stir at room temperature for 3 hours. The solvent was then 
removed under reduced pressure. The crude was purified by column chromatography 
with a gradient solvent system of 45-75% acetone to chloroform to yield DAG probe 
3.1.8 as a colorless solid (32 mg, 31%). 
1H NMR (300MHz, CDCl3)  8.01-7.98 (m, 2H), 7.85-7.79 (m, 4H), 7.65-7.60 (m, 1H), 
7.53-7.48 (m, 2H), 7.17-7.09 (m, 1H), 6.77-6.76 (m, 1H), 6.48-6.46 (m, 1H), 4.57-4.56 
(m, 1H), 4.00-3.98 (m, 2H), 3.79-3.78 (m, 1H), 3.69-3.67 (m, 1H), 3.58-3.45 (m, 7H), 
3.27-3.24 (m, 2H), 3.01-2.96 (m, 1H), 2.55-2.44 (m, 4H), 1.94-1.93 (m, 1H), 1.56-1.48 
(m, 8H), 1.25-1.23 (m, 52H), 0.88 (t, J = 6 Hz, 6H). 13C NMR (300MHz, CDCl3)  196.0, 
172.6, 171.9, 171.6, 166.6, 140.2, 136.8, 132.9, 130.1, 129.9, 128.4, 127.3, 71.4, 71.0, 
53.7, 31.9, 31.4, 30.1, 29.7, 29.6, 29.5, 29.3, 29.1, 26.1, 22.7, 14.1. MALDI-HRMS [M + 
Na]+ calcd 1081.7908; found, 1081.7811. 
Bifunctional Benzophenone/Alkyne DAG Probe with hexyl carbon chain linker 
(3.1.9) Amine 3.1.7 (45 mg, 0.079 mmol) was combined with acid 2.2.9 (62 mg, 0.103 
mmol), EDCI (20 mg, 0.103 mmol), DMAP (13 mg, 0.103 mmol), NMM (13 ul, 0.118 
mmol) in 5 mL methanol/chloroform mixture (v/v 1:4). The reaction was allowed to stir at 
room temperature overnight. The solvent was then removed under reduced pressure. 
The crude was purified by column chromatography with a gradient solvent system of 60-
100% acetone to hexane to yield DAG probe 3.1.9 as a colorless solid (40 mg, 44%). 
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1H NMR (300MHz, CDCl3 )  8.02-7.99 (m, 2H), 7.88-7.79 (m, 4H), 7.68-7.53 (m, 3H), 
7.12-7.11 (m, 1H), 4.56 (t, J = 6 Hz, 1H), 3.95-3.94 (m, 2H), 3.67-3.53 (m, 8H), 3.39-
3.36 (m, 2H), 3.2-3.18 (m, 4H), 2.46 (m, 4H), 2.31-2.29 (m, 1H), 2.20 (t, J = 6 Hz, 2H), 
1.88-1.77 (m, 2H), 1.60-1.54 (m, 10H), 1.27-1.25 (m, 56H), 0.88 (t, J = 6 Hz, 6H). 13C 
NMR (300MHz, CDCl3)  196.9, 174.3, 173.2, 173.1, 172.8, 172.4, 167.3, 140.3, 137.2, 
136.9, 133.3, 130.2, 128.6, 127.5, 80.8, 79.4, 71.4, 71.3, 60.8, 53.8, 49.7, 49.4, 49.2, 
48.9, 48.6, 48.3, 48.0, 36.3, 32.0, 31.3, 30.2, 29.8, 29.7, 29.5, 29.0, 26.5, 26.2, 25.4, 
22.8, 14.1. MALDI-HRMS [M + Na]+ calcd 1178.8436; found, 1178.8686. 
Bifunctional Benzophenone/Alkyne DAG Probe with triazole linker (3.1.10). Alkyne 
3.1.11 (69 mg, 0.175 mmol) (the synthesis of 3.1.11 was described in Matt’s 
dissertation) was dissolved in 1.5 mL THF. To this solution was added copper sulfate 
pentahydrate (43 mg, 0.175 mmol), sodium ascorbate (35 mg, 0.350 mmol), azide 3.1.6 
(104 mg, 0.175 mmol) and water (0.5 mL). The reaction was stirred at room 
temperature overnight. The solvent was then removed. The crude was dried on high vac 
for 8 hours before it was dissolved in 3 mL dry DMF. To this DMF solution was added 4-
oxo-4-(2-propyn-1-ylamino) butanoic acid (33 mg, 0.210 mmol), EDCI (82 mg, 0.43 
mmol), DMAP (21 mg, 0.175 mmol), NMM (96 ul, 0.875 mmol). The reaction was 
allowed to stir at room temperature overnight. Ethyl acetate (150 mL) was added to the 
solution and then extracted by saturated sodium chloride aqueous solution (100 mL x3). 
The organic layer was dried by magnesium sulfate, filtered and concentrated to yield the 
crude product. The crude was purified by column chromatography with a gradient 
solvent system of 50-100% acetone to hexanes to yield DAG probe 3.1.10 as a 
colorless gum (55 mg, 28%).   
1H NMR (300MHz, CDCl3)  8.00-7.95 (m, 3H), 7.83-7.77 (m, 4H), 7.62-7.59 (m, 1H), 
7.52-7.47 (m, 2H), 7.14-7.13 (m, 1H), 6.89-6.88 (m, 1H), 4.66-4.35 (m, 3H), 4.00-3.98 
(m, 2H), 3.87-3.74 (m, 3H), 3.56-3.41 (m, 5H), 3.22-3.19 (m, 3H), 2.75-2.74 (m, 1H), 
2.52 (s, 4H), 2.24 (m, 1H), 1.90-1.80 (m, 2H), 1.58-1.40 (m, 6H), 1.26-1.24 (m, 52H), 
0.87 (t, J = 6 Hz, 6H). 13C NMR (300MHz, CDCl3)  196.0, 172.7, 172.3, 172.0, 166.6, 
140.2, 137.1, 136.9, 133.0, 130.1, 130.1, 130.0, 128.8, 128.5, 127.3, 124.0, 79.7, 78.9, 
78.6, 71.9, 71.8, 71.4, 71.1, 60.4, 53.6, 50.9, 38.9, 31.9, 30.1, 29.7, 29.5, 29.4, 26.1, 
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26.0, 22.7, 22.5, 19.5, 14.2. MALDI-HRMS [M + Na]+ calcd 1146.7922; found, 
1146.7859. 
(S)-2,3-bis(hexadecyloxy)1-propanol (3.1.12). To a cold solution of diol 5.2.3 (714 
mg, 3.364 mmol) in 10 mL dry DMF was added sodium hydride (807 mg, 20.2 mmol, 
60%). The solution was stirred at 0 °C for 30 minutes under nitrogen. Then 1-
bromohexadecane (4.11 mL, 13.46 mmol) and TBAI (catalytic) were added to the 
solution which was stirred at room temperature overnight. The reaction was then 
quenched by 2 mL methanol.  Ethyl acetate (250 mL) was added to the solution and 
extracted by saturated sodium chloride (150 mL), brine (150 mL) and water (150 mL). 
The organic layer was dried by magnesium sulfate, filtered and concentrated to yield the 
crude product 3.1.11. The crude was purified by column chromatography with a gradient 
solvent system of 0-10% ethyl acetate to hexanes to yield compound 3.1.11 which was 
then dissolved in 10 mL dichloromethane. To this solution was added DDQ ( 1.145 g, 
5.05 mmol) and water (1.0 mL). The reaction was stirred at room temperature overnight. 
Ethyl acetate (150 mL) was added and then extracted by by saturated sodium chloride 
(100 mL), brine (100 mL) and water (100 mL). The organic layer was dried by 
magnesium sulfate, filtered and concentrated to yield the crude product 3.1.12. The 
crude was purified by column chromatography with a gradient solvent system of 10-20% 
ethyl acetate to hexanes to yield compound 3.1.12 as a white solid (1.10 mg, 60% from 
5.2.3).  
1H NMR (300MHz, CDCl3)  3.75-3.70 (m, 1H), 3.63-3.60 (m, 2H), 3.53-3.41 (m, 6H), 
2.25 (bs, 1H), 1.58-1.53 (m, 4H), 1.26-1.24 (m, 52H), 0.88 (t, J = 6 Hz, 6H). MALDI-
HRMS [M + Na]+ calcd 563.5379; found 563.5425 
3.2 Labeling of proteomes by DAG activity probes. 
General procedure for the labeling of proteomes. SKOV 3 proteome was prepared 
by Dr. Sherry Niessen from The Scripps Research Institute. In a 96-well plate, SKOV 3 
proteome samples (43 ul of 1.0 mg/mL protein in PBS) were incubated with synthetic 
DAG probes for 1 hr at room temperature. For heat-denatured controls, proteome 
samples were heated at 90oC for 5 min and cooled to room temperature before the 
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addition of probes. For DAG competition studies, the DAG 3.1.12 was incubated with 
the samples 1 hour in room temperature prior to the incubation of probes. After the 
probe incubation, the 96-well plate was placed on ice and photolyzed for 1 hour under 
350 nm UV lamp.  
General procedure of click reactions to derivatize alkyne tag into reporter group. 
After the photolysis procedure, to each sample was added 50 uM rhodamine-N3 (2.3.8) 
(50x stock solution in DMSO), 1mM TCEP (50x stock in H2O), 100 uM TBTA ligand (17 
x stock in DMSO:t-butanol 1:4) and 1mM CuSO4 (50x stock in water). The samples 
were shaken for 30 seconds after each addition. After all the addition, the samples were 
incubated at room temperature for 1 hour before being quenched by adding 50 ul of 
SDS-PAGE sample buffer (2x) to each well. The proteins were separated by 1D SDS-
PAGE (30 ul of quenched sample/gel lane) and visualized in-gel by a Hibachi FMBio lle 





4. CHAPTER 4. Analysis of Akt PH Domain Binding via a Rapid 
Microplate Assay Employing Synthetic Biotinylated Analogs of 
all Seven Phosphatidylinositol Polyphosphate Headgroup 
Isomers 
 
1. Background and significance 
      Signaling lipids such as phosphatidylinositol polyphosphates (PIPns) play vital role in 
molecular recognition events. These lipid molecules act as ligands in receptor binding 
events, resulting in the recruitment of protein receptors onto membrane surfaces, which 
regulates both protein subcellular localization and function. The characterization of 
these lipid-receptor binding interactions is important for understanding numerous lipid-
related biological pathways at molecular level.1 The PIPns represent an important 
signaling lipid family that controls many key cellular pathways. This is exemplified by the 
conversion of PI(4,5)P2 to PIP3 by PI-3K, which acts as the hub that controls several 
biological pathways involved in cell survival cycle. The family of PIPns consists of seven 
naturally existing isomers (PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, 
PI(3,4,5)P3), which possess different protein binding properties. This fact, along with the 
complex cell environment, complicates the study of PIP-receptor bindings to a great 
extent.  
       One of the strategies to elucidate these complex binding interactions is to build 
model systems. The conventional strategies include surface plasmon resonance (SPR) 
analysis using both membrane and individual lipid motifs, fluorescence quenching and 
polarization, monolayer penetration, vesicle pelleting, overlay assays, and 
calorimetry.78,79 In addition, innovative approaches for generating PIPn-presenting 
materials have been reported, such as the polymerized liposomes reported by 
Prestwich and co-workers,80 and dendrimers studied by Oakley and co-workers.81-83 
Though these approaches have provided significant amount of information on the 
binding events at molecular level, their disadvantages can be summarized as follows: 
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the inability to perform high-throughput analysis, expensive and inaccessible 
instrumentation, and/or detection that can be limited to specific systems. Additionally, 
since the membrane environment is simplified in these models, it would be ideal to 
perform analysis in different contexts that mimic different aspects of the cell membrane 
to fully investigate binding. Finally, it will be beneficial to have broadly accessible and 
applicable assays that have the potential for high-throughput screening. 
Microarray analysis has provided an invaluable method for probing receptor–ligand 
binding interactions, such as with carbohydrate studies.84,85 In one example,86 a library 
of diverse glycans with amino tags was immobilized onto amino-reactive glass surfaces 
to profile their binding specificities with various glycan binding proteins. Microarray 
research has also been used to determine the structural requirements of recognition 
among receptors, to quantify the effect that multivalency has on receptor affinity by 
controlling ligand density on the surface, and to detect receptor variations associated 
with disease from cell extracts.87,88 Here, we extend the application of this platform to 
study lipid-receptor binding interactions, particularly the PIP-receptor binding 
interactions.  
2. Results and Discussion 
      As was addressed previously, different types of proteins require different lipid motifs 
for recognition. Some proteins (S-type) interact primarily with the lipid polar headgroups 
while others (I-type and H-type) require the membrane context.89,90 PIPn-protein 
bindings particularly belong to the former situation due to their highly-charged 
headgroups.25,91-94 With this fact in mind, we once again utilized soluble headgroups 
corresponding to all seven PIPn isomers to probe protein binding.  
Previously, our group has also developed a platform using immobilized whole 
liposomes to detect diacylglycerol (DAG) recognition in a format that mimics cellular 
membranes, which we first used to analyze Protein Kinase C.95 We have also modified 
the assay via the immobilization of isolated PIPn headgroups motifs for rapid 
characterization of receptors that bind with high affinity to these moieties without the 
membrane context. Our initial report of this latter approach utilized a synthetic PI(4,5)P2 
analog to detect binding of the PH domain of -spectrin.96 This assay was shown to be 
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effective for sensitive detection of the binding and inhibition of PIPn receptors. Due to 
the diversity of PIPn targets exhibited by receptors, an important application of this 
approach involves the efficient delineation of the PIPn-binding specificity of receptors. 
Herein, we describe the utility of this assay for characterizing PIPn specificity through 
studies focusing on the PH domain of the prominent receptor Akt. 
The modified PIPn assay employs PIPn-TEG-biotin conjugates as the recognition 
motif for binding studies, based upon our initial study that successfully employed 
synthetic PI(4,5)P2–TEG–biotin structure 4.2.1c (Scheme 4.1). This ligand consists of 
the PI(4,5)P2 headgroup with a phosphodiester moiety at the same position as the 
parent PI(4,5)P2 lipids (1-position of the inositol ring). The phosphodiester linkage 
connects to a six-carbon hydrophobic region that is designed to mimic the 
hydrophobicity of the natural glycerolipid backbone, which is excluded. Next, a 
tetraethylene glycol (TEG) linker is employed as a spacer between the headgroup 
binding motif and the microplate surface to prevent non-specific binding. Lately, Iyer and 
co-workers showed evidence of a long tether being critical in microplate studies with 
streptavidin-coated plate as the shortening of this linker led to the drastic reductions in 
binding.97 Lastly, the biotin portion of 4.2.1c is installed for high-affinity non-covalent 
immobilization of these ligands onto streptavidin-coated microplates in an effort to avoid 
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Scheme 4.1 Microarray binding analysis for PIPn headgroups: the designed PIP ligand 
was immobilized onto the streptavidin-coated plate through its biotin moiety; next, the 
GST-fused -spectrin proteins were incubated with this PIP-coated plate to allow 
binding to occur. The excess non-bound proteins were subsequently washed away. The 

















































































a:  3,4,5PIP : R1,R2,R3= -PO3
2-
b:  3,4PIP : R1,R2= -PO3
2-,  R3= H
c:  4,5PIP : R2,R3= -PO3
2-,  R1= H
d:  3,5PIP : R1,R3= -PO3
2-,  R2= H
e:  5PIP : R3= -PO3
2-,  R1,R2= H
f:   4PIP : R2= -PO3
2-,  R1,R3= H
g:  3PIP : R1= -PO3
2-,  R2,R3= H
2.2.6:  3,4,5PIP : R1,R2,R3= -PO3
2-
2.2.5:  3,4PIP : R1,R2= -PO3
2-,  R3= H
4.2.2c:  4,5PIP : R2,R3= -PO3
2-,  R1= H
2.2.7:  3,5PIP : R1,R3= -PO3
2-,  R2= H
4.2.2e:  5PIP : R3= -PO3
2-,  R1,R2= H
4.2.2f:   4PIP : R2= -PO3
2-,  R1,R3= H
4.2.2g:  3PIP : R1= -PO3
2-,  R2,R3= H  
Scheme 4.2 Synthesis of headgroup-biotin conjugates of all seven naturally 
occuring phosphoinositide isomers. 
 
 
  In order to develop an assay that is suitable for characterizing the binding affinities 
of all PIPn family members, we extended our previous approach to produce biotinylated 
ligands corresponding to all seven PIPn headgroup isomers 4.2.1a–g (scheme 4.2). 
With the amino-tagged PIPn headgroups (2.2.5-7, 4.2.2c, e, f, g) in hand
55 (see chapter 
2), we synthesized PIPn–TEG–biotin conjugates 4.2.1a–g by reacting ligands 4.2.2a–g 
with synthetic biotin–TEG–succinimidyl ester. These conjugates were then used for 
microplate studies.   
 We first sought to apply these compounds 4.2.1a–g for side-by-side microplate 
binding analysis in order to directly compare all seven PIPn isomers and thus assess 
receptor binding specificity. In the studies, we employed the PH domain of Akt due to 
the key role this receptor plays in the cell survival cycle and since few binding studies 
have been reported using all PIPn isomers. The GST-tagged PH domain of Akt was 
expressed and purified as described previously by Nathan Lucas in the lab of our 
collaborator, Dr. Wonhwa Cho.56 In the assay, compounds 4.2.1a–g were immobilized 
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in separate rows of streptavidin-coated 96-well microplates (scheme 4.1). Next, the Akt 
PH domain was introduced to allow for recognition, followed by detection via 
chemiluminescence-based ELISA signal transduction using an HRP-tagged anti-GST 
antibody. Each step of the assay was followed by washes to remove any unbound 
species.  
 In this assay, Akt binding analysis was performed in two ways. On one hand, fixed 
concentrations of each ligand of type 4.2.1a–g were immobilized in separate rows, and 
each isomer was treated with varying concentrations of the Akt PH domain. The results 
from this approach are shown in figure 4.1A. Here, the analogs corresponding to the 
PIP3 (4.2.1a) and PI(3,4)P2 (4.2.1b) headgroups yielded sensitive dose-dependant 
responses when incubating with relatively low concentrations of the Akt PH domain (0–
20 nM). The other isomers yielded low-to-no signal and thus essentially doubled as 
negative controls for the experiment. On the other hand, varying concentrations of 
4.2.1a–g were incubated in separate wells of the microplate, followed by treatment with 
a fixed concentration of the Akt PH–GST, the results of which are shown in figure 4.1B. 
In a similar fashion, 4.2.1a and 4.2.1b yielded dose-dependant responses with minimal 
protein recruitment to the microplate surface observed for the other isomers. In the latter 
binding studies, a dual curve response is observed, which can likely be attributed to the 
combined equilibria of the binding of the receptor to the PIPn headgroup as well as the 
binding of the PIPn–TEG–biotin ligand to the microplate surface. However, this format is 
still effective for analyzing binding specificity via an experiment where the receptor 
concentration is held constant, thus avoiding any concerns that non-specific protein–
surface binding may be occurring. The data shown in figure 4.1 represent the averages 
of at least three analyses with error bars showing the standard error produced by 











Figure 4.1 Results from Akt PH domain microplate binding results using analogs 
corresponding to all seven PIPn headgroups: (A) fixed concentrations of each ligand 
4.2.1a–g were immobilized and tested against various concentrations of the Akt PH 
domain; (B) varying concentrations of 4.2.1a–g were immobilized and tested against 
fixed concentrations of the Akt PH domain. 
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These results are consistent with previous reports indicating Akt binding specificity of 
PIP3 > PI(3,4)P2 > PI(4,5)P2. Thus, the phosphates at the 3- and 4-positions are 
required for binding, while the 5-phosphate contributes as well. Similar trends were 
observed through studies using full PIPn analogs including SPR, vesicle pelleting, and 
tryptophan quenching assays.56,98,99 In the latter study, it was observed that full PIPn 
structures bound with much higher affinity than the corresponding inositol phosphates 
(InsPs), which contain a phosphate group at 1-position instead of the phosphodiester-
linked glycerolipid backbone. In the current study we observe strong binding to 
headgroup analogs bearing the traditional phosphodiester but lacking the glycerolipid 
scaffold. Thus, this provides further evidence for the importance of the phosphodiester 
group in binding, as opposed to the lipid core, which appears to not significantly 
contribute to the binding of this particular receptor.  
 As we observed in the previous report from our group, this surface-based study 
resulted in higher receptor binding affinities than membrane- and solution-phase 
analysis. In the current studies, receptor binding affinities for the surface, commonly 
termed “Kd, surf”,
88 were evaluated via Scatchard Plot analysis to be approximately 9 nM 
for 4.2.1a and 12 nM for 4.2.1b. Despite the similar affinity constants for these 
structures, ligand 4.2.1a clearly recruits more receptor to the microplate surface based 
on the enhanced amplitude of the binding curves. These values represent higher 
affinities than those previously observed for PIP3 (234 – 590 nM) and PI(3,4)P2 (350 – 
570 nM) motifs.56,98,99 However, variations in observed binding strengths are to be 
expected due to the different conditions used in the current assay. The primarily 
variations in the current study are the truncated structures of the PIPn ligands and the 
use of surfaces coated with the ligand motif, of which it is not clear which aspect or both 
may be affecting the binding. For the latter case, while binding may simply be enhanced 
by the increased charge of the coated surface, this may nevertheless be biologically 
significant since many PIPn-binding interactions seem to occur when the lipid motif is 
aggregated in some way, and indeed Akt has been reported to bind PIP3 localized in 
lipid rafts.100,101 In future studies, we will seek to analyze the effect that ligand density on 
the microplate surface has on receptor affinities to further characterize any clustering 
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effects. Furthermore, we are currently attempting to perform this assay on a glass slide 
with robotic pin printer to realize a true high-throughput microarray analysis. The amino-
tagged PIPn headgroups (2.2.5-7, 4.2.2c, e, f, g) are used instead of biotinylated 
analogs 4.2.1a-g to be immobilized on an epoxy-coated glass slide (figure 4.2). These 
amino-tagged PIPn headgroups (2.2.5-7, 4.2.2c, e, f, g) were printed on the glass slide 
by pin printer. After incubation, the glass slide was washed and then incubated with Akt 
protein. Excess proteins were washed away by buffer. Lastly, ELISA was performed, 
followed immediately by fluorescent scanning.  
 
                     




























R1, R2, R3 = H or PO3
2-
 
Figure 4.2 Picture of a pin printer and demonstration of glass slide-based 




This report describes a microplate-based binding platform for characterizing protein–
PIPn binding interactions using synthetic headgroup ligands corresponding to all seven 
naturally occurring PIPn isomers. This approach was applied for rapid side-by-side 
analysis of the binding of the Akt PH domain to the seven headgroup isomers. Results 
obtained from studies indicated highly sensitive detection of binding, and the ligand 
specificity of Akt of PIP3 > PI(3,4)P2 > PI(4,5)P2 was characterized in an efficient 
manner. This study also provides useful information regarding the structural features 
required for Akt binding, as immobilized headgroups bearing the phosphodiester 
linkage, but lacking the glycerolipid backbone of full PIPn structures, exhibited high-
affinity receptor binding outside of a membrane environment.  
The described assay will be highly beneficial for probing and perturbing protein–PIPn 
binding for numerous reasons. First, this platform is amenable for high-throughput 
screening to maximize the efficiency of analysis. In addition, the surface-based ligand 
presentation involved in this assay can mimic the presentation of lipid motifs on the 
surfaces of cell membranes, thus providing an effective model system for biological 
recognition. Furthermore, surface deposition allows for the ligand density to be 
controlled, allowing for ligand clustering effects to be analyzed. Finally, while traditional 
binding assays are limited to in vitro binding studies using protein and ligand motifs in 
solution, antibody-based signal transduction allows for the detection of a specific 
receptor target, and could thus be used for target detection in a more complex biological 
context, such as a cell extract. We are now pursuing to apply this platform to address 
important issues in protein–PIPn binding interactions. At the same time, a glass slide-




4. Materials and methods 
Experimental 
General Experimental. Generally, reagents were purchased from Acros, Aldrich or 
Advanced ChemTech and used as received. Dry solvents were obtained from a Pure 
Solv solvent delivery system purchased from Innovative Technology, Inc. Column 
chromatography was performed using 230-400 mesh silica gel purchased from Sorbent 
Technologies and C18 (17%) reverse phase SPE columns (6 mL, 2 g) purchased from 
Silicycle. NMR spectra were obtained using a Varian Mercury 300 spectrometer and a 
Bruker Avance 400 spectrometer. Mass spectra were obtained with JEOL DART-
AccuTOF spectrometer and an ABI Voyager DE Pro MALDI spectrometer with high 
resolution capabilities. Microplate chemiluminescence analysis was performed using a 
BioTek Synergy 2 multidetection microplate reader. White reacti-bind high binding 
capacity (HBC) streptavidin-coated 96-well microplates employed for 
chemiluminescence studies were purchased from Pierce Biotechnology (Rockford, IL). 
Mouse monoclonal anti-GST tag HRP-conjugate was purchased from Millipore 
(Billerica, Ma). Supersignal ELISA femto maximum sensitivity substrate was purchased 
from Pierce Biotechnology (Rockford, IL). The GST-tagged PH domain of Akt was 
expressed and purified as previously described.56 Synthetic procedures for modular 
PIPn–amine conjugates 4.2.2a-g
102, as well as biotin-TEG-succinimidyl ester 4.2.4 and 
biotinylated PI(4,5)P2 analog 4.2.1c
96 were previously described.  
 
General Procedure for the synthesis of PIP-TEG-Biotin Conjugates 4.2.1a-g.  To a 
solution of biotin–succinimidyl ester 4.2.4 in 1 mL of N,N-dimethylformamide was added 
the appropriate PIPn–amine of type 4.2.2a-g in triethylammonium bicarbonate (TEAB) 
buffer. Next, 0.5–1.5 mL of tetrahydrofuran was added to the solution until it turned 
clear. The reaction mixture was then stirred at room temperature for 10 h, at which time 
the solvent was removed under reduced pressure. Next, acetone was added to the 
residue, and the white solid that formed was filtered and washed with acetone three 
times. The white solid was dissolved in deionized water and Chelex 100 resin (Sigma, 
Na+ form) was added. This solution was then stirred for 3 h and loaded onto a C18 
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reverse phase column (6 mL, 2 g). The corresponding fractions were lyophilized to yield 
4.2.1a-g (47-99% yield). 
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)-
1D-myo-inositol 3,4,5-tris-(disodium phosphate) (4.2.1a). PI(3,4,5)P3–amine 
conjugate 4.2.2a (8 mg, 0.013 mmol) and biotin succinimidyl ester 4.2.4 (46 mg, 0.080 
mmol) yielded 4.2.1a as a white solid (8 mg, 57%). 1H NMR (300 MHz, D2O):  4.36-
4.34 (m, 1H), 4.18-4.15 (m, 1H), 3.84 (s, 2H), 3.74-3.70 (m, 4H), 3.52-3.38 (m, 18H), 
3.20-3.18 (m, 2H), 3.14-3.12 (m, 2H), 3.08-3.02 (m, 3H), 2.10-2.05 (m, 2H), 1.46-1.32 
(m, 8H), 1.20-1.16 (m, 6H).  31P NMR (121.5 MHz, D2O):  6.20 (1P), 5.11 (2P), 0.89 
(1P). MALDI-MS [M+H]+: calcd for C32H63N4O25P4S 1059.2447, found 1059.2393. 
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)-
1D-myo-inositol 3,4-bis-(disodium phosphate) (4.2.1b). PI(3,4)P2–amine conjugate 
4.2.2b (10 mg, 0.019 mmol) and biotin succinimidyl ester 4.2.4 (84 mg, 0.146 mmol) 
yielded 4.2.1b as a white solid (20 mg, 99%).  1H NMR (300 MHz, D2O):  4.38-4.36 (m, 
1H), 4.20-4.17 (m, 1H), 4.13-3.99 (m, 2H), 3.83 (s, 2H), 3.76-3.60 (m, 4H), 3.48-3.38 
(m, 18H), 3.17-3.13 (m, 2H), 3.02-3.00 (m, 1H), 2.77-2.73 (m, 1H), 2.56-2.52 (m, 1H), 
2.04 (t, J = 6Hz, 2H), 1.44-1.30 (m, 8H), 1.18-1.10 (m, 6H).  31P NMR (121.5 MHz, 
D2O):  2.16 (1P), 1.24 (1P), -0.19 (1P). MALDI-MS [M+H]
+: calcd for C32H62N4O22P3S 
979.2784, found 979.2723. 
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)-
1D-myo-inositol 3,5-bis-(disodium phosphate) (4.2.1d). PI(3,5)P2 amine conjugate 
4.2.2d (10 mg, 0.019 mmol) and biotin succinimidyl ester 4.2.4 (46 mg, 0.080 mmol) 
yielded 1d as a white solid (17 mg, 72%). 1H NMR (300 M Hz, D2O):  4.44-4.39 (m, 
1H), 4.27-4.22 (m, 1H), 4.07-4.05 (m, 2H), 3.88 (s, 2H), 3.76-3.70 (m, 4H), 3.58-3.42 
(m, 18H), 3.21-3.18 (m, 2H), 3.08-3.03 (m, 1H), 2.83-2.77 (m, 1H), 2.60-2.58 (m, 1H), 
2.08 (t, J = 6 Hz, 2H), 1.50-1.35 (m, 8H), 1.24-1.16 (m, 6H). 31P NMR (121.5 MHz, 
D2O):  1.64 (1P), 0.30 (1P), -0.31 (1P). MALDI-MS [M+H]
+: calcd for C32H62N4O22P3S 
979.2784, found 979.2639. 
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)-
1D-myo-inositol 5-disodium phosphate) (4.2.1e). PI(5)P–amine conjugate 4.2.2e (10 
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mg, 0.023 mmol) and biotin succinimidyl ester 4.2.4 (46 mg, 0.080 mmol) yielded 4.2.1e 
as a colorless crystal (14 mg, 65%).  1H NMR (300 MHz, D2O):  4.55-4.45 (m, 1H), 
4.35-4.25 (m, 1H), 4.19-4.10 (m, 1H), 3.98-3.92 (m, 2H), 3.85-3.75 (m, 2H), 3.70-3.45 
(m, 20H), 3.32-3.22 (m, 4H), 3.16-2.12 (m, 1H), 2.89-2.85 (m, 1H), 2.18-2.14 (m, 2H), 
1.70-1.40 (m, 8H), 1.40-1.20 (m, 6H).  31P NMR (121.5 MHz, D2O):  3.75 (1P), -0.30 
(1P). MALDI-MS [M+H]+: calcd for C32H61N4O19P2S 899.3121, found 899.2996. 
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)-
1D-myo-inositol 4-disodium phosphate) (4.2.1f). PI(4)P–amine conjugate 4.2.2f (10 
mg, 0.023 mmol) and biotin succinimidyl ester 4.2.4 (83 mg, 0.144 mmol) yielded 1f as 
a colorless crystal (20 mg, 93%).  1H NMR (300MHz, D2O):  4.48-4.36 (m, 1H), 4.21-
4.17 (m, 1H), 4.02-3.99 (m, 2H) 3.86-3.82 (s, 2H), 3.76-3.68 (m, 4H), 3.56-3.36 (m, 
18H), 3.18-3.14 (m, 2H), 3.04-3.00 (m, 1H), 2.79-2.73 (m, 1H), 2.58-2.51 (m, 1H), 2.08-
2.00 (t, J = 6Hz, 2H), 1.44-1.32 (m, 8H), 1.19-1.07 (m, 6H). ).  31P NMR (121.5 MHz, 
D2O):  3.99 (1P), -0.11 (1P). MALDI-MS [M+H]
+: calcd for C32H61N4O19P2S 899.3121, 
found 899.3103. 
1-(6-(14-Biotinamido-3,6,9,12-tetraoxatetradecanamido)hexyl sodium phosphate)-
1D-myo-inositol 3-disodium phosphate) (4.2.1g). PI(3)P–amine conjugate 4.2.2a (12 
mg, 0.027 mmol) and biotin–succinimidyl ester 4.2.4 (46 mg, 0.080 mmol) yielded 
4.2.1g as a colorless crystal (12 mg, 47%).  1H NMR (300 MHz, D2O):  4.50-4.44 (m, 
1H), 4.31-4.27 (m, 1H), 3.80 (s, 2H), 3.65-3.54 (m, 18H), 3.51-3.47 (m, 4H), 3.27-3.23 
(m, 4H), 3.13-3.09 (m, 1H), 2.89-2.83 (m, 1H), 2.66-2.62 (m, 1H), 2.14 (t, J = 6Hz, 2H), 
1.65-1.38 (m, 8H), 1.38-1.16 (m, 6H).  31P NMR (121.5 MHz, D2O):  4.15 (1P), -0.08 
(1P). MALDI-MS [M+H]+: calcd for C32H61N4O19P2S 899.3121, found 899.3007. 
Akt PH domain microplate binding analysis using PIPn-biotin conjugates 4.2.1a–g. 
Each binding study involved side-by-side analysis of each headgroup isomer through 
immobilization onto separate rows of a streptavidin-coated 96-well microplate. First, the 
wells to be used were incubated with 200 ul of the wash buffer for the experiment, which 
consisted of 20 mM Tris buffer at pH 8.0 with 0.05% tween as a blocking additive to 
avoid nonspecific surface adsorption, for 30 minutes. This was removed, followed by the 
addition of 100 ul of solutions of biotin-TEG-PIPn ligands of type 4.2.1a–g in wash buffer 
 
 86
into different rows. Binding experiments were run using either a fixed concentration of 
4.2.1a–g (500 nM) or by varying the ligand concentration (0, 40, 80, 140, 160, 200, 240, 
280, 320, 400, 450, 500 nM). These solutions were incubated for 1h, removed, and the 
wells were washed with 3 x 250 ul wash buffer. Next, solutions of the Akt PH domain in 
wash buffer were added. For experiments with fixed [1a–g], protein solutions with 
varying concentrations (0, 1, 3, 5, 6, 7, 8, 9, 10, 12, 15, 20 nM) were added, while for 
those with varying [1a–g], solutions with the same protein concentration (15 nM) were 
added. These solutions were incubated for 1h, removed, and the wells were washed 
with 3 x 250 ul wash buffer. Following this, 200 ul solutions of HRP-tagged anti-GST 
antibody (100 ng/mL) in wash buffer were added to each well. After a 1 h incubation, 
these solutions were removed, and the wells were washed with 3 x 250 ul wash buffer. 
Chemiluminescence detection of bound antibody was next performed using supersignal 
ELISA femto maximum sensitivity substrate. For detection, a 1:1 mixture of the 
substrate and peroxide solutions were mixed, and 100 ul of the resulting solution was 
added to each well. The microplate was then immediately placed in the microplate 
reader, and the chemiluminescence at 425 nm was repeatedly measured for 10 m. 
Several microplate readings from each experiment were then averaged, and the entire 
experiment was rerun at least 3 times and averaged to produce the data depicted in 
figure 4.1. 
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5. CHAPTER 5: Modular Synthesis of 
Bis(monoacylglycero)phosphate for Convenient Access to 
Analogues Bearing Hydrocarbon and Perdeuterated Acyl Chains 
of Varying Length. 
1. Introduction 
     Bis(monoacylglycero)phosphates (BMPs), also known as lysobisphosphatidic acid 
(LBPAs), are formed during the degradation of phosphatidylglycerol and cardiolipin and 
then enriched in the acidic compartments of cells, namely endosomes and lysosomes. 
In physiological conditions, BMP exists as the form of two isomers that are in 
equilibrium with one another (figure 5.1). The acyl chain at the sn-2 position can rapidly 
migrate to sn-3 position through acyl migration under either acidic or basic conditions. 
However, both structures contribute to the natural form of BMPs.  
Figure 5.1 Bis(monoacylglycero)phosphate (BMP) 
     This lipid has been the subject of significant interest for biochemists, cytologists, and 
physiologists in the recent years because of the important role it plays in regulating 
several biological pathways. For instance, membranes presenting BMP are known to 
enhance the degradation of sphingolipids including glucosylceramide, ceramide, GM1, 
and GM2.103,104 BMP also regulates cholesterol transport,105,106 which is aberrant in 
Niemann-Pick type C disease, and the accumulation of anti-BMP antibodies is known to 
alter cholesterol homeostasis.9 In addition, BMP is a known antigen of antiphospholipid 
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antibodies associated with antiphospholipid syndrome.105 Finally, the transport of 
stomatitus virus to late endosomes, the last step prior to cytoplasmic release of the 
nucleocapsid and infection, has been shown to require the presence of BMP.107,108  
      BMP is a minimal lipid component in the whole cell whereas it makes up about 70% 
of the inner membranes and 15% of the total membranes in late endosomes.  
Therefore, the functions of endosomes are closely associated with the unique structure 
of BMPs. BMPs tend to form monolayer membrane instead of bilayers membranes, and 
thus are untouched by the main phospholipases that would destroy phosphatidylcholine 
and phosphotidylethanolamine. BMPs, with the special pH-dependent fusogenic 
properties are ideal candidates to regulate the dynamic properties of this internal 
membrane mosaic and the concentration of BMPs controls the rate of ceramide104 and 
the endosomal cholesterol levels. It is believed that BMP membrane structure controls 
the membrane function. Therefore, BMPs are important in studying the membrane 
properties. 
       The biosynthesis of BMPs starts from phosphatidylglycerol, and occurs primarily in 
the endosomes  (figure 5.2). In the first step, the sn-2 fatty acid chain is removed from 
phosphatidylglycerol by a phospholipase A2. The resulting lysophosphatidylglycerol is 
then acylated on the sn-2’ position of the head group glycerol to generate 
lysobisphosphatidic acid through a transacylase reaction with lysophosphatidylglycerol 
as both the acyl donor and acyl acceptor. Next, the removal of the fatty acid from 
position sn-1 of the primary glycerol unit was followed by the esterification of position 
sn-2 of the primary glycerol unit probably by a transacylation reaction with another 
phospholipid as donor. 
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Figure 5.2 Biosynthetic pathway of bis(monoacylglycero)phosphate (BMP) 
      The earlier successful synthetic work of BMPs benefited from the natural 
biosynthetic pathways. The syntheses utilized chemo-enzymatic approaches through 
reaction of 2 equiv of diacylglycerol with a phosphoryl dichloride, followed by acyl chain 
removal using phospholipase A2. Lately, chemical synthesis has been achieved to 
access BMPs from simple glycerol precursors.109 In these reports, the primary focus has 
been the synthesis of (S,S)-2,2 -BMP structures, in which methods were developed to 
minimize acyl migration to successfully produce this target. In the generation of (S,S)-
3,3 -BMPs, rationally induced acyl migration has been effective for the synthesis of this 
regioisomer from the corresponding (S,S)-2,2 -BMP structure.18,109 
      This chapter will describe a modular synthetic strategy that allows the access of 
BMPs with various chain lengths at sn-3 positions. These molecules are being used to 
study the impact of BMP chain length on membrane property studies, which are 
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currently being performed by our collaborator, Dr. Gail Fanucci at the University of 
Florida.  
2. Results and discussion 
     Synthetic BMP analogs are of great value as chemical tools for understanding their 
biological and structural effect. In the current study, we developed novel (S,S)-3,3 -BMP 
analogues bearing labeled acyl chains for use in characterizing the effect of this lipid on 
membrane structure. For this purpose, a particularly advantageous structural design 
involves the incorporation of perdeuterated acyl chains into the BMP structure. Lipid 
probes with specifically deuterated domains are beneficial for structural studies 
employing NMR and neutron scattering, and have previously been synthesized. 
Furthermore, since we are interested in determining how the identities of the acyl chains 
affect packing within a membrane environment, we sought to synthesize a number of 
(S,S)-3,3 -BMP analogs bearing different chain lengths of both normal saturated and 
perdeuterated lipid tails. 
     The efficient production of a number of BMP analogues containing diversity in the 
acyl chains would benefit from a modular synthesis in which the lipid tails are introduced 
at a late stage. The initial synthetic approach we developed for this purpose is indicated 
in scheme 5.1. This route commenced with commercially available and 
enantiomerically pure (S)-acetonide-protected glycerol (5.2.2), which contains the 
appropriate stereochemistry for the targeted (S,S)-3,3 -BMP derivatives. Protection of 
the hydroxyl group of 5.2.2 as a para-methoxybenzyl (PMB) ether was followed by 
acetonide deprotection to produce diol 5.2.3, as previously described.110 Next, the 
primary hydroxyl group of 5.2.3 was selectively protected as a mono-methoxytrityl 
(MMT) ether to generate alcohol 5.2.4, and then a tert-butyldiphenylsilyl (TBDPS) group 
was installed at the remaining secondary hydroxyl to produce fully protected glycerol 
derivative 5.2.5. The MMT protecting group was next removed and the resulting alcohol 
5.2.6, was converted to phosphodiester 5.2.7 using phosphoramidite chemistry. Finally, 
PMB-deprotection generated diol 5.2.8 as a core scaffold for the production of a range 

























































Scheme 5.1 Synthetic route to the core scaffold of BMPs 
 
     Compound 5.2.8 acts as a convenient modular precursor to BMP analogues as 
different lipid tails can be appended to this diol, followed only by global deprotection to 
the final targets (scheme 5.2). Here, coupling chemistry was used to introduce all 
saturated acyl chains of even length between 12 and 18 carbons in both normal 
saturated and perdeuterated form to produce protected (S,S)-3,3 -BMP phosphotriester 
intermediates 5.2.9a–h. These specific acyl chain motifs were selected to study the 
effect of the length of the lipid tail on biological and physiochemical properties, and 
because the corresponding perdeuterated precursors of these fatty acids are 
commercially available. Finally, global deprotection using TBAF was achieved to access 
5.2.10 a–h,106 consisting of a number of (S,S)-3,3 -BMP probes with acyl chains of 
varying lengths composed of either perdeuterated or natural hydrocarbon acyl chains. 
The final deprotection step proceeded in high yield for the formation of certain 
derivatives, such as bis-palmitoyl derivative 5.2.9c (91%). However, this yield tended to 
decrease with compounds with shorter acyl chains, likely due to problems in isolating 
these compounds as a result of their amphiphilic nature. Other than this challenge, the 
described synthesis is effective, with most steps proceeding in ~85 to 95% yield. 
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Scheme 5.2 Synthetic route to eight BMP analogs 
     Since BMPs are known to undergo acyl chain migrations, it is important to confirm 
the identity of the products from the deprotection producing 5.2.10a–h. In previous 
reports of acyl chain migrations, sn-2-to-sn-3 migration has primarily been noted, 
suggesting that the primary driving force for this transformation is the relief of steric 
strain upon the shift to the less substituted sn-3 position. In fact, quantitative sn-2-to-sn-
3 migration has been reported in the synthesis of BMPs and other glycerolipids under 
certain conditions.110 Based on this evidence, the reverse sn-3-to-sn-2 migration was 
not expected to be problematic in the deprotection of 5.2.9a–h. This was confirmed via 
1H NMR analysis, as the typical chemical shifts for the hydrogens on the (S,S)-3,3 -BMP 
isomer (~  3.9–  4.2) dominated the spectra of 5.2.10a–h (see 1H NMR spectra in the 
experimental section), with minimal of the characteristic peaks of the (S,S)-2,2 -isomer 
(~  3.8,  5.0), both of which have been previously described.109 Thus, this approach is 
effective for accessing a range of analogues of the (S,S)-3,3 -isomer of BMP. 
3. Materials and methods 
General experimental: Generally, reagents were purchased from Acros or Aldrich and 
used as received. Perdeuterated fatty acids were purchased from Cambridge Isotopes. 
Dry solvents were obtained from a Pure Solv solvent delivery system purchased from 
Innovative Technology, Inc. Column chromatography was performed using 230–400 
mesh silica gel purchased from Sorbent Technologies. NMR spectra were obtained 
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using a Bruker AC250 spectrometer updated with a TecMag data collection system, a 
Varian Mercury 300 spectrometer, and a Bruker Avance 400 spectrometer. Mass 
spectra were obtained with either a JEOL DART-AccuTOF spectrometer or a Voyager 
DE MALDI-TOF spectrometer, each with high resolution capabilities. Optical rotation 
values were obtained using a Perkin–Elmer 241 polarimeter. 
NMR spectra of the following compounds can be accessed online through our published 
paper.111 
3-O-(4-Methoxybenzyl)-1-O-((4-methoxyphenyl)diphenylmethyl)-sn-glycerol 
(5.2.4). Enantiomerically pure alcohol 5.2.2 was purchased from Acros Organics, 
converted to diol 5.2.3 using a literature procedure, and the product matched previous 
characterizations.77,112 Diol 5.2.3 (0.080 g, 0.377 mmol) was then dissolved in dry 
pyridine (5 mL), to which was added 4-methoxytrityl chloride (0.233 g, 0.754 mmol) and 
4-dimethylaminopyridine (0.005 g, 0.038 mmol). The solution was stirred at rt for 24 h. 
The reaction mixture was then quenched with methanol (0.5 mL), and the solvent was 
removed under reduced pressure. The resulting residue was purified by column 
chromatography with silica gel and a gradient solvent of 10–40% ethyl acetate/hexanes 
to yield 5.2.4 as a white solid (0.171 g, 94%). [ ]D
296K 0.3 (c 3.0, CH3OH/CHCl3 (v/v 
1:1)); 1H NMR (300 MHz, CDCl3):  7.41 (d, J=6.0 Hz, 4H), 7.16–7.30 (m, 10H), 6.83 
(dd, 1J=12.0 Hz, 2J=9.0 Hz, 4H), 4.45 (s, 2H), 3.91–4.02 (m, 1H), 3.80 (s, 3H), 3.78 (s, 
3H), 3.49–3.60 (AB of ABX, JAX=6 Hz, JAB=12 Hz, JBX=6 Hz, 2H), 3.15–3.24 (AB of 
ABX, JAB=9 Hz, JAX=6 Hz, JBX=6 Hz, 2H), 2.40 (d, J=6.0 Hz, 1H); 
13C NMR (100.6 MHz, 
CDCl3):  159.2, 158.5, 144.3, 135.4, 130.3, 130.0, 129.3, 128.3, 127.8, 126.9, 113.7, 




Alcohol 5.2.4 (0.866 g, 2.89 mmol), tert-butyldiphenylsilyl chloride (0.984 g, 3.58 mmol) 
and imidazole (0.393 g, 3.58 mmol) were combined in dry pyridine (60 mL), and the 
reaction was allowed to stir at rt for 24 h. The reaction mixture was then concentrated 
and the resulting crude was purified by column chromatography with silica gel and a 
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gradient solvent of 5–15% ethyl acetate/hexanes to yield crude 5.2.5 as a colorless oil. 
Compound 5.2.5 was generally passed on to the next step without complete purification 
due to difficulties in removing all byproducts. However, a sample of this compound was 
isolated to homogeneity for the purpose of characterization. [ ]D
296K 0.85 (c 1.0, 
CHCl3); 
1H NMR (400 MHz, CDCl3):  7.64 (d, J=8 Hz, 2H), 7.59 (d, J=8 Hz, 2H), 7.18–
7.37 (m, 16H), 7.04 (d, J=8 Hz, 2H), 6.76 (dd, 1J=16 Hz, 2J=8 Hz, 4H), 4.21–4.29 (AB, 
JAB=12 Hz, 2H), 3.96–4.05 (m, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 3.41–3.58 (AB of ABX, 
JAB=16 Hz, JAX=8 Hz, JBX=8 Hz, 2H), 3.13–3.22 (m, 2H), 1.02 (s, 9H); 
13C NMR 
(100.6 MHz, CDCl3):  158.9, 158.3, 144.6, 135.9, 135.8, 133.9, 130.6, 130.4, 129.4, 
129.0, 128.5, 127.6, 127.4, 126.6, 113.5, 112.9, 86.1, 72.6, 72.0, 71.5, 65.0, 55.2, 55.1, 
30.9, 27.0, 19.3; MALDI-HRMS [M+Na]+ calcd: 745.3320, found: 745.3336. 
2-O-(tert-Butyldiphenylsilyl)-3-O-(4-methoxybenzyl)-sn-glycerol (5.2.6) 
Crude compound 5.2.5 from the previous procedure and camphorsulfonic acid (0.102 g, 
0.44 mmol) were dissolved in 75 mL methanol/methylene chloride mixture (v/v 2:1), and 
the solution was allowed to stir at rt for 3 h. The solvent was then removed under 
reduced pressure, and the residue was purified by column chromatography with silica 
gel and a gradient solvent of 5–35% ethyl acetate/hexanes to yield 5.2.6 as a colorless 
oil (0.732 g, 87% from 5.2.4). [ ]D
296K +28.6 (c 1.50, CHCl3); 
1H NMR (300 MHz, CDCl3): 
 7.63–7.69 (m, 4H), 7.32–7.41 (m, 6H), 7.10 (d, J=9.0 Hz, 2H), 6.81 (d, J=9.0 Hz, 2H), 
4.24–4.32 (AB, JAB=12 Hz, 2H), 3.88–3.96 (m, 1H), 3.78 (s, 3H), 3.61–3.65 (AB, 
JAB=6 Hz, 2H), 3.38–3.53 (AB of ABX, JAB=9 Hz, JAX=6 Hz, JBX=6 Hz, 2H), 2.09 (t, 
J=6.0 Hz, 1H), 1.06 (s, 9H); 13C NMR (100.6 MHz, CDCl3):  159.1, 135.8, 133.4, 130.0, 
129.9, 129.8, 129.2, 127.7, 127.6, 113.7, 72.9, 71.9, 71.3, 64.8, 55.2, 27.0, 19.3; 
MALDI-HRMS [M+Na]+ calcd: 473.2119, found: 473.2093. 
2-Cyanoethyl bis-(3-O-(4-methoxybenzyl)-2-O-(tert-butyldiphenylsilyl)-sn-glycer-1-
yl) phosphate (5.2.7) 
Alcohol 5.2.6 (1.19 g, 2.53 mmol) and bis-N,N-diisopropylamino cyanoethyl phosphine 
(0.381 g, 1.27 mmol) were stirred in 10 mL dry methylene chloride. 1H-tetrazole (5.6 mL 
of a 0.45 M solution in acetontrile, 2.52 mmol) was added and the solution was allowed 
to stir at rt for 48 h. To the stirred reaction mixture, tert-butylhydroperoxide (0.50 mL, 
 
 95
5.06 mmol) was added. After 1 h, the reaction was quenched by adding 50 mL of 
saturated sodium thiosulfate aqueous solution. Next, the resulting solution was 
extracted with methylene chloride (2 80 mL), and the organic layers were combined 
and dried with magnesium sulfate. The solvent was then removed under reduced 
pressure, and the resulting residue was purified by column chromatography with silica 
gel and a gradient solvent of 20–60% ethyl acetate/hexanes to yield 5.2.7 as a colorless 
oil (1.09 g, 84%). [ ]D
296K +12.2 (c 7.25, CHCl3); 
1H NMR (300 MHz, CDCl3):  7.65 (d, 
J=9.0 Hz, 8H), 7.30–7.43 (m, 12H), 7.09 (d, J=6.0 Hz, 4H), 6.81 (d, J=6.0 Hz, 4H), 
4.22–4.29 (m, 4H), 3.88–4.06 (m, 8H), 3.78 (s, 6H), 3.34–3.44 (m, 4H), 2.43 (t, 
J=6.0 Hz, 2H), 1.05 (s, 18H); 13C NMR (100.6 MHz, CDCl3):  159.2, 136.0, 133.7, 
133.3, 130.0, 129.3, 127.8 127.7, 113.8, 73.0, 71.0, 70.9, 70.3, 70.0, 69.0, 68.9, 61.6, 
60.5, 55.4, 27.0, 19.4, 14.3; 31P NMR:  0.534; MALDI-HRMS [M+Na]+ calcd: 
1308.4168, found: 1308.4135. 
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-sn-glycer-1-yl) phosphate (5.2.8).  
Phosphotriester 5.2.7 (1.09 g, 1.07 mmol) was dissolved in methylene chloride (20 mL) 
and water (1 mL), and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 1.21 g, 
5.35 mmol) was added. The reaction was then allowed to stir at rt for 12 h. Next, 60 mL 
of 10% sodium bicarbonate solution was added, which was extracted with methylene 
chloride (2 80 mL). The organic layers were then combined, concentrated, and the 
residue was purified by column chromatography with silica gel and a gradient solvent of 
5–20% acetone/methylene chloride to give 5.2.8 as a colorless oil (0.762 g, 92%). 
[ ]D
296K 12.6 (c 13.4, CHCl3); 
1H NMR (300 MHz, CDCl3):  7.63–7.68 (m, 8H), 7.32–
7.48 (m, 12H), 3.95–4.15 (m, 6H), 3.85 (t, J=6.0 Hz, 2H), 3.48–3.58 (m, 4H), 2.57 (t, 
J=6.0 Hz, 2H), 2.49 (br s, 1H), 1.06 (s, 18H); 13C NMR (100.6 MHz, CDCl3):  135.9, 
135.8, 133.2, 130.2, 128.1, 128.0, 116.4, 71.9, 71.8, 67.6, 67.5, 62.5, 62.0, 27.1, 19.4; 
31P NMR:  0.378; MALDI-HRMS [M+Na]+ calcd: 798.3018, found: 798.2960. 
General procedure for the synthesis of compounds of type 5.2.9 
Fatty acid (4 equiv for normal fatty acid; 2.5 equiv for deuterated fatty acid) was 
dissolved in methylene chloride. N,N -Dicyclohexylcarbodiimide (4 equiv for normal fatty 
acid or 3 equiv for deuterated fatty acid) and 4-dimethylaminopyridine (4 equiv for 
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normal fatty acid or 3 equiv for deuterated fatty acid) were added to the solution. The 
reaction mixture was allowed to stir for 10 min, followed by the addition of 
phosphotriester 5.2.8. The solution was then allowed to stir for 12 h at rt, at which point 
the precipitate that formed was filtered off and the solvent was removed under reduced 
pressure. The residue was purified by column chromatography with silica gel and a 
gradient solvent of 30–40% ethyl acetate/hexanes to yield 5.2.9a–h. 
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-stearyl-sn-glycer-1-yl) phosphate 
(5.2.9a) 
Phosphotriester 5.2.8 (0.114 g, 0.147 mmol) and stearic acid (0.167 g, 0.588 mmol) 
yielded 5.2.9a as a colorless oil (0.171 g, 89%). [ ]D
296K +1.66 (c 9.4, CHCl3); 
1H NMR 
(300 MHz, CDCl3):  7.60–7.70 (m, 8H), 7.34–7.47 (m, 12H), 3.87–4.12 (m, 12H), 2.51 
(t, J=6.0 Hz, 2H), 2.07–2.18 (m, 4H), 1.46–1.55 (m, 4H), 1.25 (s, 56H), 1.05 (s, 18H), 
0.88 (t, J=6.0 Hz, 6H); 13C NMR (100.6 MHz, CDCl3):  173.1, 135.6, 135.5, 132.9, 
132.7, 129.8, 129.7, 127.6, 127.5, 115.8, 69.5, 67.9, 64.2, 61.5, 29.5, 29.1, 29.0, 26.6, 
24.6, 22.5, 19.2, 19.1, 13.9; 31P NMR:  0.759; MALDI-HRMS [M+Na]+ calcd: 
1330.8237, found: 1330.8277. 
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-stearyl-D35-sn-glycer-1-yl) 
phosphate (5.2.9b). Phosphotriester 5.2.8 (0.200 g, 0.258 mmol) and deuterated 
stearic acid D35 (0.212 g, 0.663 mmol) yielded 5.2.9b as a colorless oil (0.280 g, 71%). 
[ ]D
296K +1.44 (c 1.9, CHCl3); 
1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.34–
7.47 (m, 12H), 3.88–4.14 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 1.05 (s, 18H); 13C NMR 
(100.6 MHz, CDCl3):  173.4, 135.8, 135.7, 133.1, 132.9, 130.0, 129.9, 127.8, 127.7, 
116.0, 69.8, 69.7, 68.1, 68.0, 64.3, 61.7, 28.6, 28.4, 28.2, 28.0, 27.8, 26.8, 19.4, 19.3; 
31P NMR:  0.752; MALDI-HRMS [M+Na]+ calcd: 1401.2636, found: 1401.2641. 
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-palmitoyl-sn-glycer-1-yl) 
phosphate (5.2.9c).  Phosphotriester 5.2.8 (0.200 g, 0.258 mmol) and palmitic acid 
(0.265 g, 1.03 mmol) yielded 5.2.9c as a colorless oil (0.266 g, 82%). [ ]D
296K +0.14 (c 
13.3, CHCl3); 
1H NMR (300 MHz, CDCl3):  7.67 (t, J=6.0 Hz, 8H), 7.34–7.48 (m, 12H), 
3.82–4.14 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 2.06–2.19 (m, 4H), 1.46–1.57 (m, 4H), 1.26 
(s, 48H), 1.05 (s, 18H), 0.88 (t, J=6.0 Hz, 6H); 13C NMR (100.6 MHz, CDCl3):  173.8, 
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136.3, 136.2, 133.6, 133.5, 133.4, 130.5, 130.4, 128.3, 128.2, 116.6, 70.3, 70.1, 68.6, 
68.5, 64.9, 64.8, 62.2, 30.2, 30.0, 29.9, 29.8, 29.6, 27.3, 25.3, 23.2, 19.8, 14.6; 31P 
NMR:  0.752; MALDI-HRMS [M+Na]+ calcd: 1274.7611, found: 1274.7509. 
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-palmitoyl-D31-sn-glycer-1-yl) 
phosphate (5.2.9d).  Phosphotriester 5.2.8 (0.125 g, 0.161 mmol) and deuterated 
paltimic acid D31 (0.116 g, 0.403 mmol) yielded 5.2.9d as a colorless oil (0.180 g, 
85%). [ ]D
296K +1.56 (c 6.2, CHCl3); 
1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 
7.34–7.45 (m, 12H), 3.87–4.15 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 1.05 (s, 18H); 13C NMR 
(100.6 MHz, CDCl3):  173.6, 136.1, 136.0, 133.3, 133.2, 133.1, 130.2, 128.0, 116.3, 
70.0, 69.9, 68.3, 64.6, 64.5, 62.0, 61.9, 28.6, 28.5, 28.4, 28.3, 27.0, 19.7, 19.6, 19.5; 31P 
NMR:  0.752; MALDI-HRMS [M+Na]+ calcd: 1337.1168, found: 1337.1210. 
4.7.5. 2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-myristoyl-sn-glycer-1-yl) 
phosphate (5.2.9e).  Phosphotriester 5.2.8 (0.128 g, 0.165 mmol) and myristic acid 
(0.151 g, 0.660 mmol) yielded 5.2.9e as a colorless oil (0.177 g, 90%). [ ]D
296K +1.64 (c 
2.1, CHCl3); 
1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.33–7.47 (m, 12H), 
3.89–4.16 (m, 12H), 2.52 (t, J=6.0 Hz, 2H), 2.12–2.16 (m, 4H), 1.50–1.54 (m, 4H), 1.26 
(s, 40H), 1.05 (s, 18H), 0.88 (t, J=6.0 Hz, 6H); 13C NMR (100.6 MHz, CDCl3):  173.3, 
135.8, 135.7, 132.9, 130.0, 129.9, 127.8, 127.7, 116.1, 69.8, 69.6, 68.1, 68.0, 64.4, 
64.3, 61.7, 33.9, 31.9, 29.1, 26.8, 24.8, 22.7, 19.3, 14.1; 31P NMR:  0.752; MALDI-
HRMS [M+Na]+ calcd: 1218.6985, found: 1218.6965. 
4.7.6. 2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-myristoyl-D27-sn-glycer-1-
yl) phosphate (5.2.9f). Phosphotriester 5.2.8 (0.120 g, 0.155 mmol) and deuterated 
myristic acid D27 (0.099 g, 0.387 mmol) yielded 5.2.9f as a colorless oil (0.164 g, 85%). 
[ ]D
296K +1.46 (c 1.6, CHCl3); 
1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.33–
7.47 (m, 12H), 3.86–4.15 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 1.06 (s, 18H); 13C NMR 
(100.6 MHz, CDCl3):  173.6, 136.1, 136.0, 133.3, 133.2, 133.1, 130.3, 130.2, 128.0, 
116.3, 70.0, 69.9, 68.3, 64.5, 62.0, 34.2, 28.3, 25.2, 19.7, 19.6, 19.5; 31P NMR:  
0.759; MALDI-HRMS [M+Na]+ calcd: 1273.0084, found: 1,273.0082. 
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-lauroyl-sn-glycer-1-yl) phosphate 
(5.2.9g). Phosphotriester 5.2.8 (0.122 g, 0.157 mmol) and lauric acid (0.126 g, 
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0.629 mmol) yielded 5.2.9g as a colorless oil (0.158 g, 88%). [ ]D
296K +1.86 (c 5.3, 
CHCl3); 
1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.32–7.44 (m, 12H), 3.87–
4.16 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 2.06–2.18 (m, 4H), 1.50–1.54 (m, 4H), 1.26 (s, 
32H), 1.05 (s, 18H), 0.88 (t, J=6.0 Hz, 6H); 13C NMR (100.6 MHz, CDCl3):  173.6, 
136.1, 136.0, 133.3, 133.1, 130.3, 130.2, 128.0, 116.3, 70.0, 69.9, 68.3, 64.6, 62.0, 
61.9, 29.9, 29.7, 29.6, 29.5, 29.4, 27.0, 25.0, 22.9, 19.5, 14.4; 31P NMR:  0.759; 
MALDI-HRMS [M+Na]+ calcd: 1162.6359, found: 1162.6335. 
2-Cyanoethyl bis-(2-O-(tert-butyldiphenylsilyl)-3-lauroyl-D23-sn-glycer-1-yl) 
phosphate (5.2.9h). Phosphotriester 5.2.8 (0.122 g, 0.157 mmol) and deuterated lauric 
acid D23 (0.088 g, 0.393 mmol) yielded 5.2.9h as a colorless oil (0.172 g, 92%). [ ]D
296K 
+1.60(c 1.9, CHCl3); 1H NMR (300 MHz, CDCl3):  7.66 (t, J=6.0 Hz, 8H), 7.33–7.46 (m, 
12H), 3.86–4.18 (m, 12H), 2.51 (t, J=6.0 Hz, 2H), 1.05 (s, 18H); 13C NMR (100.6 MHz, 
CDCl3):  173.6, 136.1, 136.0, 133.1, 130.2, 128.0, 116.3, 70.0, 69.9, 68.3, 64.5, 62.0, 
61.9, 34.2, 28.5, 28.3, 28.0, 27.0, 19.7, 19.6, 19.5; 31P NMR:  0.759; MALDI-HRMS 
[M+Na]+ calcd: 1208.9000, found: 1208.9042. 
General procedure for the synthesis of compound 5.2.10 
Phosphotriester 5.2.9 (1 equiv) and tetrabutylammonium fluoride trihydrate (TBAF, 15–
20 equiv) were dissolved in 5 mL of THF, and the reaction was allowed to stir at rt 
overnight. The solvent was then removed under reduced pressure, and the resulting 
residue was dissolved in 100 mL of methanol/chloroform mixture (v/v 1:4), and 
extracted with 40 mL of 8 mM aqueous ammonium acetate solution. Next, the organic 
layer was concentrated, and the resulting residue was purified by column 
chromatography with 20 g silica gel and a gradient solvent of 5–16% 
methanol/methylene chloride to yield a yellowish solid as the crude product. The crude 
product was then washed with water and then methanol to provide a white solid, which 
was dissolved in methanol/chloroform mixture (v/v 1:4) and filtered. The filtrate was then 
concentrated under reduced pressure to yield 9 as a white powder. 
Bis-(3-stearyl-sn-glycer-1-yl) phosphate ammonium salt (5.2.10a). Phosphotriester 
5.2.9a (0.094 g, 0.0719 mmol) was treated with tetrabutylammonium fluoride trihydrate 




296K +0.33 (c 1.2, MeOH/CHCl3); 
1H NMR (300 MHz, CD3OD/CDCl3):  3.75–
4.35 (m, 10H), 2.30–2.40 (m, 4H), 1.58–1.66 (m, 4H), 1.27 (s, 56H), 0.83–0.92 (m, 6H); 
13C NMR (100.6 MHz, CD3OD/CDCl3):  174.1, 68.4, 66.6, 64.7, 33.8, 31.7, 29.5, 29.4, 
29.3, 29.1, 29.0, 24.6, 22.4, 13.7; 31P NMR:  2.483; MALDI-HRMS [C42H83O10P+Na]
+ 
calcd: 801.5616, found: 801.5597. 
Bis-(3-stearyl-D35-sn-glycer-1-yl) phosphate ammonium salt (5.2.10b). 
Phosphotriester 5.2.9b (0.062 g, 0.0450 mmol) was treated with tetrabutylammonium 
fluoride trihydrate (0.213 g, 0.675 mmol) in 5 mL THF and yielded 5.2.10b as a white 
powder (0.034 g, 87%). [ ]D
296K +2.03 (c 3.2, MeOH/CHCl3); 1H NMR (300 MHz, 
CD3OD/CDCl3):  3.78–4.28 (m, 10H), 1.27 (s, 7H), 0.83–0.92 (m, 2H); 
31P NMR:  
2.813; MALDI-HRMS [C42H12D70O10PNa+Na]
+ calcd: 893.9848, found: 893.9797. 
Bis-(3-palmitoyl-sn-glycer-1-yl) phosphate ammonium salt (5.2.10c). 
Phosphotriester 5.2.9c (0.266 g, 0.213 mmol) was treated with tetrabutylammonium 
fluoride trihydrate (1.00 g, 3.19 mmol) in 5 mL THF and yielded phosphate 5.2.10c as a 
white powder (0.143 g, 91%). [ ]D
296K +0.36 (c 1.4, MeOH/CHCl3); 
1H NMR (300 MHz, 
CD3OD/CDCl3):  3.70–4.30 (m, 10H), 2.28–2.42 (m, 4H), 1.55–1.68 (m, 4H), 1.27 (s, 
48H), 0.80–0.95 (m, 6H); 13C NMR (100.6 MHz, CD3OD/CDCl3):  174.0, 66.5, 66.4, 
64.7, 33.7, 31.7, 29.5, 29.3, 29.1, 29.0, 28.7, 24.6, 22.4, 13.6; 31P NMR:  2.806; 
MALDI-HRMS [C38H75O10P+Na]
+ calcd: 745.4990, found: 745.4944. 
Bis-(3-palmitoyl-D31-sn-glycer-1-yl) phosphate ammonium salt (5.2.10d) 
Phosphotriester 5.2.9d (0.180 g, 0.137 mmol) was treated with tetrabutylammonium 
fluoride trihydrate (0.648 g, 2.05 mmol) in 5 mL THF and yielded phosphate 5.2.10d as 
a white powder (0.051 g, 46%). [ ]D
296K +0.27 (c 4.1, MeOH/CHCl3); 
1H NMR (300 MHz, 
CD3OD/CDCl3):  3.85–4.28 (m, 10H), 1.18–1.35 (m, 2H); 
31P NMR:  2.483; MALDI-
HRMS [C38H12D62O10PNa+Na]
+ calcd: 829.8367, found: 829.8643. 
Bis-(3-myristoyl-sn-glycer-1-yl) phosphate ammonium salt (5.2.10e). 
Phosphotriester 5.2.9e (0.177 g, 0.148 mmol) was treated with tetrabutylammonium 
fluoride trihydrate (0.700 g, 2.22 mmol) in 5 mL THF and yielded phosphate 5.2.10e as 
a white powder (0.046 g, 45%). [ ]D
296K +0.96 (c 1.2, MeOH/CHCl3); 
1H NMR (300 MHz, 
CD3OD/CDCl3):  3.85–4.18 (m, 10H), 2.36 (t, J=9.0 Hz, 4H), 1.55–1.70 (m, 4H), 
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1.27(s, 40H), 0.89 (t, J=6.0 Hz, 6H); 13C NMR (100.6 MHz, CD3OD/CDCl3):  174.4, 
68.7, 66.7, 65.0, 34.1, 32.0, 29.6, 29.3, 24.9, 22.7, 14.0; 31P NMR:  1.804; MALDI-
HRMS [C34H67O10P+Na]
+ calcd: 689.4370, found: 689.4360. 
Bis-(3-myristoyl-D27-sn-glycer-1-yl) phosphate ammonium salt (5.2.10f). 
Phosphotriester 5.2.9f (0.265 g, 0.212 mmol) was treated with tetrabutylammonium 
fluoride trihydrate (0.969 g, 3.07 mmol) in 5 mL THF and yielded phosphate 5.2.10f as a 
white powder (0.030 g, 19%). [ ]D
296K +0.31 (c 2.3, MeOH/CHCl3); 
1H NMR (300 MHz, 
CD3OD/CDCl3):  3.85–4.25 (m, 10H), 1.20–1.36 (m, 5H); 
31P NMR:  1.931; MALDI-
HRMS [C34H12D54O10PNa+Na]
+ calcd: 765.7282, found: 765.7543. 
Bis-(3-lauroyl-sn-glycer-1-yl) phosphate ammonium salt (5.2.10g). Phosphotriester 
5.2.9g (0.158 g, 0.139 mmol) was treated with tetrabutylammonium fluoride trihydrate 
(0.875 g, 2.77 mmol) in 5 mL THF and yielded phosphate 5.2.10g as a white powder 
(0.039 g, 45%). [ ]D
296K +0.23 (c 2.0, MeOH/CHCl3); 
1H NMR (300 MHz, 
CD3OD/CDCl3):  3.82–4.25 (m, 10H), 2.36 (t, J=9.0 Hz, 4H), 1.55–1.70 (m, 4H), 1.28 
(s, 32H), 0.89(t, J=6.0 Hz, 6H); 13C NMR (100.6 MHz, CD3OD/CDCl3):  173.9, 68.2, 
66.2, 64.6, 33.6, 31.5, 29.1, 28.8, 24.4, 22.2, 13.3; 31P NMR:  2.413; MALDI-HRMS 
[C30H58O10PNa+Na]
+ calcd: 655.3558, found: 655.3541. 
Bis-(3-lauroyl-D23-sn-glycer-1-yl) phosphate ammonium salt (5.2.10h). 
Phosphotriester 5.2.9h (0.260 g, 0.219 mmol) was treated with tetrabutylammonium 
fluoride trihydrate (1.38 g, 4.38 mmol) in 5 mL THF and yielded phosphate 5.2.10d as a 
white powder (0.029 g, 20%). [ ]D
296K +0.60 (c 2.0, MeOH/CHCl3); 
1H NMR (300 MHz, 
CD3OD/CDCl3):  3.85–4.25 (m, 10H), 1.20–1.38 (m, 15H); 
31P NMR:  2.490; MALDI-
HRMS [C30H12D46O10PNa+Na]





6. CHAPTER 6. Synthesis of lysophosphatidylcholine (LPC) to 
facilitate the research in the role of lysophospholipase A-I in 
lysophosphatidic acid (LPA) production. 
1. Introduction 
       Lysophosphatidic acid (LPA) is an important lipid that is involved in many biological 
processes, such as cell proliferation and survival, cell migration and invasion, tumor 
progression, wound healing and many others.16,17 However, the biosynthetic pathway(s) 
to produce LPA in biological fluids has not yet been fully understood. In other to 
investigate this issue, our collaborators Ms. Alyssa Bolen and Dr. Gabor Tigyi purified a 
phospholipase A1 (PLA1) from thrombin-activated human platelets. This PLA1 was 
indentified by proteomic studies as acyl-protein thioesterase 1, a novel PLA1. It was 
observed that the addition of this enzyme greatly increased the production of sn-2-
esterified polyunsaturated lysophosphatidylcholines (LPCs) and the corresponding 
LPAs in blood.  Since LPCs are precursors of LPAs in biosynthetic pathways and the 
conversion of LPCs into LPAs rely on lysophospholipase D or autotaxin (ATX), they 
extended the investigation to study ATX’s regioisomeric preference on LPC (sn-1 LPC 
v.s. sn-2 LPC, see figure 6.1).  In order to do so, 2-oleyl-sn-glycero-3-phosphocholine 
was needed to be synthesized with ether linkage to prevent acyl chain migration. We 
set out to synthesize this molecule to support their research work.  
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Figure 6.1 Lysophosphatidylcholine (LPC) 
 
Scheme 6.1 Synthesis of sn-2 lysophosphatidylcholine 
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2. Results and Discussion 
      The synthetic route to 2-Oleoyl-sn-glycero-3-phosphocholine is shown in scheme 
6.1. The synthesis began with 3-O-(4-Methoxybenzyl)-sn-glycerol 5.2.3, which contains 
a built-in stereo center needed for the targeted compound, 2-Oleoyl-sn-glycero-3-
phosphocholine 6.1.1. The selective primary alcohol protection of compound 5.2.3 with 
tert-butyldiphenyl chlorosilane was followed by etherization of the secondary alcohol 
with oleyl triflate to afford 6.1.3. The PMB deprotection of 6.1.3 led to compound 6.1.4. 
The one-pot phosphorylation of 6.1.4 afforded 6.1.5.  Compound 6.1.5 was surprisingly 
found with ethyl cyano protecting group removed from the phosphodiester. Followed up 
by mass spectrometry, this was found to happen during the purification process. The 
removal of the silyl protecting group of 6.1.5 by TBAF yielded the targeted product 6.1.1. 
It is worthy to mention that a similar but different scheme was performed with the silyl 
group deprotected first and PMB deprotection as the final step.  This has led to the 
extreme difficulty of final purification. The slightly revised synthetic scheme has given 
pure product with very easy purification steps as mentioned above. The racemic 
compound 6.1.1 has also been previously synthesized in a different way.113,114  
        Using this synthetic sn-2 LPC, it was found that ATX preferred the sn-1 over the 
sn-2 regioisomer of LPC. Therefore, a LPA production pathway in blood is proposed as 
follows: 1) activated platelets release PLA1; 2) PLA1 produces sn-2 LPCs; 3) these 
newly produced sn-2 LPCs undergo acyl migration to yield sn-1 LPCs, which are the 
preferred substrates of ATX. 4) ATX cleaves the sn-1 LPCs to generate sn-1 LPA 
species. 
General experimental.  
Generally, reagents were purchased from Acros, Aldrich or AK Scientific, Inc., Alfa 
Aesar and used as received. Dry solvents were obtained from a Pure Solv solvent 
delivery system purchased from Innovative Technology, Inc. Column chromatography 
was performed using 230–400 mesh silica gel purchased from Sorbent Technologies. 
NMR spectra were obtained using a Varian Mercury 300 spectrometer. Mass spectra 
were obtained with a Voyager DE MALDI-TOF spectrometer. Optical rotation values 
were obtained using a Perkin–Elmer 241 polarimeter. 
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3-O-(4-Methoxybenzyl)-1-O-(tert-Butyldiphenylsilyl)-sn-glycerol (6.1.2). Diol 5.2.3 
was prepared from S-glycerol acetonide (purchased from AK Scientific, Inc.) according 
to a known procedure,77 same compound has also been prepared by our group.111 Diol 
5.2.3 (0.430 g, 2.026 mmol) was stirred in dry DMF (20 mL). To this solution, tert-
butyldiphenyl chlorosilane (0.525 mL, 2.026 mmol) was added, followed by imidazole 
(0.359 g, 5.270 mmol). The reaction mixture was stirred at room temperature overnight. 
The solvent was then concentrated at a reduced pressure. The resulting residue was 
dissolved in CHCl3 (100 mL) and extracted by H2O (50 mL x 2). The organic layer was 
collected, dried by magnesium sulfate and condensed to yield the crude product, which 
was then purified by column chromatography with silica gel and a gradient solvent of 
15–35% ethyl acetate/hexanes to yield 4 as a colorless oil (0.73 g, 80%).  The product 
matched previous characterizations.111 
1H NMR (300 MHz, CDCl3):  7.62–7.65 (m, 4H), 7.34–7.42 (m, 6H), 7.20-7,25 (m, 2H), 
6.84-6.87 (m, 2H), 4.45 (s, 2H), 3.88–3.92 (m, 1H), 3.79 (s, 3H), 3.69–3.71 (m, 2H), 
3.50-3.54 (m, 2H), 2.47 (d, J=6.0 Hz, 1H), 1.06 (s, 9H); MALDI-HRMS [M+Na]+ calcd: 
473.2119, found: 473.2093. 
1-O-(tert-Butyldiphenylsilyl)-2-oleyl-3-O-(4-Methoxybenzyl)-sn-glycerol (6.1.3). 
Compound 6.1.2 (0.660 g, 1.465 mmol) was combined with oleyl triflate (2.900 g, 7.240 
mmol) (prepared from a known precedureand proton sponge (1.10 g, 5.15 mmol) in dry 
dichloromethane (40 mL). The solution was heated to reflux and stirred overnight. The 
solvent was then removed under reduced pressure to yield the crude product 6.1.3, 
which was purified by column chromatography with silica gel and a gradient solvent of 
5–10% acetone/hexanes to yield 6.1.3 as a yellowish oil (0.714 g, 71%). 
1H NMR (300 MHz, CDCl3):  7.66–7.75 (m, 4H), 7.32–7.40 (m, 6H), 7.22-7.30 (m, 2H), 
6.83-6.91 (m, 2H), 5.35-5.41 (m, 2H), 4.47-4.52 (m, 2H), 3.73-3.80 (m, 3H), 3.38 -3.70 
(m, 7H), 2.04 (m, 4H), 1.58 (m, 2H), 1.33 (m, 24H), 1.03-1.06 (m, 9H), 0.90-0.94 (m, 
3H); 13C NMR (100.6 MHz, CDCl3):  159.14, 135.99, 135.64, 133.57, 129.90, 129.48, 
129.21, 129.13, 127.66, 127.43, 113.69, 113.59, 79.48, 73.02, 71.38, 69.71, 63.50, 
55.16, 32.70, 31.99, 30.18, 29.78, 29.72, 29.58, 29.33, 26.20, 22.76, 19.25, 14.21; 




Compound 6.1.3 (0.325 g, 0.463 mmol) was combined with 2,3-dichloro-5,6-
dicyanobenzoquinone (0.315 g, 1.389 mmol) in dichloromethane (10 mL) and H2O (1 
mL).  The reaction mixture was stirred at room temperature. After 10 hours, saturated 
sodium bicarbonate (100 mL) was added to quench the solution, which was then 
extracted twice by chloroform (100 mL x 2).  The organic layers were dried by 
magnesium sulfate and condensed to yield the crude product 6.1.4, which was carried 
on to the next step without further purification. Crude compound 6.1.4 was combined 
with bis-N,N-diisopropylamino cyanoethyl phosphine (0.205 g, 0.606 mmol), 1H-
tetrazole (0.740 mL of a 0.45 M solution in acetontrile, 0.333 mmol)  in dichloromethane 
(10 mL) and the solution was allowed to stir at room teperature for 1 h. To this stirred 
solution, choline tosylate (0.334 g, 1.212 mmol) 1H-tetrazole (2.690 mL of a 0.45 M 
solution in acetontrile, 1.212 mmol) were added and the solution was allowed to stir at 
room temprerature for another 12 h.  To this solution, tert-butylhydroperoxide (0.470 mL, 
4.848 mmol) was added. After 1 h, the reaction was quenched by adding 50 mL of 
saturated sodium thiosulfate aqueous solution. Next, the resulting solution was 
extracted with methanol/methylene chloride (v/v 1:4, 80 mL 2), and the organic layers 
were combined and dried with magnesium sulfate. The solvent was then removed under 
reduced pressure, and the resulting residue was purified by column chromatography 
with silica gel and a gradient solvent of 5–30% methanol/dichloromethane to yield 6.1.5 
as a colorless oil (0.060 g, 17 % yield over 2 steps). 
1H NMR (300 MHz, CDCl3):  7.65–7.69 (m, 4H), 7.26–7.38 (m, 6H), 5.32-5.35 (m, 2H), 
4.14-4.18 (m, 2H), 3.89-3.91 (m, 2H), 3.49-3.74 (m, 2H), 3.28-3.30 (m, 2H), 3.22 (s, 9H), 
1.99-2.01 (m, 4H), 1.47-1.49 (m, 2H), 1.19-1.23 (m, 24H), 1.02 (s, 9H), 0.86 (t, J=6.0 Hz, 
3H); 31P NMR:  0.59; MALDI-HRMS [M+Na]+ calcd: 746.4939, found: 746.4946. 
2-Oleoyl-sn-glycero-3-phosphocholine (6.1.1). Compound 6.1.5 (0.060 g, 0.080 
mmol) and tetrabutylammonium fluoride trihydrate (TBAF, 0.126 g, 0.40 mmol) were 
dissolved in THF (10 mL), and the reaction was allowed to stir at rt overnight. The 
solvent was then removed under reduced pressure, and the resulting residue was 
purified by column chromatography with 3 g of silica gel and a gradient solvent of 10–
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50% methanol/chloroform to yield 6.1.1, but mixed with TBAF. The crude product 6.1.1 
was then stirred with sodium form in H2O for 3 h. The solution was directly loaded onto 
a C18 reverse phase column. The column was eluted with H2O-methanol and the pure 
product 6.1.1 came out with 80% methanol/H2O. The fractions with 6.1.1 were collected 
and condensed to yield a off-white paste compound 6.1.1 (0.025 g, 62 %). The product 
matched previous characterizations.113,114 
1H NMR (300 MHz, CD3OD/CDCl3, v/v 1:2):  5.33-5.36 (m, 2H), 4.4-4.28 (m, 2H), 3.96 
(m, t, J=6.0 Hz, 2H), 3.49-3.74 (m, 5H), 3.34-3.36 (m, 2H), 3.21 (s, 9H), 1.99-2.04 (m, 
4H), 1.52-1.59 (m, 2H), 1.25-1.32 (m, 24H), 0.86 (t, J=6.0 Hz, 3H); 31P NMR:  4.01; 





7. Chapter 7. Miscellaneous synthetic probes and compounds 
 
1. Synthesis of rhodamine 6G and rhodamine B. 
     For a collaborative research project with Dr. Jon Camden, we synthesized 





































7.1.1 a-b7.1.5 a-b7.1.4 a-b7.1.3
















Scheme 7.1 Synthesis of various rhodamines. 
 
A combination of two reported procedures was adopted to synthesize the rhodamine 
compounds.115,116 
General procedure to synthesize rhodamine 7.1.1a-b. o-Ethylamino-p-cresol and 
phthalic anhydride (for 7.1.1a) or phthalic anhydride (D4) (for 7.1.1b)  were combined in 
16 mL 1,2-dichlorobenzene. The reaction was refluxed at 180 C with Dean-Stark 
apparatus overnight. The reaction was then cooled to room temperature and diethyl 
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sulfate and sodium hydroxide was added. The reaction mixture was stirred at 100-110 C 
overnight. The solvent was then removed under reduced pressure. The crude was 
purified by column chromatography with a gradient solvent system of 6-10% 
methanol/dichloromethane with 1% triethylamine. The collected product was then dried 
and was re-dissolved in 5 mL ethanol. 10 mL of 14% potassium bromide was added 
and the solution was stirred at room temperature overnight. Ethanol was then removed 
and the rhodamine bromide salt was filtered to yield rhodamine 7.1.1a-b.  
Rhodamine 6G (7.1.1a). o-Ethylamino-p-cresol (410 mg, 2.712 mmol) and phthalic 
anhydride (200 mg, 1.350 mmol), diethyl sulfate (0.256 mL, 1.04 mmol) and sodium 
hydroxide (36 mg, 0.67 mmol) was used. 5 mL Ethanol and 10 mL of 14% potassium 
bromide used to precipitate the rhodamine bromide salt as greenish needles 7.1.1a (70 
mg).  
1H NMR (300 MHz, CDCl3)  8.31 (d, J = 9 Hz, 1H), 7.83 7.74 (m, 2H), 7.34-7.27 (m, 
1H), 6.73 (s, 2H), 6.65 (s, 2H), 4.03 (q, J = 6 Hz, 2H), 3.64-3.55 (m, 4H), 2.31 (s, 6H), 
1.40 (t, J = 9 Hz, 6H), 0.99 (t, J = 6 Hz, 3H). MALDI-HRMS [M + H]+ calcd for 423.2329; 
found, 423.2320. 
Rhodamine 6G (D4) (7.1.1b). o-Ethylamino-p-cresol (205 mg, 1.356 mmol) and 
phthalic anhydride (103 mg, 0.678 mmol), diethyl sulfate (0.1 mL, 0.702 mmol) and 
sodium hydroxide (18 mg, 0.450 mmol) was used. 5 mL Ethanol and 10 mL of 14% 
potassium bromide used to precipitate the rhodamine bromide salt as greenish needles 
7.1.1a (40.5 mg).  
1H NMR (300 MHz, CDCl3)  7.12 (t, J = 6 Hz, 2H), 6.73 (s, 2H), 6.65 (s, 2H), 4.04 (q, J 
= 6 Hz, 2H), 3.62-3.53 (m, 4H), 2.30 (s, 6H), 1.41 (t, J = 9 Hz, 6H), 1.01 (t, J = 6 Hz, 
3H).  
Rhodamine B (7.1.2). 3-Dimethylaminophenol (286 mg, 2.08 mmol) and 1,2,4-
benzene-tricarboxylic anhydride (200 mg, 1.04 mmol) were combined in 16 mL 1,2-
dichlorobenzene. The reaction was refluxed at 180 C with Dean-Stark apparatus 
overnight. The reaction was then cooled to room temperature and the precipitate was 
filtered off. The solvent was then removed under reduced pressure. The crude was 
purified by column chromatography with a gradient solvent system of 10-25% 
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methanol/dichloromethane to yield rhodamine B 6.6.2. The product was further purified 
on a C18 reverse-phase column (2 g) The collected product was then dried and was re-
dissolved in 5 mL ethanol. 10 mL of 14% potassium bromide was added and the 
solution was stirred at room temperature overnight. Ethanol was then removed and the 
rhodamine bromide salt was filtered to yield rhodamine 7.1.1a-b.  
1H NMR (300 MHz, D2O)  8.00-7.97 (m, 2H), 7.75-7.73 (m, 2H), 7.09-7.02 (m, 2H), 





2. Synthesis of Inositol (1,4,5)-Trisphosphate (InsP3). 
  In a collaborative project with Chi-Linh Do-Thanh in our group to deveplop a 
fluorescent bis-cyclen tweezer receptor for inositol (1,4,5)-trisphosphate, I synthesized 





















































7.2.17.2.2 7.2.3  
Scheme 7.2 Synthesis of Inositol (1,4,5)-Trisphosphate (InsP3). 
The synthesis started with D-myo inositol. The preparation until 1D-2,3,6-O-Tris-
(benzyloxymethyl)-myo-inositol 4,5-bis-(dibenzyl phosphate) (7.2.2) was previously 
reported.96,102 Phosphorylation of the last free alcohol yielded compound 7.2.3 which 
then underwent a global protecting group deprotection to form the inositol (1,4,5)-
trisphosphate 7.2.1. 
1D-2,3,6-O-Tris-(benzyloxymethyl)-myo-inositol 1,4,5-tis-(dibenzyl phosphate) 
(7.2.3). To a solution of 7.2.2 (67 mg, 0.063 mmols) and 1-H-tetrazole (0.56 mL, 0.253 
mmol, 0.45 M in acetonitrile) in methylene chloride (15 mL) under nitrogen gas was 
added dibenzyl N,N-diisopropylphosphoramidite (0.30 mL, 0.91 mmol), and the mixture 
was then stirred at rt for 10 h. The reaction solution was then cooled to 0 °C, and m-
CPBA (158 mg, 57 86%) was added. The mixture was stirred at this temperature for 60 
min and then slowly warmed to rt after the removal of the cooling bath. The solution was 
next diluted to 100 mL with methylene chloride and washed with saturated aqueous 
sodium bicarbonate (2  60 mL), and the resulting aqueous phase was extracted once 
more with methylene chloride (60 mL). The organic phases were dried with magnesium 
sulfate, filtered, and concentrated, and the residue was then purified by chromatography 
on silica gel (15-35% acetone/hexanes) giving tris-phosphodiester 7.2.3 (75 mg, 90%) 
as a syrup. [ ]D
296K 24.3 (c = 1.0, CHCl3);  
1H NMR (300 MHz, CDCl3)  7.21 7.28 (m, 
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45H), 4.91 5.10 (m, 16H), 4.68 4.88 (m, 3H), 4.62-4.66 (m, 2H), 4.56 4.62 (m, 3H), 
4.44 4.56 (m, 2H), 4.36-4.42 (m, 2H), 4.29 (t, 1H), 4.20 (t, 1H); 31P NMR (161.8 MHz, 
CDCl3)  0.091. MALDI-HRMS [M + Na]
+ calcd for C72H75O18P3, 1343.41; found, 
1343.44. 
(-)-D-myo-Inositol 1,4,5-trisphosphate hexakis sodium salt (7.2.1). To a solution of 
1D-2,3,6-O-Tris-(benzyloxymethyl)-myo-inositol 1,4,5-tis-(dibenzyl phosphate) (7.2.3, 75 
mg, 0.057 mmol) in methanol (50 mL) was added palladium hydroxide on charcoal (15 
mg). The mixture was then stirred under 1 atm of hydrogen (balloon) for 3 days at rt. 
Next, the catalyst was removed by filtration, and the residue was with washed with 
methanol. The solvent was the removed under vacuum, and the crude product was 
dissolved in water and stirred for 3 h with Chelex 100 resin (Sigma, Na+ form). The resin 
was removed by filtration, and the filtrate was lyophilized to give InsP3 (2, 29 mg, 94%) 







3. Synthesis of phosphatidylinositol (3,4,5)-trisphosphate.  
     In order to obtain a phosphatidyinositol polyphosphate with lipid backbone that can 
be incorporated into liposome, we designed a rapid synthetic route to access lipid as 























































Scheme 7.3 Synthesis of phosphatidylinositol (3,4,5)-trisphosphate. 
 
     First of all, the lauric acid was activated into an NHS ester which was reacted with 
amino-tagged PI(3,4,5)P3 to generate PI(3,4,5)P3 7.3.1.  
Phosphatidylinositol (3,4,5)-trisphosphate (7.3.1).  Lauric acid (200 mg, 1.0 mmol) 
was dissolved in 10 mL THF. To this solution was added N-hydroxy succinimide (115 
mg, 1.0 mmol) and DCC (206 mg, 1.0 mmol). The reaction was stirred at room 
temperature overnight. The by-product DCU was filtered off and the filtrate was 
concentrated to yield the crude NHS ester which was then purified through a short silica 
gel column with a solvent system of 1:20 acetone/dichloromethane to yield the pure 
NHS ester as a white solid (239 mg, 85%). The lauryl NHS ester (18 mg, 0.064 mmol) in 
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1 mL DMF was added amino-tagged PI(3,4,5)P3 (10 mg, 0.013 mmol) in 1 mL TEAB 
(1M, pH=7.5). About 0.5 mL of THF was added to this solution. The reaction was stirred 
at room temperature overnight. The solvent was then removed under reduced pressure. 
The yielded crude was washed by acetone (10 mL x3) and then dissolved in 5 mL 
deionized water. The solution was filtered and the filtrate was lyophilized to generate 
compound 7.3.1 as a white solid (7 mg, 58%). 
1H NMR (300MHz, D2O)  4.23-4.21 (m, 2H), 3.88-3.77 (m, 6H), 3.02-3.00 (m, 2H), 
2.06-2.04 (m, 2H), 1.46-1.40 (m, 6H), 1.19-1.10 (m, 18H), 0.70-0.69 (m, 6H). 31P NMR 
(161.8 MHz, D2O)  4.57, 3.25, 2.56, 0.75. MALDI-HRMS [M + Na]





4. Synthesis of phosphatidylinositol (3, 5)-bisphosphate fluorescein conjugate.  
     A soluble PI(3,5)P2-fluorescein conjugate was requested by our collaborator, Dr. Jon 
Andresen from the University of Missouri-Kansas City. Adopting the modular PIPns 
probe synthetic strategy, we derivatized the amino-tagged PI(3,5)P2 into 5(6)-


































2.2.7 7.4.2 7.4.1  
Scheme 7.4 Synthesis of PI(3,5)P2 fluorescein conjugate. 
 
 
Phosphatidylinositol (3,5)-bisphosphate (7.4.1). 5(6)-carboxyfluorescein (50 mg, 
0.133 mmol) was dissolved in a mixture of 1 mL THF and 1 mL DMF. To this solution 
was added N-hydroxy succinimide (31 mg, 0.266 mmol) and DCC (55 mg, 0.266 mmol). 
The reaction was stirred at room temperature for 1.5 hours. The solvent was then 
removed under reduced pressure. The crude was washed by ethyl ether (20 mL x3). 
The solid was then dissolved in 10 mL chloroform and filtered. The filtrate was 
concentrated to yield the CBF-NHS ester, which was next dissolved in 1 mL DMF. To 
this solution was added amino-tagged PI(3, 5)P3 (4.5 mg, 0.0072 mmol) in 1 mL TEAB 
(1M, pH=7.5). About 0.5 mL of THF was added to the solution. The reaction was stirred 
at room temperature overnight. The solvent was then removed under reduced pressure. 
The yielded crude was washed by cold acetone (10 mL x3) and then dissolved in 5 mL 
deionized water with 200 mg sodium form. The solution stirred at room temperature for 
3 hours and then was directly loaded onto a C18 reverse-phase column (2 g). The 
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column was eluted with deionized water (10 mL). The combined water fractions were 
lyophilized to generate compound 7.4.1 as an orange solid (3.6mg, 50%). 
1H NMR (300MHz, D2O)  8.13-7.93 (m, 2H), 7.49-7.47 (m, 1H), 7.19-7.18 (m, 2H), 
6.70-6.54 (m, 4H), 4.40-4.39 (m, 2H), 3.98-3.84 (m, 6H), 3.13-3.11 (m, 2H), 1.60-1.30 
(m, 8H). 31P NMR (161.8 MHz, D2O) 2.40, 0.83, -0.87. MALDI-HRMS [M + H]
+ calcd 




5. Synthesis of azido-tagged lipids. 
Originally, we designed azido-tagged lipids (compound 7.5.1 & 7.5.2) to be used in the 
liposome immobilization studies. However, better results were observed with the 
triazole-linked azido lipids rather than the amide-linked ones. This may be caused by 
the lower hydrophilicity of amide than triazole.  Here, I include the synthetic procedures 





























































Scheme 7.5 Synthesis of azido-tagged lipids. 
Benzyl (2,3-dihydroxypropyl)carbamate (7.5.4).  3-Amino-1,2-propanediol 7.5.3 (1.0 
g, 11.0 mmol) was dissolved in 25 mL toluene, along with phthalic anhydride (1.55 g, 
10.5 mmol). The reaction was heated to 135oC with Dean-Stark apparatus overnight. 
The reaction was extracted by chloroform (200 mL)/saturated sodium chloride solution 
(150 mL x 3). The organic layer was collected, dried by magnesium sulfate, filtered and 
concentrated to yield product 7.5.4 as a white solid (1.10 g, 47%).  
2,3-Bis(hexadecyloxy)propan-1-amine (7.5.6).  Diol 6.5.4 was dissolved in 15 mL cold 
DMF. To this solution was added sodium hydride under nitrogen. The reaction was 
stirred at 0 C for 15 minutes then room temperature for 10 minutes. 1-
Bromohexadecane (1.7 mL, 5.43 mmol) was added to the solution which was then 
refluxed at 135 C overnight. The reaction wan then cooled to room temperature and 
quenched by 1 mL water. The solvent was removed under reduced pressure. The crude 
was extracted by dichloromethane (200 mL)/saturated sodium chloride solution (150 mL 
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x 3). The organic layer was dried by magnesium sulfate, filtered and concentrated to 
yield the crude product 7.5.5, which was directly used in the next reaction without 
further purification. Crude 7.5.5 was dissolved in 25 mL methanol along with 2 mL 
hydrazine monohydrate. The reaction was refluxed overnight. Then the solvent was 
removed under reduced pressure. The crude was purified by column chromatography 
using a gradient solvent system of 2-10% ammonia saturated 
methanol/dichloromethane to yield amine 7.5.6 as an off-white solid (306 mg, 60% from 
7.5.4). 
Azido-TEG-ether-lipids (7.5.1). Azido acid 7.5.6 (51 mg, 0.185 mmol) was combined 
with DCC (50 mg, 0.241 mmol), DMAP (29 mg, 0.241 mmol) in 5 mL dichlormethane. 
The reaction was stirred at room temperature for 20 minutes. Then amine 7.5.6 (100 mg, 
0.185 mmol) was added to the solution. The reaction was stirred at room temperature 
overnight. The solvent was then removed under reduced pressure. The yielded crude 
was purified by column chromatography using a gradient solvent system of 50-100% 
ethyl acetate/hexane then 5% methanol/dichloromethane to yield lipid 7.5.1 as a white 
solid (32 mg, 22%). 
Azido-TEG-ester-lipids (7.5.2). 3-Amino-1,2-propanediol 7.5.3 (247 mg, 2.706 mmol) 
was combined with azido acid 6.5.7 (500 mg, 1.804 mmol), EDCI (517 mg, 2.706 mmol), 
HOBt (366 mg, 2.706 mmol), triethylamine (0.4 mL, 2.706 mmol) in 5 mL dry DMF. The 
reaction was stirred at room temperature overnight. The solvent was then removed 
under reduced pressure. The crude was purified by column chromatography using a 
gradient solvent system of 5-20% methanol/dichloromethane with 1% acetic acid to 
yield diol 7.5.8. Diol 6.5.8 was dissolved in 30 mL chloroform. To this solution was 
added paltimic acid (1.85 g, 7.216 mmol), DCC (1.49 g, 7.216 mmol) and DMAP (0.88 
g, 7.216 mmol). The reaction was stirred at at room temperature overnight. The solvent 
was then removed under reduced pressure. The crude was purified by column 
chromatography using a gradient solvent system of 10-20% acetone to chloroform to 
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